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ABBREVIATIONS 
ACLE – acute cutaneous lupus erythematosus  
ACR – American College of Rheumatology  
AIHA – autoimmune haemolytic anaemia 
CCLE – chronic cutaneous lupus erythematosus 
CNS – central nervous system  
DIF - direct immunofluorescene   
DN T cell – double negative T cell 
F: M – female is to male ratio 
hpf – high power field 
IL – interleukin  
ITP – immune thrombocytopenic purpura 
LE – lupus erythematosus 
pCLE – paediatric cutaneous lupus erythematosus – cutaneous lupus occurring in   
paediatric age group 
pSLE – paediatric systemic lupus erythematosus – onset of SLE in paediatric age group 
SLE – systemic lupus erythematosus  
SCLE – subacute cutaneous lupus erythematosus 
SLEDAI - Systemic Lupus Erythematosus Disease Activity Index 
TH – T helper cell 
TTP – thrombotic thrombocytopenic purpura 
UP/UC – urine protein/urine creatinine 
yrs – years  
 
INTRODUCTION 
“..the very protean nature of SLE complicates any description of patients who have the 
disease…”(1) 
Systemic lupus erythematosus (SLE) is a chronic, heterogeneous, multifactorial autoimmune 
disease involving multiple organ systems, the definite aetiology of which remains unknown. It 
can present with a vast variety of symptoms and clinical manifestations due to which, SLE has 
often been referred to as „the great mimicker‟ in the past. 
SLE is the commonest collagen vascular disease occurring in children(2). About 15% of all 
patients with SLE develop the disease prior to their sixteenth birthday(3). The disease can occur 
at any age and its onset in childhood is not uncommon(4). The clinical course and manifestations 
of paediatric SLE (pSLE) is known to be different from that in adults(5) and so do the 
mucocutaneous features associated with SLE(6). 
Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)(Annexure I)(1) is one of the 
tools used for measuring disease activity, which aids in the follow up of patients and taking 
decisions with regard to change of therapy(7). 
The discovery of TH17 cells and interleukin-17/interleukin-23 (IL-17/IL-23) axis has provided 
new openings in understanding the pathogenesis of SLE(8) and also suggests a potential 
therapeutic target(9). Evident from the several animal and human studies on TH17/IL-17 in the 
last decade(10), the role of IL-17 in a variety of diseases including SLE has become  the new 
arena of research activities. 
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pSLE is not a well researched subject in the sub-continent(4) and studies on cutaneous 
manifestations of pSLE are limited(6,11). Till date, there have been no studies from India on 
the expression of IL-17 in cutaneous lupus erythematosus. 
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AIMS AND OBJECTIVES 
Primary objective:  
To study the profile of mucocutaneous lesions in patients with paediatric onset systemic 
lupus erythematosus  
Secondary objectives:  
1. To study the association of SLEDAI score with 
 lupus specific cutaneous lesions 
 lupus non-specific cutaneous lesions 
2. To study the expression of interleukin – 17 in skin biopsies of lesions seen in paediatric 
onset SLE and to study its association with disease activity (SLEDAI score) 
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REVIEW OF LITERATURE 
History of SLE 
Lupus was first described by a French dermatologist named Theodore Biett in 1828(12). For 
several years after its initial description, the disease was mainly thought to be associated 
with dermatological features only, before internal organ involvement was appreciated. 
Cazenave coined the word „lupus erythematosus‟ in 1851, literally meaning the „red wolf‟. 
This was due to the „wolf-bite‟ appearance of the malar rash (butterfly rash) which is quite 
characteristic of SLE. The global symbol of lupus erythematosus and support for its patients 
is a „purple butterfly‟(13).  
Epidemiology 
The incidence of SLE varies across the world depending on the race, ethnicity, predominant 
age group, sex and nation of origin of the population being studied(14). The estimated 
worldwide prevalence of SLE is found to be 17 to 48 per 100,000(15). In the west, the 
incidence of SLE has been reported to be 0.3 - 11.4 per 100,000 people per year and 
prevalence has been found to be 3 to 53 per 100,000 men and 17-283 per 100,000 women, 
lower in Caucasian population and higher in Africans(16). More than 2 decades ago, the 
estimated prevalence of pSLE in the west was 0.6 per 100,000(17) and has risen to 3.3-8.8 
per 100,000 children according to more recent literature(18,19). The mean annual incidence 
of pSLE according to western literature is about 0.3 to 0.9 per 100,000 children-
years(18,20). 
5 
 
The incidence and prevalence of pSLE  is higher in Asians and Blacks, who also tend to 
have a more severe disease and higher chance of having nephritis, in comparison to the 
white population(21,22). SLE is not rare or uncommon in children in India as previously 
thought(4). However, there are no definite incidence studies for pSLE in India.  
Demography  
Age  
SLE predominantly affects people in their 2
nd
, 3
rd
 and 4
th
 decades of life and is more 
common in adult women of childbearing age but may occur in men and in any age group. 
The age of onset of SLE has a definite influence over the clinical and immunological 
features and prognosis(23). pSLE has been associated with greater  and early onset damage 
due to disease activity(21). The risk of damage due to disease activity is found to inversely 
correlate with age at disease onset in pSLE, so earlier the onset of SLE, worse is the 
prognosis(24). 
While most studies include patients with onset of SLE before the age of 16 to 19 as 
pSLE(6,21,25,26), the age for defining pSLE or juvenile onset SLE has been different in 
various studies across the world and there is a lack of uniformity(27). 
About 10%- 25% of all SLE cases are children and teenagers and have the onset of disease 
before the age of 19(4,20,24,27–32). About 23% of 556 pSLE patients recruited by the 
Pediatric Rheumatology International Trial Organization (PRINTO) had onset of SLE 
before 10 years of age(3). The disease is quite infrequent below the age of 5 years(25).  The 
mean age of diagnosis of pSLE  was 11.9 years in a study on 1,015 patients(26). Mean age 
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of diagnosis is known to vary with the age group chosen by the investigators researching 
pSLE cases(29).  
Gender 
In a multicentre trial across 39 countries involving 1,015 pSLE patients, the female to male 
ratio was 5:1(26). In the Pediatric Rheumatology International Trial Organization (PRINTO) 
series of 556 patients, the female to male ratio in patients with disease onset before 10 years 
was 5.3:1 and in those with disease onset after 10 years of age was 5.8:1 (3). The female 
predominance increases with age of onset of SLE in the second and third decade of 
life(20,30) to almost 9:1(33).  
Studies done at Delhi(25), Vellore (34), Chandigarh(35) Mumbai(36) and Kolkata(37)  have 
reported a female to male ratio of 9:1, 6:1, 5.7:1, 5.2:1, 3.8:1 in pSLE patients, respectively. 
The demographic data of various studies on pSLE have been tabulated (4,11,23,25,25,34-
51) (Tables 1 and 2). 
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 Table 1: Demographic data on pSLE (studies from India) 
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Study design Cs Cs P R R R R R B 
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10.5 10 - - 9.37 
Inclusion age 
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<16 
 
≤16 <14 
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5.2:1 5.7:1 3.8:1 2.9:1 6:1 7:1 4.9:1 9.3: 1 2.3: 1 
 
 R – Retrospective, P – Prospective, Cs – Cross-sectional, B – Bidirectional 
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     Table 2: Demographic data on pSLE (excluding Indian studies) 
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Study design P P R R Cs P B P P R P R P P 
Number of 
patients 
198 45 78 207 56 230 256 50 33 153 49 31 57 34 
Mean age at 
diagnosis in 
yrs 
12.6 
12.8 ± 
2.5 
14 ± 
2.7 
10 ± 
2.7 
15 16.4 
13.1±
3.17 
12.9± 
2.4 
- 
13.5 ± 
5.5 
- 12.3 13 14 
Inclusion age 
group in yrs 
<17 <16 8-18 2-16 9-18 <  18 3-18 <16 5-17 - <18 - 4-15 5-14 
 
F:M ratio 
 
5.6: 1 4:1 10: 1 2.7: 1 5.2: 1 9: 1 4.7:1 9: 1 6.6: 1 5.9: 1 6: 1 4.2: 1 4.2: 1 
10.3 : 
1 
 
       R – Retrospective, P – Prospective, Cs – Cross-sectional, B – Bidirectional   
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Clinical manifestations and Diagnosis  
The clinical features of SLE include a vast spectrum ranging from pure cutaneous 
manifestations to florid multisystem involvement. Mucocutaneous lesions are second most 
common presenting complaint as well as second most common manifestation of 
SLE(52,53). Almost 85% of pSLE patients would have had some form of cutaneous 
involvement during the course of their disease(29,31) and cutaneous lesions may be the 
presenting symptom in 60 to 80%(29). In their cohort of pSLE, Tucker et al found that 
incidence of mucocutaneous symptoms over 5 years equaled that of joint involvement which 
was found to be 85%(31). 
 Similar data has been obtained from retrospective Indian studies on pSLE. Mucocutaneous 
features were found in about 60% of patients at presentation(34,40) and 70 to 83% of them 
had the same at some point of time during the course of their disease(25,40).  
A relatively higher incidence of malar rash, renal, haematological and neurological 
involvement has been noted in pSLE patients from Eastern and Northern India(36). Pande et 
al(25) have also reported an enhanced severity and a different clinical pattern of pSLE in 
Indian patients in comparison to that of developed nations. The diversity of the Indian 
population, the differences in lifestyle, regional and environmental differences probably 
account for the variation in clinical features of pSLE reported(36).  
Data on pSLE in India and across the world including systemic involvement and 
immunological parameters have been tabulated (4, 11, 23, 25, 34-46, 48-51) (Tables 3 and 
4). 
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     Table 3: Systemic involvement (cumulative) and immunological parameters in pSLE (studies from India)  
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publication 
2013 2012 2010 2009 2009 1997 1994 1993 1989 
Mucocutaneous 36 62.5 54 57.4 57.1 50 59 - - 
Renal 52 60 54 100 77.1 56 49.1 78.8 75 
CNS Lupus 24 25 25 14.8 21.4 43.2 27.1 25.3 45 
Arthritis 60 30
b 
68 42.6 65.7 56 86.6 90.4 60 
Serositis - - - 16.6 - - - - - 
Pericarditis - - 2.3 - 2.8 18.6
 
10.2
 
28.9
 
30
 
Pleuritis - - - - 2.8 12.5
a 
22
a 
28.9
a 
20
a 
Haematological 
involvement 
- 45 54 18.5 - 31.2 50.8
i 
13.2 75
i
 
ANA 100 - 96 96.3 - 100 100 100 100 
Anti -dsDNA 84 - 70 57.4 77.1 72.7 92.3 65.9 87.5 
Low C3/C4 76 - 68 77.8 80 58.3 50 79.5/76.9 75 
      The figures are in percentage; *clinical features at the time of diagnosis/presentation,a – pulmonary/pleuropulmonary involvement, i – anaemia 
(Hb<10g %) 
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                 Table 4 : Systemic involvement (cumulative) and immunological parameters in pSLE (excluding Indian studies) 
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2012 2012 2011 2009 2009 2008 2008 2005 2003 1999 1999 1998 1998 
Mucocutaneous - - 92.3 - - - - - - - - 77 - 
Renal 82 80 71.7 67 62.5 55 49.1
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56 58.8 67.3 61
c 
84 50 
CNS 16 26 32 24.2 20.4
f 
27 11.3 14 4.6 36.7 26 21 26 
Arthritis 58 82
b 
39.7 - 59.3 67 83 78 57.5 85.7 100 39 88 
Serositis 36 ~20 - - - - - 14 15 - - 19 32 
Pericarditis - - 21.7 - 16.7 15 17 - - 16.3 26 12 - 
Pleuritis - - 21.7 - 18.5 14 17.4 - - 28.5 48 9 6
a 
Haematological 78 91 69.2 26% 38.5
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63 16.1
d 
- 79.7 20.4
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84
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58 15
d 
ANA 67 98 - - - 100 96.9 - - 100 100 93 - 
Anti -dsDNA 95 69 - - 60.7 84 67 74 - 89.7 93 45 - 
Low C3 - - 8.9 - - - - - - - - - - 
                  The figures are in percentage; *clinical features at the time of diagnosis/presentation, a – pulmonary/pleuropulmonary involvement,  
                   b – musculoskeletal, c – proteinuria, d – haemolytic anaemia, e- anaemia, f- encephalopathy, i – anaemia (Hb<10g %) 
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Criteria for diagnosing SLE 
In 1973, the American Rheumatism Association(ARA) laid the classification criteria for 
SLE(54). In 1982, the American College of Rheumatology(ACR) revised the same(55) and 
latest revision was done in 1997(56) (Annexure II). For the purpose of classifying a patient 
as SLE, the patient should have at least four of the eleven criteria either simultaneously or 
serially. Dermatological manifestations itself form 4 of the 11 criteria emphasizing the 
importance of dermatological manifestations of SLE. The ACR criteria have been 
extensively used both in the clinic as well as for research purposes. It has a sensitivity of 
86% and specificity of 93%. However, it has been pointed out that the ACR criteria are 
biased towards mucocutaneous manifestations(53) as it is sufficient for a person to be 
diagnosed with SLE with four dermatological manifestations alone immaterial of systemic 
involvement. Another flaw in the ACR criteria is that it does not include SCLE which is one 
of the specific lesions for LE(53). The diagnostic criteria are same for children and 
adults(33) and children have been found to meet the SLE ACR criteria earlier than 
adults(28). 
A new classification criteria named Systemic Lupus Erythematosus International 
Collaborating Clinic (SLICC) criteria (Annexure II) has been used preferentially, and is 
found to have a greater sensitivity, but lesser specificity in comparison to the ARA 
criteria(57). To classify a patient as having SLE based on the SLICC criteria, the patient 
should have biopsy proven lupus nephritis with ANA or anti-dsDNA (OR) the patient 
should satisfy four of the criteria, which includes at least one clinical and one 
immunological criteria.  According to the abstract of  annual scientific meeting of the ACR 
in November2012, the SLICC criteria has also been validated for use in pSLE (58). 
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Mucocutaneous involvement in SLE 
Cutaneous lesions in SLE were classified as lupus specific and lupus non-specific by 
Gilliam and Sonthemier in 1981 based on histopathology and clinical appearance of the skin 
lesions(59). Minor modifications and additions have been subsequently made and skin 
lesions in lupus have been classified as in the table-5. 
Disease course and demographics of cutaneous lupus have been reported to be different in 
children and cutaneous lesions of lupus are more strongly associated with systemic 
symptoms in pSLE than in adults(6). Association of CLE with systemic disease varies from 
less than 1% for LE tumidus to almost 100% in case of ACLE(60). A flare of cutaneous 
lesion in SLE is important since it often precedes a systemic flare (29) and alerts the 
physician about appropriate alteration in therapy. The pattern of mucocutaneous lesions in a 
given individual also provides a clue to where the patient‟s illness may be placed in the 
spectrum of lupus erythematosus(61).    
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Table 5- Gilliam and Sontheimer classification of LE-associated skin lesions (53,62) 
 
A. Histopathologically specific (LE-specific) skin lesions 
 
1. Acute cutaneous LE (ACLE) 
Localized ACLE 
Generalized ACLE 
Toxic epidermal necrolysis-like ACLE 
 
2. Subacute cutaneous LE (SCLE) 
Annular 
Papulosquamous 
Mixed patterns 
 
3. Chronic cutaneous LE (CCLE, syn. DLE) 
„Classic‟ DLE (a) Localized (b) Generalized 
Hypertrophic (verrucous) DLE 
Lupus erythematosus panniculitis/profundus 
Mucosal LE 
LE tumidus 
Chilblain LE 
DLE–lichen planus overlap 
 
B. Histopathologically non-specific (LE-non-specific) skin lesions 
 
1. Cutaneous vascular disease 
Vasculitis 
(a) Leukocytoclastic 1. Palpable purpura 2. Urticarial vasculitis 
(b) Panarteritis nodosa-like 
 
Vasculopathy 
(a) Degos disease-like 
(b) Atrophie blanche-like 
(c) Periungual telangiectasia 
(d) Livedo reticularis 
(e) Thrombophlebitis 
(f) Raynaud‟s phenomenon 
(g) Erythromelalgia (erythemalgia) 
 
 
2. Alopecia (non-scarring) 
„Lupus hair‟ 
Telogen effluvium 
Alopecia areata 
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3. Sclerodactyly 
4. Rheumatoid nodules 
5. Calcinosis cutis 
 
6. LE-non-specific bullous lesions* 
Epidermolysis bullosa acquisita-like bullous LE 
Dermatitis herpetiformis-like bullous LE 
Pemphigus erythematosus Senear–Usher 
Bullous pemphigoid 
Porphyria cutanea tarda 
 
7. Urticaria 
8. Papulo-nodular mucinosis 
9. Anetoderma/cutis laxa/mid-dermal elastolysis 
10. Acanthosis nigricans (type B insulin resistance) 
11. Erythema multiforme (Rowell‟s syndrome) 
12. Leg ulcers 
13. Lichen planus 
*Bullous LE has been reclassified as a lupus specific lesion(63) 
LE specific skin lesions 
 
Figure 1: Venn diagram illustration of the relationship between the clinical types of 
lupus specific skin lesions {incorporated from Walling and Sonthemier et al(64)} 
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These skin lesions occur only in patients with lupus erythematosus. They are characterized 
by the presence of interface dermatitis which refers to an inflammatory process occurring at 
the level of the basement membrane zone of the interfollicular epidermis(53).  However, the 
lupus involving the deeper layers of skin as in LE tumidus and LE panniculitis may not 
reveal interface dermatitis. Lupus specific lesions are known to occur in almost 85% of all 
patients with SLE at some point of time during the course of the disease and play an 
important role in making the diagnosis of SLE(65)  
Acute cutaneous LE (ACLE) 
An ACLE rash is an important predictor of concurrent systemic involvement or an 
impending one. Isolated ACLE without systemic involvement is relatively rare(6). In the 
pSLE age group, ACLE rash has been noted to have a relatively higher age of onset and a 
high female predominance of 12:1(6). In a British study on 38 patients with pediatric 
cutaneous LE(6), 34% of them had ACLE.  
 It is further subdivided as follows: 
Malar rash (localized ACLE, butterfly rash) 
The malar rash is a subtype or a localized presentation of ACLE. It consists of fixed 
erythema or erythematous macules or infiltrated plaques which may eventually coalesce and 
involve the bilateral malar areas and the nasal bridge, although the involvement may not be 
contiguous. It can also extend to the ears, involve the forehead and V-area of neck, but 
characteristically spares the nasolabial fold and heals without scarring(53).  
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The malar rash with arthralgia has been described as the classical presentation of a patient 
with pSLE and is present in about 1/3 of patients at initial presentation(66) and occurs in 
about 70% during the course of their disease(66) . In a retrospective study from Vellore, the 
incidence of malar rash at presentation in pSLE was found to be 57.1%(34).  
Although reported to be more common in pSLE than in adults(25,28,50,51), Hoffman et 
al(45) found no statistically significant difference in the incidence of malar rash in pediatric 
and adult SLE (69.6% and 58.6% respectively) (65).  
Generalized ACLE  
It is less common when compared to malar rash  and commonly heralds or coincides with a 
systemic flare of SLE or may also suggest prolonged disease activity(14). Its presence may 
be actively associated with lupus nephritis.  
It is a symmetrically distributed erythematous maculopapular rash which may have an 
urticated appearance, with accentuation over photoexposed areas. It may involve the acral 
areas (including palms and soles) but characteristic sparing of the knuckles is noted.  Some 
patients may develop lesions over non-UV-exposed site(53). The relative involvement of 
various sites according to a study on pCLE was head and neck 75%, trunk and upper limb 
50% each and in lower extremities it was 38%(6). It may be associated with facial and 
periorbital edema and sometimes simulates a drug rash. It resolves without scarring, leaving 
behind post inflammatory hypopigmentation and/or hyperpigmentation. The prevalence of 
generalized ACLE reported in pSLE is 32%(6). 
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 Uncommonly, an acute LE rash can have a TEN (toxic epidermal necrolysis) like 
presentation.  
Subacute cutaneous LE (SCLE) 
SCLE is relatively rare in children(67). The reported prevalence in one study was 
16%(6/38)(6). Majority of children with SCLE (83%) have been reported to have 
concomitant SLE in comparison to adults(50%)(6). 
SCLE is a highly photosensitive condition and includes annular or polycyclic lesions which 
may show central clearing and a papulosquamous or psoriasiform variant. Sometime 
vesiculobullous lesions may be seen along the margins of the annular lesions. They are 
characteristically non-indurated in comparison to LE tumidus and DLE lesions(53). They 
resolve without scarring but may leave behind residual telangiectasia and dyspigmentation.   
The central area of the face is usually spared in SCLE. In children, the SCLE lesions may be 
more widespread in distribution in comparison to other lupus specific lesions(6). Unlike 
adults, SCLE in paediatric population may occur over lower limbs also which reflects the 
differential pattern of sun exposure in children(6). Annular and scaly lesions, similar to 
SCLE lesions are also known to occur in infants with neonatal lupus erythematosus(33,53). 
Patients with SCLE have a different immunogenetic background and manifest specific 
clinical and serological features(14,68).  About 15% of patients with SCLE have mild 
systemic symptoms, however, upto 50% of patients may fulfill 4 out 11 ACR criteria(69).  
Drug induced SCLE has been reported in adults and is uncommon in children. It may occur 
as a result of treatment with hydrochlorothiazide, ACE-inhibitors, terbinafine, etc and 
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characterized by photodistributed SCLE lesions, seropositivity for anti-Ro and anti-La 
antibodies and few extracutaneous features(53).  
Chronic cutaneous LE (CCLE) or Discoid LE (DLE)  
CCLE has been reportedly found in 20% (5/25) of patients with pSLE(6).  
Classic DLE is characterized by erythematous, dyschromic discoid plaques, with 
telangiectasia, follicular plugging, surface atrophy and adherent scales in photoexposed 
areas – commonly face, pinna and scalp but can also occur over non exposed areas of scalp, 
trunk, inguinal folds, palms and soles. About 10% of DLE lesions occur over the scalp and 
cause disfiguring scarring alopecia. DLE occurring in a Blaschko linear pattern has been 
reported to occur in pSLE(33). The progression of isolated DLE to SLE in children has been 
found to be the same for localized and generalized form of the disease(70,71) and occurs in 
about 15-31% patients(20,70–73). A long-term and thorough follow up of children with 
DLE is thus advocated(71).  
LE panniculitis 
It is characterized by tender, indurated nodules, sometimes depressed plaques and may be 
associated with surface epidermal changes in the form of erythema or hyperpigmentation. It 
has rarely been reported in pSLE(74). It was found to be the initial manifestation of pSLE in 
0.7% patients in a study involving 278 pSLE patients(75). 
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Chilblain LE 
It is characterized by erythematous to violaceous papules and plaques over the acral areas/ 
cold exposed areas. While chilblain lesions can occur as a result of frost bite, in case of 
chilblain LE, they may persist beyond the winter months for weeks together. Upto 20% 
patients with chilblain LE develop SLE(53) and is more common in females(76). It is 
commonly associated with anti-SSA antibodies(77). It is not very common in the pSLE 
group(11) and its incidence was reported to be about 9.4% in a study on pSLE(45).   
A familial variant of chilblain lupus has been described and is more likely to present in 
childhood(78,79). Isolated chilblain LE in children has been reported to progress to SLE(6).  
LE tumidus (LET) 
The LET variant of CCLE rarely occurs in children(80). It is characterized by succulent 
looking reddish to violaceous urticarial papules and plaques. They are found to be one of the 
most photosensitive variants of CCLE and resolve without scarring. Less than 1% of LET is 
associated with systemic symptoms(53).  
Bullous LE 
Bullous LE, classified as a non specific lupus lesion under the Gilliam and Sontheimer 
classification, has been reclassified as a LE specific lesion(63). It is an uncommon clinical 
subset of SLE, characterized by sub-epidermal vesicles and bullae occurring on mostly 
photoexposed areas, but may extend beyond and also involve mucosa(81,82). It occurs due 
to autoantibodies against collagen VII or other antigens at the dermo-epidermal junctional 
zone(63). Although it occurs commonly in a setting of ACLE/ SCLE with high disease 
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activity, it must be differentiated from blistering occurring in ACLE as a result of basal cell 
vacuolation(53).   
Bullous LE is quite rare in children and more commonly reported in females(82). It is 
associated with lupus nephritis, a finding which is appreciated in the adult population as 
well(82). It may be the initial clinical manifestation of the disease or may also be a marker 
for relapse of SLE, thus substantiating the fact that skin lesions could be an indicator of 
disease activity(81,82).    
Histopathology of lupus specific lesions 
Histopathology of LE specific lesions include – epidermal changes such as epidermal 
atrophy and  follicular plugging, interface changes at the level of dermo-epidermal junction 
including vacuolization, basement membrane thickening and deposition of mucin in the 
interstitium, sclerotic changes in the dermis and/or subcutis and perivascular and 
periadnexal lymphocytic infiltrate intermingled with neutrophils and karyorrhectic debris. 
However, not all features may be appreciated in a single specimen nor any of these features 
are definitively diagnostic for cutaneous lupus erythematosus. For example, interface 
dermatitis may also be seen in patients with a drug rash, erythema multiforme or graft versus 
host disease. Thus the diagnosis of particular form of specific LE namely ACLE, SCLE and 
DLE is dependant on the specific constellation of features described above along with 
clinical correlation. It may not always be possible to differentiate histopathologically 
between ACLE, SCLE and DLE(53).  
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Histopathology of ACLE shows characteristic interface dermatitis, basal cell vacuolization, 
and perivascular inflammatory infiltrate of lymphocytes mostly in the upper dermis and 
mucin deposits in the deeper reticular dermis.  
Histopathology of SCLE is similar to that of ACLE with hydropic degeneration of the basal 
cell layer with colloid bodies in the lower epidermis and papillary dermis. The inflammatory 
infiltrate and hyperkeratosis is less prominent in comparison to lesions of DLE. 
Histopathology of DLE includes hyperkeratosis and follicular plugging, thinning of the 
stratum malpighii, basilar hydropic degeneration, thickened basement membrane and a 
predominantly lymphocytic infiltrate along the dermo-epidermal junction, around hair 
follicles and other appendageal structures with mesenchymal mucin deposition. 
Histopathology of DLE lesions in children is similar to those in adults except that epidermal 
changes may be absent or less prominent(70). Basal cell vacuolization and perivascular and 
periadnexal lymphocytic infiltrate have a greater diagnostic significance in childhood(70).  
Histopathology of bullous LE is characterized by an appearance similar to dermatitis 
herpetiformis with sub-epidermal blisters and neutrophilic microabscesses in upper dermis 
but there is an absence of eosinophils and plenty of mucin deposits along with karyorrhectic 
debris in the upper dermis(53).   
Direct immunofluorescene (DIF) in SLE 
DIF done from lesional skin in LE shows a „lesional lupus band‟. Although the term is used 
infrequently, it refers to a band like pattern along the basement membrane of a full house of 
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antibodies including IgG, C3 and also IgM and IgA. However, this may not be diagnostic of 
the type of specific lesion, nor does its absence exclude LE(53).  
A „non-lesional‟ lupus band, which is a DIF done from an unexposed and uninvolved skin 
such as that from the skin of the buttocks or inner arm or thigh, if positive, is strongly 
associated with SLE(53). This is particularly helpful in diagnosing SLE in case of atypical 
clinical presentation and equivocal serological markers.  
Lesional DIF in Bullous LE shows linear or granular deposits of IgG, IgM, IgA and 
complement along the basement membrane(53).  
LE non-specific skin lesions  
There are a number of cutaneous lesions occurring in SLE which do not have a diagnostic 
significance but are a common cutaneous feature of SLE and may be found to occur in other 
conditions as well. They generally reflect a higher lupus disease activity and are associated 
with multi-system involvement(65). One may have a single or more than one type of lupus 
non-specific lesion concomitantly. 
Of the 25 pSLE patients in a study, 60%(15) were found to have lupus non- specific lesions 
and 8 of them had concomitant lupus specific lesions(6). Cutaneous vascular disease was the 
commonest LE non- specific subtype found in 36%(9) patients in the above study(6).  While 
there are many lupus non- specific lesions mentioned in the classification, some of the more 
common ones are discussed below.  
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Cutaneous vascular disease  
Cutaneous vascular disease includes vasculitis as well as vasculopathy. Data on pSLE shows 
that 36% of pSLE patients have cutaneous vascular disease(6) and in another study 42% 
were reported to have vasculitis(11). This was much higher in comparison 10-20% occurring 
in adult SLE(6). Data from Indian studies have shown that 8-48% of pSLE patients have 
vasculitis(25,39).   
Vasculitis may be leukocytoclastic vasculitis or panareteritis like lesions. Vasculitis in SLE 
may manifest as urticarial lesions, palpable purpurae, nodules (erythema nodosum like 
lesions), ulceration, necrosis and gangrene (11,83). They usually occur as a result of 
microinfarcts or vascular involvement of the small dermal vessels at tips of fingers(11) and 
larger vessels may be involved in polyarteritis nodosa–like lesions.  
Urticarial vasculitis – Urticarial vasculitis has been reported to occur in pSLE(84). These 
lesions resemble urticarial wheals, may be pruritic but the lesions usually last for more than 
24 hrs and resolve with post-inflammatory hyperpigmentation. It may be associated with 
complement deficiencies(85).  
Vasculitis often occurs with active systemic disease, especially renal involvement and 
suggests a poor prognosis(83).  
Vasculopathic lesions include Degos disease like lesions and atrophie blanche like lesions. 
Periungual telangiectasia, thrombophlebitis, livedo reticularis, Raynaud‟s phenomenon and 
erythromelalgia are other manifestations of cutaneous vascular disease(53).  
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Thrombophlebitis - It has been reported in association with SLE, however, it is not very 
common and may coexist with predisposing procoagulant state.  
Raynaud‟s phenomenon - It is the blanching of fingers and acral areas on exposure to cold 
and usually occurs in winters. The blanching is usually followed by a reactive erythematous 
discolouration and/or a livedoid hue. Presence of Raynaud‟s phenomenon with specific LE 
lesions may indicate an LE overlap or mixed connective tissue disorder(53).  
The incidence of Raynaud‟s phenomenon is much lesser in pSLE compared to adults with 
SLE and varies from 2 to 25%. It was seen in only 7% of 57 pSLE patients in a Chinese 
study(11).Data from Indian studies have reported its occurrence in 12.5% to 29% of pSLE 
patients(25,39).     
Alopecia 
The occurrence of alopecia in pSLE varies from 16% to 32% according to studies across the 
world (6,11) and 13 to 83% according to Indian studies (25,39).  
Diffuse non-scarring alopecia, lupus hair and alopecia areata are the three forms of hair 
involvement described in SLE, of which diffuse non-scarring alopecia (or telogen 
effluvium) is the commonest. Total alopecia has also been reported(4).  
Alopecia has been reported as the presenting symptom in 45.7% of pSLE patients(34). It is  
a common symptom seen in both pediatric and adult SLE patients and no significant 
difference has been noted with age of onset(45).  
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Non-scarring alopecia forms one of the clinical criteria in the SLICC SLE criteria(57) 
(Annexure II). New onset alopecia or recurrence of the same, with abnormal diffuse or 
patchy hair loss is one of the parameters used in the assessment of disease activity under 
SLEDAI.  
Lupus hair and/or telogen effluvium may occur as a result of high disease activity along with 
an ACLE rash. Telogen  effluvium usually occurs as a result of catabolic effects of severe 
disease and high levels of circulating proinflammatory  cytokines(86). About 20 to 60% of 
adult patients with SLE have been reported with telogen effluvium during or after a systemic 
exacerbation(65) and was found to correlate with disease activity(87). 
Scarring alopecia usually occurs as a post inflammatory sequelae, secondary to discoid lupus 
of the scalp(86). 
Urticaria 
Chronic urticaria is rare in children(88), however, urticarial rash was reported to occur in 
about 80% of 104 pSLE patients in a study from Oman(89).   
Almost half of adult patients with SLE(44%) have been reported to have urticaria and was 
found to correlate with disease activity(90). While there are few studies on urticaria in 
pSLE, Spadoni et al(88) retrospectively found that 5 % (271/5419) of patients with chronic 
autoimmune urticaria had pSLE  and two patients had chronic urticaria as the initial 
manifestation of SLE. Thus follow up of children and adolescents with chronic autoimmune 
urticaria is advised in view of possible connective tissue disorders such as paediatric 
lupus(88).  
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Papular mucinosis 
It usually presents as -tender indurated erythematous papules and plaques typically on the 
arms and may involve the trunk. They are characterized by excessive mucin deposits on 
histology, but lack other features of a lupus specific lesion. Its occurrence in pSLE has been 
reported(91) but its prevalence is not known.   
Acanthosis Nigricans 
Acanthosis nigricans occurs in a scenario of insulin resistance. Auto-antibodies to insulin 
receptor have been reported in patients with SLE and may be the underlying 
pathomechanism of acanthosis nigricans in such patients.  68% (26 out of 38) of patients 
with anti insulin receptor antibodies were found to have SLE(92) and resolution of 
acanthosis nigricans has been found to occur with treatment given for SLE(93). While 
acanthosis nigricans has been rarely reported in pSLE, neuropsychiatric lupus presenting 
with acanthosis nigricans in a child has been reported(94).  
Nail changes 
Certain LE non-specific nail changes may be associated with active ACLE including 
periungual erythema and nail fold telangiectasias, abnormal cuticle, nail bed erythema and 
splinter haemorrhages which may occur secondary to vasculitis and disease activity(53). 
Periungual gangrene was reported in 9% (5 out of 57) of patients with pSLE in a study by 
Wananukul et al(11)  
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Other Important Mucocutaneous Features 
Photosensitivity  
It forms one of the ACR criteria (Annexure II) and has been defined as the occurrence of 
skin rash due to an unusual reaction to sunlight by patient history or as observed by the 
physician. Data from Indian studies have reported photosensitivity in 20% to 50% of pSLE 
patients(4,34). 
Oral and Nasal ulcers 
They are not specific lesions but are common and form one of the 11 ARA criteria 
(annexure), one of the clinical criteria of the SLICC SLE criteria (Annexure II) as well as 
one of the parameters used to assess disease activity scoring under SLEDAI (Annexure I). 
Oral ulcers are usually painless but may occasionally be painful, especially on contact with 
irritant food stuff. They are more likely to involve the hard palate and less often, the buccal 
mucosa(29,33). The lesions involving the hard palate may range from subtle hyperaemia, 
striking erythema, petechial rash and true ulcers(29). There may be residual 
hyperpigmentation on resolution of the lesion. 
Nasal mucosa in pSLE may be involved in the form of hyperaemia, superficial erosions and 
very rarely true septal ulcers with perforation might occur(29).  
Oral ulcers have been reported in 12% to 44% of Indian pSLE patients(36,39). Nasal 
ulceration is not very common, might often go unnoticed and there is no data on nasal ulcers 
in pSLE.   
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Neonatal Lupus Erythematosus 
It is caused by the passive transplacental transfer of maternal anti-Ro and anti-La antibodies 
from the mother to the fetus which reacts with fetal antigens, and is thus an acquired 
autoimmune condition(33). Of prime importance is the autoimmune activity of the 
antibodies with the fetal cardiac conduction system, especially occurring around the 4
th
 or 5
th
 
month of gestation which may lead to varying degrees of congenital heart block and related 
complications. The infant may develop SCLE like rash usually after UV exposure [triggered 
or worsened by phototherapy used in children with hyperbilirubinaemia](33), usually 
involving the centrofacial and periorbital region. Dickey et al(6) reported occurrence of skin 
lesions involving the head region in all the 15 neonatal LE patients seen and 47% of the 
mothers of neonatal LE patients were known to have autoimmune disease, while 40% were 
asymptomatic but detected to have auto-antibodies later.   
Most of the non-cardiac complications resolve by about 5 to 8 months as the maternal 
antibodies are cleared(33,53). 
SLEDAI - Systemic Lupus Erythematosus Disease Activity Index(1) 
SLEDAI is the most commonly used and preferred index to measure disease activity in 
children with SLE(95,96) and is the most convenient to use(97).  
There are multiple indices to measure activity of systemic disease in SLE such as SLEDAI 
(Systemic Lupus Erythematosus Disease Activity Index)(1), BILAG (British Isles Lupus 
Assessment Group)
 
, SLAM (Systemic Lupus Activity Measure), European Consensus 
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Lupus Activity Measurement (ECLAM) and  Systemic Lupus International Collaborating 
Clinics/American College Of Rheumatology (SLICC/ACR) Damage Index(97).  
SLEDAI is a global disease activity index which was developed more than 2 decades ago(1) 
by a group of rheumatologists with  expertise  in  lupus as a result of incorporation of 
clinician‟s global judgment. The index consists of 24  most  important  descriptors which 
were  retained  for  the development  of  SLEDAI from the initial list of 37 descriptors that 
had been used to describe disease activity in lupus in literature.    
 It has been adequately validated and widely used for research purposes as well as for day to 
day application at the rheumatology clinics. The parameters include clinical, biochemical, 
hematological indices and immunological markers which can be objectively assessed.  
Of the 24 parameters in the SLEDAI scoring system, 4 are dermatological (including 
cutaneous rash, alopecia, mucosal ulcers and features of vasculitis like ulcers, gangrene and 
others or evidence of vasculitis on skin biopsy) 
Systemic Lupus Erythematosus Disease Activity Index (SLEDAI)(1), has undergone minor 
alterations referred to as the SELENA SLEDAI and SLEDAI 2000(98) (Annexure I). The 
advantage of using SLEDAI 2000 (SLEDAI-2K) is that it takes into account not only new 
onset proteinuria, rash, oral ulcers or alopecia, but also the persistence of these parameters in 
the patient which indicates ongoing disease activity(98). Various investigators have  
categorized patients into arbitrarily chosen ranges of SLEDAI scores, for example  mild 
(<8), moderate (8-18) and severe disease activity (>18) (36) or alternatively  no activity 
(score -0), mild activity (1-5), moderate activity (6-10), high activity (11-19), and very high 
activity (20 and above)(99). 
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Duration of disease may affect disease activity and associated damage. It has been noticed 
that SLE associated skin damage is greater in patients with higher disease duration, 
especially when disease duration is more than five years(26).  
Patients with pSLE have been reported to have higher SLEDAI scores at presentation and 
during follow-up(5,18,28,100) than their adult counterparts. The mean SLEDAI score has 
been reported to increase with age in pSLE patients, however, there has been no statistically 
significant difference between the SLEDAI scores of the age groups studied(101). SLEDAI 
has also been used in Indian pSLE patients in the past(36).  
Skin lesions in SLE & Disease Activity  
Till date, there have been no studies on pSLE related skin manifestations and their 
association with disease activity.   
Beyond the description and histopathology, differentiating the type of skin lesions is 
important from the perspective of disease activity. The type of skin lesions whether LE 
specific or not correlates positively with disease activity and predictive of the course of 
systemic disease(65,83,102,103). 
Patients who have non-specific cutaneous lesions of lupus have been found to have a higher 
systemic disease activity, in comparison with those with the lupus specific cutaneous 
lesions(65).  The number of different types of skin lesions in a given patient with SLE  and 
individual types of skin lesions have also been found to correlate with disease 
activity(65).The number of different types of LE specific skin lesions has also been directly 
linked with higher chances of systemic involvement(104) 
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Higher disease activity score conferred by lupus non-specific lesions in comparison to lupus 
specific lesions is probably due to the widespread immune complex mediated damage 
occurring in non specific LE lesions while the pathophysiology responsible for lupus 
specific lesions is T-cell mediated immune responses(65).   
Interleukin – 17  
TH17 cells are a separate set of T cells which secrete IL-17 and have been identified to play 
a role in pathogenesis of SLE in animal models as well as human studies(8). 
History  
IL-17 was first identified in 1995(105) and subsequently found to have proinflammatory 
properties involved in defence from infections even prior to discovery of TH17 cells. 
More than 2 decades ago, Mosmann et al(106) proposed the presence of two types of T 
helper cells namely TH1 and TH2 cells, based on their relative expression of cytokines and 
their role in various immunological and inflammatory processes. Nonetheless, the TH1-TH2 
paradigm of CD4+ T cells alone could not account for many observations in the field of 
immunology. The works of Cua et al(107) and Murphy et al(108) on murine models of 
interaction between IL-23 and IL-12 ultimately led to the discovery of TH17 cells, their 
discovery being just a decade old. This novel group of T-cells was found to secrete IL-17 
and was thus named TH17 cells.  
 
 
33 
 
Innate role of TH17/ IL-17 
TH17 cells are involved in providing regulated immunity against bacterial infection, tissue 
repair and maintenance of integrity of epithelial barrier(10). 
IL-17 has a role in neutrophil activation, recruitment of macrophages and polymorphs, 
abscess formation, induction of antimicrobial peptide expression and thus in the defence 
against infective organisms(10). Additionally, IL-17 has  synergistic action with other 
proinflammatory cytokines, particularly IL-1β, tumor necrosis factor (TNF)-α, and 
interferon(IFN)-γ(8). 
Various animal models and laboratory studies have shown that TH17 immunity and IL-17 
are involved in immune response and host defence against Toxoplasma gondii, Candida 
albicans, Mycoplasma pneumoniae, Bacteroides fragilis, Citrobacter rodentium, Listeria 
monocytogenes (10,109,110). 
Production of TH17 cells and IL-17 
The induction of TH17 cells is known to have a unique physiological trigger. The innate 
immune system  recognizes the apoptosis of the tissue cells due to any invading organism 
and elicits a response in the form of differentiation of TH17 CD4+ cells(10). 
TH17 cells secrete IL-17, possess IL-23 receptor. IL-23, an interleukin of the IL-12 family, is 
known to be the primary factor inducing the differentiation of naïve CD4+T cells to TH17 
cells and is necessary for the differentiation and survival of TH17 cells(111). The 
development of TH17 cells from naive CD4 +T cells involves priming of the latter in the 
presence of TGF-β and inflammatory cytokines like IL-21, IL-6, and IL-23(8).  
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TH17 cells produce a variety of cytokines namely IL-6, IL-10, IL-17(IL-17A and IL-17F), 
IL-21, IL-22, TNFα and CCL20 and  have an effect on multiple immunopathological 
processes in various tissues(10,110). IL-17 A and IL-17F are always synthesized in a 
dimeric state (either homodimeric IL-1 7A/IL-1 7A or IL-l 7F /IL-17F or heterodimeric IL-1 
7A/IL-17F).  
While TH17 cells are the primary producers of IL 17, it is also produced by 
CD3+CD4−CD8− T cells (double negative T cells or DN T cells), TCRɤd+T cells, NK T 
cells and certain NK cells(8,110). IL-17 production by NK cells occurs during the phase of 
early innate immune response, where it plays a role in neutrophil recruitment and 
activation(110) 
TH17/ IL-17 and autoimmunity   
TH17 cells play an important role in autoimmune inflammatory processes as well. In the 
recent years, IL-17 has gained status of one of the prime cytokines involved in the 
pathogenesis of multiple autoimmune disorders. Dysregulated activation of TH17 cells and 
continuous production of IL-17 has been noted in experimental autoimmune 
models(10,110).   
Expression of IL-17 has been detected in sera and target tissues of patients with various 
diseases, including rheumatoid arthritis, multiple sclerosis, SLE, inflammatory bowel 
disease, Behcet‟s disease, Kawasaki disease and asthma(112). Recent pathogenic 
mechanisms of several autoimmune and inflammatory disorders including psoriasis, 
rheumatoid arthritis (RA), inflammatory bowel disease (IBD) , systemic sclerosis  and 
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systemic lupus erythematosus implicate IL-17 as one of the major cytokines involved in its 
pathogenesis (8).  
TH17 cells have also found to play a role in the development and pathophysiology of allergic 
contact dermatitis and atopic dermatitis(110). 
Role of TH17 cells/ IL-17 in SLE  
While the aetiopathogenesis of SLE is not clearly known, it can be said that it is a 
multifactorial disease affected by genetic predisposition and environmental influences. 
Immunological factors play a central role in the pathogenesis of lupus erythematosus. The 
TH1/TH2 paradigm fails to account for all the immunological features of SLE(111) which 
has given way to the identification of the role of the TH17 cells.  
Prior to the establishment of TH17 type of T cells, Wong et al(113) had proposed the 
simultaneous rise of TH1 and TH2 cytokines in SLE. They also found raised plasma levels of 
IL-12, IL-17, IL-18 and IL-4 in their cohort of 36 SLE patients in comparison to healthy 
matched controls(113).  However, the effects of simultaneous rise of TH1 and TH2 cytokines 
can be accounted for with the discovery of TH 17 cells.  
The activated IL-23/IL-17 axis plays a key role in the autoimmune mechanisms and 
subsequent inflammation in SLE(114). Low IL-2 and enhanced production of the 
inflammatory cytokines IL-6 and IL-21 in patients with SLE, give rise to a cytokine milieu 
which is ideal for the generation of TH17 cells(8). In combination with IL-17, role of 
cytokines including IL-12 and IL-18 has been proposed in the pathogenesis of SLE(113). 
Furthermore, the persistent activation of plasma dendritic cells by immune complexes 
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containing nucleic acids in the blood can cause sustained generation and amplification of 
TH17 response in SLE(8). 
TH17/ IL-17 and B cells in SLE – SLE is characterized by production of a plethora of 
autoantibodies and deposition of immune complexes which plagues multiple organ systems. 
Therefore, the role of B cells in its immunopathology is indisputable. It has been shown that 
in combination with or even singly, TH17 cells and  IL-17 plays a role in proliferation, 
differentiation and survival of B cells(115). In a study by Dong et al, IL-17 was found to 
induce excessive production of anti-ds-DNA IgG and total IgG in cultures of peripheral 
blood mononuclear cells derived from patients with lupus nephritis(116). Higher IL-17 
production in patients with SLE is said to amplify the immune response by increasing target 
organ damage and by enhancing the production of antibodies by B cells(8). Thus it is 
suggested that IL-17 may also play a role in B-cell activation in SLE(8). 
IL-17 and Cutaneous Lupus Erythematosus 
While there are studies on the serum IL-17 levels in SLE(114) and also in pSLE(35), the 
studies on tissue IL-17 expression in skin lesions associated with SLE/ cutaneous lupus 
erythematosus are scarce(112,117). Till date, there are no studies on IL-17 tissue expression 
in skin lesions of lupus erythematosus from India. It has been suggested that evaluation of 
cutaneous biopsies for TH17 related cytokines may be necessary for confirming the link 
between lupus and 1L-17(9). 
In a study by Balanescu et al, serum levels of both IL-17F and IL-17A were found to be 
higher in patients with DLE, SCLE and SLE in comparison with healthy cohorts and the 
serum concentration of IL-17F was found to be higher than IL-17A(111). Patients with DLE 
37 
 
and SLE were also found to have a higher percentage of TH17 cells while patients with 
SCLE had a higher number of CD3+IL-17+ lymphocytes. Thus it has been suggested that 
different lymphocyte subsets  probably have a different immunological role of in various 
clinical subtypes of SLE(111).  
One of the studies on evaluation of the role of IL-17 in specific skin lesions of lupus 
erythematosus showed positive tissue staining with IL-17A antibodies in 84.8% of the 
cutaneous specimens(112). It was also demonstrated that high expression of interferon-α and 
IL-17 may play a role in pathogenesis of CLE and positive correlation in their pattern of 
expression in the skin lesions of CLE has been demonstrated(112). Oh et al(112) also 
established stronger IL-17 staining in the epidermis in CLE in comparison to healthy 
controls, which could be secondary to IL-17 production by TH17 cell in the dermis. 
However, a non- specific staining of keratinocytes in epidermis has also been suggested 
occurring as a result of polyclonality of IL-17 antibody(112).  Another study showed that all 
lesions of cutaneous lupus including DLE, SCLE and even macroscopically normal skin of 
patients with SLE had a significantly higher number of IL-17A positive cells (lymphocytes, 
fibroblasts and endothelial cells) when compared to healthy controls(117).  Thus significant 
elevation of IL-17 expression in lesions of CLE propose a direct implication of IL-17 in its 
immunopathogenesis(112,117).  
Il-17 serology and Tissue Damage in SLE  
IL-17 producing T cells play a role in the pathogenesis of lupus nephritis and have been 
found in the kidneys of patients with lupus nephritis(8).  
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Studies have shown that serum levels of IL-17 were higher in patients with SLE and IL-17 
levels in SLE correlated with disease activity/SLEDAI scores(114,115). 
In a study conducted in PGIMER, Chandigarh on patients with pSLE , it was found that 
serum IL-17 levels were found to be high in patients with haematological and cutaneous 
involvement and IL-17 has been suggested as a prognostic marker in pSLE(35). Significant 
correlation between cytokine IL-17 and SLEDAI in pSLE patients was also observed(35). 
There has been no correlation of serum levels of IL-17 with SLEDAI, anti ds-DNA and anti-
SSA antibodies(111).  
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MATERIALS AND METHODS 
Setting – The study was conducted at the Department of Dermatology, Venereology and 
Leprosy, Christian Medical College and Hospital (CMCH). The patients were screened at 
the Dermatology and Paediatric Rheumatology outpatient clinics. Referrals from adult 
rheumatology and internal medicine in-patients with paediatric onset SLE were also 
included in the study.  
Study design – A hospital based cross-sectional study was conducted where in consecutive 
patients fulfilling the inclusion criteria were recruited into the study. Additionally, patients 
who developed new onset, recurrent or persistent mucocutaneous lesions were reviewed at 
subsequent follow up visits and details were recorded. 
Study duration -The study was conducted from April 9, 2011 to July 9, 2013 (27 months) 
Inclusion criteria  
1)  Patients diagnosed to have SLE by the ACR criteria (1997)(56) (Annexure II) 
with the onset of disease at ≤ 16 years  of age      
Exclusion criteria  
1) Patients diagnosed with SLE when they were > 16 years  
2) Patients who were not willing to be included in the study 
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Methods  
     Patients who fulfilled the inclusion criteria were included in the study. The patients 
recruited included newly diagnosed cases of SLE as well as those who had onset of SLE ≤ 
16 years of age and were on treatment and follow up. All the subjects and the parents/legal 
guardian of the subjects were informed about the purpose of the study (Annexure III-V) and 
child assent (Annexure VI-VIII) in subjects less than 18 years as well as informed consent 
was obtained (Annexure IX-XI). 
The patients were examined by the principal investigator and a detailed proforma was filled 
(Annexure XII) as per details obtained from the patient and the parent or guardian. The 
following details were collected and subsequently entered in an electronic database on 
Epidata (version 3.1), a data management software.  
Demographic details 
Socio-demographic data including age at study visit, gender, address, duration of disease 
and age at diagnosis were recorded. Age at diagnosis was defined as the age at which the 
patient was diagnosed to have SLE based on the ACR criteria as per the information 
obtained from the patient‟s past medical records, where available. In patients without 
documents, the age at diagnosis was recorded as per the history provided by the patient or 
guardian. 
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History pertaining to the disease  
1. Presenting mucocutaneous complaints were recorded.  
2. Systemic complaints (which the patient had at the time of study visit or in the 
preceding ten days) were recorded. 
3.  Treatment the patient had been on including systemic and topical medications (if 
any) in the last three months were recorded. 
4. Past mucocutaneous lesions of the patient obtained by reviewing the past medical 
records were recorded. 
Clinical Examination 
Each patient was examined by the principal investigator for skin lesions and the findings 
were confirmed by the guide.  The lesions related with SLE, classified as specific or non-
specific according to the Gilliam and Sonthemier classification(53,62) were recorded. Other 
miscellaneous lesions not related with SLE, which the patient presented with, were also 
recorded. The diagnosis of the lesions was based on clinical features and confirmed by skin 
biopsy, whenever necessary.  
Cumulative mucocutaneous involvement was calculated by combining details of past 
mucocutaneous features and those which the patients had during the study period.  
The systemic examination was assisted by the paediatric rheumatologist (co-investigator) 
and the findings were recorded. 
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Laboratory investigations 
These included a haemogram, anti-nuclear antibody (ANA), anti-double stranded DNA 
(anti- dsDNA), anti-Sm, anti- SSa, anti- SSb, anti- RNP, lupus anticoagulant, anti-
cardiolipin antibody, direct Coomb‟s test, serum C3 and C4, urine routine and microscopy 
and UP/UC ratio. 
Investigations including antinuclear antibody (ANA), anti- SSa, anti- SSb, anti- RNP, lupus 
anticoagulant, anti-cardiolipin antibody, direct Coomb‟s test may have been performed at 
any single given point of time from the time of diagnosis of SLE and not necessarily at the 
time of inclusion of the patient into the study.    
SLEDAI scoring 
 SLEDAI score was calculated according to SLEDAI-2K (Annexure I) for every patient at 
the study visit as well as during the subsequent follow-up visits in case of the nested cohort 
of patients who had new, persistent or recurrent mucocutaneous lesions after the first study 
visit. After the first study visit, the details of follow up visits in patients without any 
mucocutaneous lesions were not recorded. 
A detailed history was taken with reference to symptoms relevant to parameters measured in 
the SLEDAI including fever, central nervous system manifestations of the disease (seizures, 
psychosis, cranial nerve disorder, lupus headache and cerebrovascular accident), joint 
swelling or tenderness and proximal muscle ache or weakness. Patients were examined for 
leg and digital ulcers, gangrene, tender finger nodules, periungual infarction and splinter 
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hemorrhages. Other cutaneous manifestations scored for the purpose of SLEDAI were 
inflammatory rash, oral or nasal mucosal ulcers and diffuse or patchy hair loss.   
Laboratory findings included in SLEDAI were total leukocyte counts, platelet counts, C3, 
C4 levels and estimation of double stranded DNA antibodies. Urine analysis findings were 
noted. Based on the pre-assigned scores in the SLEDAI-2K scoring system, the score was 
calculated for all the patients at every visit with the primary investigator. The maximum 
possible score is 105 and minimum is 0.  
Skin biopsy  
A punch biopsy of the lesional skin for histopathology was done in selected consenting 
patients presenting with active cutaneous lesions of SLE for studying the expression of IL-
17 and/or for the purpose of confirmation of clinical diagnosis by histopathology.   
The biopsy sample obtained was fixed, processed and embedded in paraffin wax, and each 
tissue specimen was serially sliced into sections of 4 µm for routine haematoxylin and eosin 
staining, special staining including Periodic Acid-Schiff Diastase, stains for mucin and for 
immunohistochemical staining with anti-interleukin- 17 antibodies (rabbit polyclonal 
antibodies raised against amino acids 24-155 of IL-17 of human origin, purchased from 
Genetix Biotech Asia Pvt Ltd was used)(Annexure XIII) . The protocol followed for 
automated immunostaining with anti-IL-17 antibody has been enclosed as Annexure XIV. 
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Histopathology  
On histopathology, the specimens were classified as: 
1. Lupus specific lesion – the diagnosis was based on characteristic 
histopathological features(118).  
2.  Suggestive of lupus specific lesion – histological features were highly 
suggestive, but not characteristic of a lupus specific lesion. 
The lesions were suggestive of lupus specific lesion if  
a. There was absence of mucin deposits in presence of all other features 
including interface change and superficial and deep inflammation with 
thickened basement membrane or 
b. There was absence of basement membrane thickening but other features like 
interface change, mucin deposits and superficial and deep inflammation were 
present  
3. Non-specific lupus lesion such as leukocytoclastic vasculitis and vasculopathic 
reaction.  
IL-17 expression in immunostained skin biopsy specimens 
Positive control used for IL-17 was a normal kidney tissue which showed positive staining 
of the glomeruli (IL-17 product information- Annexure-XIII). The sweat glands of the skin 
biopsy specimen served as the internal positive control(112). 
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The slides thus prepared by automated immunostaining were examined by the principal 
investigator at 10x and 40x magnification under a light microscope. The total number of 
fibroblasts, endothelial cells and lymphocytes showing positive IL-17 staining on 
immunohistochemistry were counted in 5 high power fields (40x) on an Olympus CX31 
microscope individually by the primary investigator and a pathologist (co-investigator) and 
an average of the two counts was taken for studying its correlation with SLEDAI score.  
Statistical analysis  
The prevalence of the various cutaneous lesions in SLE was expressed as numbers and 
percentages. 
The comparison of SLEDAI scores with type of skin lesions was done using t-test and 
Kendall‟s tau statistics. Kendall tau coefficient (τ) is calculated in statistical analysis for the 
purpose of analyzing the statistical association of a binary variable (ex. malar rash being 
present or absent) against a numerical score (ex. disease activity index such as SLEDAI 
score). If the agreement between the two is perfect then τ is 1 and if the 
disagreement between the two is perfect then τ is -1. 
Correlation between the levels of expression of IL-17 in skin lesions and SLEDAI scores 
was studied. This was done using the two scores as continuous variables and calculating the 
correlation coefficient (Spearman‟s Rho correlation coefficient). The data was analyzed 
using SPSS version 17.0.  
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Sample size calculation to study IL-17 expression in skin biopsies 
The required sample size to show a correlation of 0.5 for IL-17 count with SLEDAI score 
was found to be 24 subjects (biopsies in 24 subjects with active lupus related cutaneous 
lesions) when it is anticipated that there was no relation, with 80% power and 5% level of 
significance. i.e., population correlation = 0, n = 24.  
[Reference for sample size calculation: Oh SH, Roh HJ, Kwon JE, Lee SH, Kim JY, Choi 
HJ, et al. Expression of interleukin-17 is correlated with interferon-α expression in 
cutaneous lesions of lupus erythematosus. Clin. Exp. Dermatol. 2011 Jul; 36(5):512–20] 
Institutional Review Board approval and funding  
The study was discussed and reviewed by the Institutional Review Board (Research and 
Ethics committee) and the study was approved (IRB No - 7626)(Annexure XV).  FLUID 
Research grant was provided for the histopathological examination and anti-IL-17 antibody 
immunoistochemistry of the biopsy specimens.  
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RESULTS 
Demographic profile   
During the study period of 27 months, 140 patients with paediatric onset SLE (patients with 
onset of SLE ≤ 16 years) were included in the study. At the time of inclusion into the study, 
113/140 (80.7%) patients were ≤ 16 years of age and 27/140 (19.3%) were aged > 16 years. 
Age  
The mean age at diagnosis of SLE was 11.8  2.9 years (range 0.3 to 16) (fig-2) while the 
mean age of the patients at the time of inclusion in the study was 13.9 ± 3.9 years (range 0.3 
to 33) (fig-3). The mean age at diagnosis in males was 10.9 ± 3.4 years and in females it was 
11.8 ± 2.8 years.  
 
Figure 2: Bell curve showing age distribution of patients at the time of diagnosis of 
SLE 
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Figure 3: Bell curve showing age distribution of the patients at the time of inclusion 
into the study 
 
Gender distribution of patients with pSLE (Table-6) 
There were a total of 115 females and 25 males with female to male (F: M) ratio of 4.6:1.  
The F: M ratio in the pre-pubertal (<8 years), pubertal (8-12 years) and post-pubertal (>12 
years) age group(119) was 2.2: 1, 4.8: 1 and 5.8: 1 respectively. 
Region 
The pSLE patients included referred and self-reporting patients predominantly from 
southern and eastern India. The patients were predominantly from Tamil Nadu (58, 41.4%), 
West Bengal (23, 16.4%) and Andhra Pradesh (22, 15.7%).  The remaining patients were 
from Kerala (9, 6.4%), North Eastern states (8, 5.7%), Orissa (4, 2.9%), Karnataka (2, 
1.4%), other Indian states (11, 7.8%) and Bangladesh (3, 2.1%). 
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Table 6: Gender distribution and F: M ratio 
Age at diagnosis Male Female Total F: M ratio 
<8 Years 
Pre- pubertal 
6 13 19 2.2: 1 
8-12 years 
Pubertal 
8 38 44 4.8: 1 
>12 Years 
Post-pubertal 
11 64 75 5.8: 1 
 
Spectrum of lesions seen in paediatric SLE during the course of disease (Table-7) 
A total of 109/140 (77.9%) patients had documented mucocutaneous lesions during the 
course of their disease, of which 107/140 (76.4%) had lesions recorded in the past and 
100/140 (71.4%) had mucocutaneous lesions during the study period.  
 
Alopecia and oral ulcers were seen in 90/140 (64.2%) and 76/140 (54.3%) of the patients 
respectively. Among lupus specific lesions, malar rash was the most frequent lesion seen in 
34.2% of patients. 
 
 
Of the 100 patients with mucocutaneous lesions during the study period 
Lupus specific = 54 Lupus non-specific =73
Total  number of patients with mucocutaneous lesions during the course of their 
disease =109 
Past = 107 Present =100
Total number of pSLE patients =140 
Female =115 Male =25
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Table 7 : Spectrum of lesions seen in pSLE 
Lesion 
Lesions 
during study 
period  
(n=100) 
Past 
recorded 
lesions 
(n=107) 
Total number of 
patients with 
lesions during 
disease course 
(n=109) 
Percentage  of 
pSLE patients 
with lesions 
(n=140) 
Alopecia 50 61 90 64.2 
Oral ulcers 43 51 76 54.3 
ACLE 36 44 67 47.8 
 Malar rash 26 30 48 34.2 
 Generalized ACLE 20 21 36 25.7 
Cutaneous vascular 
disease* 
35 26 49 35 
CCLE 20 13 25 17.9 
SCLE 9 2 10 7.1 
Chronic urticaria 5 8 10 7.1 
*Cutaneous vascular disease included palpable purpura, urticarial vasculitis, digital ulcer 
and gangrene, periungual telangiectasia, livedo reticularis and Raynaud’s phenomenon   
 
Mucocutaneous lesions observed during the study period (Fig-4, Tables 8 & 9) 
One hundred (71.4%) patients were observed to have mucocutaneous lesions during the 
study period. 93/100 patients had skin lesions (with or without mucosal lesions) and 7/100 
patients had only oral mucosal lesions. Among the 93 patients, 20 (21.5%) patients had only 
lupus specific lesions, 39 (41.9%) patients had only lupus non-specific lesions and 34 
(36.5%) patients had of them had both lupus specific and lupus non-specific lesions 
simultaneously(Fig-4).   
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  Figure 4: Venn diagram showing patients with lupus specific lesions only, lupus non-
specific lesions only and patients with both types of lesions simultaneously 
 
Lupus specific lesions (Table-8) 
Fifty-four (54%) patients had lupus specific lesions. ACLE was seen in 36 patients, in whom 
the lesions were localized to the malar area in 26 patients and were generalized in 20 
patients. Twenty patients had CCLE, it was disseminated in 14 patients and 6 had localized 
DLE. SCLE was seen in 9 patients with papulosquamous lesions in all and 3 of them having 
annular lesions additionally. Lupus panniculitis was seen in 2 patients and 1 patient had 
bullous LE. 
Lupus non-specific lesions (Table-8) 
Seventy-three out of 100 patients had lupus non-specific lesions. Diffuse non-scarring 
alopecia was the most frequent lesion seen in 45 patients followed by Raynaud‟s 
phenomenon in 17 patients and 16 patients had palpable purpura. Of the 16 patients with 
palpable purpura, 7 underwent biopsy, of them 1 patient had leukocytoclastic vasculitis, 3 
had vasculopathic reaction and the remaining 3 had perivascular inflammatory infiltrate with 
no evidence of vasculitis.  
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Table 8 : Lupus specific and non-specific lesions in pSLE patients 
Lesion  Frequency  Percentage 
(n=100*) 
Percentage 
(n=140**) 
LUPUS SPECIFIC LESIONS 54 54 38.6 
Acute cutaneous LE (ACLE) 36 36 25.7 
a. Malar rash  26 26 18.5 
b. Generalized ACLE 20 20 14.3 
Chronic cutaneous LE 20 20 14.3 
a. Disseminated DLE 14 14 10 
b. Localized DLE 6 6 4.2 
c. LE Panniculitis 2 2 1.4 
Subacute cutaneous LE (SCLE) 9 9 6.4 
a. Papulosquamous 9 9 6.4 
b. Annular 3 3 2.1 
Bullous LE 1 1 0.7 
LUPUS NON- SPECIFIC LESIONS  73 73 52.1 
Non Scarring Alopecia 50 50 35.7 
a. Diffuse non-scarring alopecia  45 45 32.1 
b. Lupus hair  11 11 7.8 
c. Alopecia areata 2 2 1.4 
Cutaneous Vascular disease 35 35 25 
a. Raynaud‟s phenomenon 17 17 12.1 
b. Palpable purpura 16 16 11.4 
c. Periungual telangiectasia 7 7 5 
d. Digital ulcer/gangrene 4 4 2.8 
e. Livedo reticularis  4 4 2.8 
f. Urticarial vasculitis  2 2 1.4 
Acanthosis nigricans  7 7 5 
Urticaria 5 5 3.5 
Papulo-nodular mucinosis 1 1 0.7 
Sclerodacytly 1 1 0.7 
Erythema multiforme  1 1 0.7 
Leg ulcers 1 1 0.7 
*total number of patients with mucocutaneous lesions during the study period 
**total number of pSLE patients in the study 
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Mucosal lesions (Table-9) 
49/100 patients had mucosal lesions of whom 7 had mucosal involvement without cutaneous 
features. Erythema and/or ulceration of the hard palate was seen in 43/100 patients. Other 
unrelated lesions included geographic tongue, oral aphthae, angular cheilitis which were 
seen in 8 (5.7%) patients. One patient (0.7%) had nasal erosions. 
Table 9 :  Mucosal involvement observed in patients with pSLE   
Mucosal lesions  Frequency  Percentage 
(n=100) 
Percentage 
(n=140) 
Hard palate involvement 43 43 30.7 
Other oral lesions (geographic 
tongue, aphthae, angular cheilitis) 
8 8 5.7 
Nasal erosions  1 1 0.7 
 
Photosensitivity  
A history of photosensitivity was present in 46/140 (32.9%) of the patients.  
Miscellaneous lesions (Table-10) 
Various other skin lesions were recorded in patients with pSLE. These included lesions 
related with the past mucocutaneous involvement (post inflammatory hyperpigmentation, 
scarring alopecia), other SLE-related lesions (palmar erythema, acquired ichthyosis), 
treatment related skin lesions, infections, infestations and others.  Of the three patients with 
scabies, one had crusted scabies. 
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Table 10 : Miscellaneous lesions in patients with pSLE  
 Miscellaneous lesions Frequency  Percentage 
(n=140) 
Post inflammatory hyperpigmentation  53 37.9 
Cushingoid facies  23 16.4 
Palmar telangiectasia 19 13.5 
Acquired ichthyosis  19 13.5 
Striae  16 11.4 
Tinea versicolor  16 11.4 
Acne vulgaris  13 9.3 
Scarring alopecia  8 5.7 
Seborrhoea capitis 8 5.7 
Acneiform eruption 7 5 
HCQ* induced pigmentation  6 4.2 
Pediculosis capitis  6 4.2 
Periungual hyperpigmentation 5 3.5 
Nail changes  4 2.9 
Oral candidiasis  3 2.1 
Scabies (including crusted scabies) 3 2.1 
Herpes zoster  2 1.4 
Vitiligo 2 1.4 
Lichen spinulosus 2 1.4 
Keratosis pilaris  2 1.4 
Papular urticaria 2 1.4 
Ciclosporine induced hypertrichosis 2 1.4 
Granuloma annulare 1 0.7 
Tinea corporis  1 0.7 
Verruca vulgaris  1 0.7 
Hidradenitis suppurativa  1 0.7 
Palmoplantar hyperhidrosis 1 0.7 
Follicular atrophoderma 1 0.7 
*hydroxychloroquine 
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Follow-up data of pSLE patients with mucocutaneous lesions (Table-11) 
Thirty (25%) out of the 120 patients on follow up were seen by the primary investigator for 
recurrent, new onset or persistent SLE related mucocutaneous lesions over subsequent out-
patient visits. These follow up visits ranged from 2 to 7 visits (mean number of follow up 
visits was 2.6 ± 1.3) over a period of 27 months. One of the patients died of septicaemia, 
seven months after inclusion into the study.  
Of these 30 patients, 15 patients had both skin lesions and mucosal lesions, 13 patients had 
only skin lesions, and 2 patients had only mucosal lesions. Of the 28 patients with skin 
lesions, 13 patients had both lupus specific and lupus non-specific lesions, 11 patients had 
only lupus non-specific lesions while 4 patients had only lupus specific lesions during the 
follow-up visits. Mucosal involvement was mainly in the form of hard palate 
erythema/ulceration.  
Table 11: Mucocutaneous lesions in pSLE patients seen on follow up.  
Lesion  Frequency  Percentage 
(n=30*) 
Percentage 
(n=140**) 
LUPUS SPECIFIC LESIONS 17 56.7 12.1 
Acute cutaneous LE (ACLE) 11 36.7 7.8 
a. Malar rash  10 33.3 7.1 
b. Generalized ACLE 6 20 4.2 
Chronic cutaneous LE 7 23.3 5 
a. Disseminated DLE 4 13.3 2.8 
b. Localized DLE 3 10 2.1 
c. LE Panniculitis 1 3.3 0.7 
Subacute cutaneous LE (SCLE) 4 13.3 2.8 
a. Papulosquamous 4 13.3 2.8 
b. Annular 1 3.3 0.7 
LUPUS NON- SPECIFIC LESIONS 24 80 17.1 
Non Scarring Alopecia 19 63.3 13.6 
a. Diffuse non-scarring alopecia  19 63.3 13.6 
b. Lupus hair  3 10 2.1 
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Lesion  Frequency  Percentage 
(n=30*) 
Percentage 
(n=140**) 
c. Alopecia areata 2 6.7 1.4 
Cutaneous Vascular disease 11 36.7 7.8 
a. Raynaud‟s phenomenon 6 20 4.2 
b. Palpable purpura 3 10 2.1 
c. Periungual telangiectasia 3 10 2.1 
d. Digital ulcer/gangrene 1 3.3 0.7 
e. Livedo reticularis  1 3.3 0.7 
f. Urticarial vasculitis  2 6.7 1.4 
Urticaria 3 10 2.1 
Acanthosis nigricans  1 3.3 0.7 
Papulo-nodular mucinosis 1 3.3 0.7 
MUCOSAL LESIONS  18 60 12.8 
Hard palate ulcer/erythema 17 56.7 12.1 
Geographic tongue  1 3.3 0.7 
Aphthae 1 3.3 0.7 
MISCELLANEOUS     
PIH 14 46.7 10 
Acquired ichthyosis 7 23.3 5 
Palmar telangiectasia 6 20 4.2 
Acne 5 16.7 3.6 
Tinea versicolor 4 13.3 2.8 
Scarring alopecia 3 10 2.1 
Herpes zoster  2 6.7 1.4 
Granuloma annulare 1 3.3 0.7 
Acneiform eruption 1 3.3 0.7 
Tinea corporis 1 3.3 0.7 
Nail changes 1 3.3 0.7 
Seborrhoea capitis 1 3.3 0.7 
Oral candidiasis 1 3.3 0.7 
HCQ* induced pigmentation  1 3.3 0.7 
Pediculosis capitis  1 3.3 0.7 
Periungual hyperpigmentation 1 3.3 0.7 
*total number of patients with multiple follow up visits during the study period 
**total number of pSLE patients in the study 
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Systemic involvement (Fig-5) 
Cumulative systemic involvement including details of systemic disease till the end of the 
study was recorded. More than half of the patients were found to have lupus nephritis (76, 
54.3%), 37 (26.4%) had arthritis and 20 (14.3%) had CNS lupus. Haematological 
involvement included autoimmune haemolytic anaemia (AIHA) in 28 (20%) patients, 
immune thrombocytopenic purpura (ITP) in 16 (11.4%) patients and thrombotic 
thrombocytopenic purpura (TTP) in 2 (1.4%) patients. Fifteen (10.7%) patients had serositis 
in the form of pericardial effusion (12, 8.6%) and combined pleural and pericardial effusion 
(3, 2.1%). Four (2.9%) patients had pancreatitis, while 3 (2.1%) had myositis. 
 
 
 
Figure 5: Bar diagram showing systemic involvement in pSLE 
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Medication history (Fig-6) 
Ninety-seven out of 140 pSLE patients were on oral steroids (69.3%) and 95/140 (67.9%) 
were on hydroxychloroquine. Other adjuvant immunosuppressants that the patients were 
being treated with included mycophenolate mofetil (36, 25.7%), azathioprine (10, 7.1%), 
methotrexate (4, 2.9%) and cyclophosphamide (3, 2.1%). Six patients (4.2%) with skin 
lesions had received treatment with topical steroids prior to their inclusion in the study.  
There were 8/140 (5.7%) who were treatment naïve at the time of inclusion into the study 
with disease duration ranging from 0 to 3 months.  
 
 
Figure 6: Medication history  
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Results of laboratory investigations (Table-12) 
Investigations relevant to SLE and SLEDAI scoring were performed. Thirty-eight (27.1%) 
patients with pSLE were found to be anaemic (Hb < 10g %) and 95 (88.8%) patients found 
to have a positive direct Coomb‟s test. One hundred and twenty seven (91.1%) patients were 
tested ANA positive, 89/137 (65%) patients had high anti-ds-DNA levels (>100 IU/ml), 
64/140 (45.7%) patients had low serum C3 (<90 mg/dL) and 44/136 (32.4%) had low serum 
C4 levels (<9 mg/dL). Anti-Smith (anti-Sm) antibodies were present in 42/102 (41.2%) 
pSLE patients, anti-SSa antibodies were present in 37/108 (34.3%) patients while anti-SSb 
antibodies were present in 5/104 (4.8%) patients. Lupus anticoagulant was positive in 
46/122 (32.9%) patients and anti-cardiolipin antibody was positive in 27/123 patients 
(19.3%). There were 47 (33.8%) patients with proteinuria, 36 patients with pyuria (25.7%), 
28 (20%) having haematuria and 14 (10%) patients had urinary casts.   
Table 12: Results of laboratory investigations   
Investigation  Frequency (n) Percentage  
Haematological investigations    
ANA 127 (139) 91.4 
Direct Coomb‟s test 95(107) 88.8 
Anti ds-DNA (>100 IU/ml) 89(137) 65 
Anti RNP (>20 U/ml) 44(88) 50 
Low C3 (<90mg/dL) 64(140) 45.7 
Low C4 (<9mg/dL) 44(136) 32.4 
Anti Sm (>20 U/ml) 42(102) 41.2 
Anti SSa (>20 U/ml) 37(108) 34.3 
Anti SSb (>20 U/ml) 5(104) 4.8 
Lupus Anticoagulant  46(122) 32.9 
Anti-cardiolipin antibody (>12 U/ml) 27(123) 19.3 
Anaemia  (Hb < 10g/dl) 38 (140) 27.1 
Thrombocytopenia (<1,00,000/ mm
3
) 10 (140) 7.1 
Leukopenia (<3000 WBC/mm
3
) 3 (140) 2.1 
Urine Examination    
Proteinuria  47 (139) 33.8 
Pyuria  36 (140) 25.7 
Haematuria 28 (140) 20 
Urinary casts 14 (140) 10 
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SLEDAI score  
A total of 190 records were obtained for 140 patients including the follow up visits of the 30 
patients. 110 patients out of 140 had only a single study visit, while the remaining 30 
patients were seen over multiple follow up visits in view of recurrent, new or persistent 
mucocutaneous complaints. The maximum SLEDAI score seen in our study was 35 out of a 
maximum of 105 and the minimum score was zero. The mean SLEDAI score was found to 
be 8.79 ± 7.14 and the median SLEDAI (interquartile range) score was 8 (2-14) (fig- 7).  
 
Figure 7: SLEDAI score of 140 patients over 190 visits with the primary investigator 
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Association of lupus specific and non-specific lesions with SLEDAI score (Table-13) 
The association of SLEDAI score with lupus specific and lupus non-specific lesions was 
studied. The presence of skin lesions, either specific or nonspecific or both was found to 
have a statistically significant positive association with SLEDAI score (p <0.001). However, 
the strength of association was found to be marginally greater when there was co-existence 
of both lupus specific and lupus non-specific lesions in a patient (Kendal tau coefficient 
0.336), than with the presence of either lesion (Kendal tau coefficient 0.285). Patients with 
only lupus specific lesion/s or only lupus non-specific lesion/s did not show any statistically 
significant correlation with SLEDAI score.  
Table 13: Association of lupus specific and lupus non-specific lesions with SLEDAI 
score 
Lesion 
Number* 
(n) 
SLEDAI score 
Median (IQ) 
p value 
 
Kendal tau  
correlation  
coefficient 
 
Either lupus specific 
or lupus non-specific 
lesion/s 
Present 130 8.5 (4-15.2) 
<0.001 0.285 
Absent 60 4 (2-8) 
Both lupus specific & 
lupus non-specific 
lesions 
Present 34 13.5 (8- 20) 
<0.001 0.336 
Absent 156 6 (2-12) 
Only lupus specific 
lesions 
Present 32 6 (4-10) 
0.635 -0.029 
Rest 158 8 (2-14) 
Only  lupus non-
specific lesions 
Present 64 8 (2-14) 
0.608 0.032 
Rest 126 6 (2-13.2) 
*Number refers to frequency of skin lesions observed in 140 patients during the study period 
over 190 visits  
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The median SLEDAI score in patients with individual lupus specific and lupus non-specific 
lesions was calculated and their association with SLEDAI score was further analyzed 
(Tables-14-16 and Fig-8-10). It was found that ACLE and CCLE was found to have a 
statistically significant association with SLEDAI score (p <0.001 and 0.008 respectively). A 
single patient had bullous LE lesions and also had a high SLEDAI score of 34; however, its 
association with SLEDAI score was statistically insignificant.  
Malar rash and generalized ACLE lesions were found to have a statistically significant 
positive association with highest Kendall tau coefficient of 0.2 in case of malar rash.  In 
relation to lupus non-specific lesions statistically significant positive association with 
SLEDAI score was found with cutaneous vascular disease (p <0.001) and diffuse non 
scarring alopecia (p <0.001). Acanthosis nigricans was found to have statistically significant 
negative association with SLEDAI score (Kendal tau coefficient was minus 0.15).  
  
63 
 
Table 14 : Association of lupus specific lesions with SLEDAI score  
Lesion  
Number 
(n) 
SLEDAI score   
Median (IQ) 
p value 
Kendal 
tau  
correlatio
n  
coefficient 
ACLE 
Present 41 9 (6-18) 
<0.001 0.231 
Absent 149 6 (2-13) 
CCLE 
Present 21 10 (8-16.5) 
0.008 0.163 
Absent 169 6 (2-14) 
SCLE 
Present 11 6 (4-13) 
0.939 0.005 
Absent 179 8 (2-14) 
Bullous LE 
Present 1 34 
0.087 0.105 
Absent 189 8 (2-14) 
 
 
Table 15: Subtypes of lupus specific lesions and their association with SLEDAI score 
Lesion  
Number 
(n) 
SLEDAI score 
Median (IQ) 
p 
value 
Kendal tau  
correlation  
coefficient 
Malar rash 
/Localized ACLE 
Present 32 9.5 (6-18.7) 
0.001 0.2 
Absent 158 6 (2-13.2) 
Generalized ACLE 
Present 22 8 (6-19) 
0.022 0.141 
Absent 168 6.5 (2-14) 
Disseminated DLE 
Present 14 10 (6-16) 
0.082 0.107 
Absent 176 7 (2-14) 
Papulosquamous 
Present 12 7 (4-15.2) 
0.675 0.026 
Absent 178 8 (2-14) 
Localized DLE 
Present 7 12 (8-17) 
0.096 0.102 
Absent 183 7 (2-14) 
Annular 
Present 4 3 (2-7) 
0.166 -0.85 
Absent 186 8 (2-14) 
LE panniculitis 
Present 3 10.5 (3.5 -15.2) 
0.628 0.03 
Absent 187 7.5 (2-14) 
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Figure 8: Median SLEDAI score in the presence and absence of lupus specific lesions  
 
 
 
Figure 9: Median SLEDAI score in the presence and absence of lupus specific lesions 
(subtypes)  
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Table 16: Association of lupus non-specific lesions with SLEDAI score 
Non specific lesions  
Number 
(n) 
SLEDAI score 
Median  (IQ) 
p value 
Kendal tau  
correlation  
coefficient 
Non-scarring alopecia 
Present 62 10 (7-16) 
<0.001 0.256 
Absent 128 6 (2-12) 
a. Diffuse non- 
scarring alopecia 
Present 55 10 (8-16) <0.001 0.261 
Absent 135 6 (2-12) 
  
b. Lupus hair 
Present 11 18 (8-19) 
0.44 0.124 
Absent 179 7 (2-14) 
c. Alopecia areata 
 
Present 3 8 (6-10) 
0.836 0.013 
Absent 187 8 (2-14) 
Cutaneous vascular 
disease 
Present 40 14 (6.5-18.7) 
<0.001 0.265 
Absent 150 6 (2-12) 
a. Palpable purpura 
Present 20 16.5 (14-22) 
<0.001 0.355 
Absent 170 6 (2-12) 
b. Raynaud‟s 
phenomenon 
Present 18 12 (4-24) 
0.092 0.104 
Absent 172 7 (2-13.7) 
c. Periungual 
telangiectasia 
Present 7 18 (8–22) 
0.011 0.157 
Absent 183 7 (2-14) 
d. Livedo reticularis 
Present 4 17.5 (7-30.2) 
0.066 0.113 
Absent 186 7.5 (2-14) 
e. Digital 
ulcer/gangrene 
Present 4 15.5 (9.7-18.2) 
0.059 0.117 
Absent 186 7 (2-14) 
f. Urticarial 
vasculitis 
Present 3 4 (2-23) 
0.936 -0.005 
Absent 187 8 (2-14) 
Acanthosis nigricans 
Present 7 2 (0-5) 
0.011 -0.156 
Absent 183 8 (3-14) 
Urticaria 
Present 6 7.5 (3.5-11) 
0.985 -0.001 
Absent 184 8 (2-14) 
Sclerodactyly 
 
Present 1 4 
0.516 -0.040 
Absent 189 8 (2-14) 
Papulo-nodular mucinosis 
Present 1 6 
0.682 -0.065 
Absent 189 8 (2-14) 
Erythema multiforme 
Present 1 22 
0.115 0.097 
Absent 189 8 (2-14) 
Leg ulcers 
 
Present 1 16 
0.245 0.072 
Absent 189 8 (2-14) 
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Figure 10: Median SLEDAI score in the presence and absence of various lupus non-
specific lesions 
 
Mucosal lesions  
Mucosal lesions including hard palate involvement and nasal erosions, were found to have a 
statistically significant association with SLEDAI score (p<0.001) and the Kendal tau 
coefficient was 0.342.  
Lesion  Number (n) 
SLEDAI score 
Median (IQ) 
p value 
Kendal tau  
correlation  
coefficient 
 Mucosal lesions  Present  50 14 (8-19) <0.001 0.342 
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Expression of IL-17 in skin biopsies of lupus specific and lupus non-specific lesions 
(Tables 17 & 18) 
IL-17 immunohistochemistry staining was done on skin biopsies of 22 patients. The clinical 
diagnosis included lupus specific lesions in 15 patients and lupus non-specific lesions in 7 
patients. The expression of IL-17 in skin biopsies was expressed as number of IL-17 positive 
cells (fibroblasts, endothelial cells and lymphocytes) in 5 high power fields. The IL-17 count 
in the lupus specific and lupus non-specific lesions along with SLEDAI score at the 
corresponding visit has been tabulated below (Tables-17 & 18).  
Of the 15 patients with lupus specific lesions, 7 had ACLE, 5 had DLE and 3 had SCLE. In 
these patients the IL-17 count ranged from 24 to 400. It was found to be higher than 200 for 
the SCLE specimens, ranged from 24 to 280 for the ACLE specimens and 24 to 112 for all 
the DLE specimens.  Mean IL-17 count was higher in patients with SCLE than those with 
ACLE (p = 0.01) and CCLE (p <0.01). No statistical difference was noted in mean IL-17 
count in patients with ACLE and DLE (p = 0.39). In patients with non-specific lesions, the 
IL-17 count ranged from 57 to 307. It was found that the mean IL-17 count in lupus non-
specific lesions (146, median=168) was higher than the mean count in lupus specific lesions 
(134.2, median 80) but was not statistically significant (p = 0.83). 
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Table 17: IL-17 in lupus specific lesions 
Type of lesion 
(n=15) 
Clinical 
impression 
Histopathologic 
features 
Average IL-17 
count  (no of cells 
in 5 hpf) 
SLEDAI 
score 
Scaly papule - elbow SCLE LE specific 400 13 
Erythematous scaly 
plaque - arm 
SCLE s/o LE specific 400 8 
Erythematous  
macular rash – 
abdomen 
ACLE s/o LE specific 280 8 
Scaly papule – cheek SCLE s/o LE specific 204 18 
Erythematous papule 
– cheek 
ACLE s/o LE specific 194 8 
Erythematous papule 
– chin 
DLE s/o LE specific 112 7 
Erythematous plaque 
with scaling – 
preauricular area 
DLE s/o LE specific 89 10 
Erythematous plaque - 
forehead 
ACLE s/o LE specific 80 3 
Erythematous 
macular rash - back 
ACLE s/o LE specific 62 17 
Plaque over scalp with 
alopecia 
DLE s/o LE specific 44 22 
Erythematous  papule 
–  arm 
ACLE s/o LE specific 41 6 
Plaque over scalp with 
alopecia 
DLE LE specific 31 2 
Erythematous 
macular rash – cheek 
ACLE LE specific 28 22 
Erythematous   
macular rash – back 
ACLE LE specific 24 16 
Discoid plaque – arm DLE LE specific 24 19 
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Table 18: IL-17 count in lupus non-specific lesions 
Type of lesion 
(n=7) 
Clinical 
impression 
Histopathologic 
features 
Average IL-
17 count (no 
of cells in 5 
hpf) 
SLEDAI 
score 
Purpuric papule - 
palm 
Cutaneous 
vasculitis 
Vasculopathic reaction 307 27 
Erythematous 
papule – arm 
Urticarial 
vasculitis 
mucin deposits + 
thickened basement 
membrane+ perivascular 
lymphocytic infiltration 
178 19 
Purpuric papule - 
thigh 
Cutaneous 
vasculitis 
Interface dermatitis + 
dermal edema + 
telangiectasia 
+perivascular 
lymphocytic infiltrate 
171 14 
Purpuric papule - 
wrist 
Cutaneous 
vasculitis 
mucin deposits 
+thickened basement 
membrane+ perivascular 
and periadnexal 
neutrophilic and  
lymphocytic infiltration 
168 14 
Erythematous 
papule –leg 
Cutaneous 
vasculitis 
Vasculopathic reaction 82 20 
Purpuric macule - 
shin 
Cutaneous 
vasculitis 
Leukocytoclastic 
vasculitis 
59 9 
Erythematous 
papule - forearm 
Cutaneous 
vasculitis 
Vasculopathic reaction 57 18 
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Correlation of expression of IL-17 in lupus specific and lupus non-specific lesions with 
SLEDAI score (Fig 11 &12) 
There was no significant linear correlation between the IL-17 count in lupus specific lesions 
and SLEDAI score (Spearman‟s Rho R = -0.235) (fig-11). A linear correlation existed 
between IL-17 count of the seven patients with lupus non-specific lesions and SLEDAI 
score (R
 
= 0.487) (fig-12). However, the numbers studied were small.  
 
Figure 11 : IL-17 count in lupus specific lesions Vs SLEDAI score. The above scatter diagram depicts no 
linear relationship between them (R= -0.235).  
 
 
Figure 12 : IL-17 count in lupus non-specific lesions Vs SLEDAI score. The above scatter diagram shows 
a linear relationship between SLEDAI and IL-17 scores in lupus non-specific lesions (R= 0.487).   
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DISCUSSION 
Paediatric SLE forms about 10%- 25% of all SLE cases(4,20,24,27–32). Skin and mucosa 
are one of the most common „organs‟ involved in pSLE seen in 60%-90%of the patients(29). 
Mucocutaneous involvement forms an important component of the ACR(56) and SLICC 
SLE criteria(57) as well as the various disease activity and damage scoring systems(120).   
Our primary objective was to study the profile of mucocutaneous lesions occurring in pSLE 
as there are limited prospective studies on the same from India. Skin lesions in SLE have a 
prognostic significance and are important indicators of disease activity(65,103). Further, 
there have been no Indian studies on IL-17 expression in biopsy specimens of cutaneous 
lesions of lupus erythematosus.   
The comparative profile of demographic data and data on mucocutaneous involvement in 
our study and other studies on pSLE has been tabulated (Tables 19-22) 
Age  
In our study, the age of the patients at the time of inclusion in the study ranged from 0.3 to 
33 years with a mean of 13.9 ± 3.9 years. The mean age of diagnosis of SLE was 11.8 ± 2.9 
years and was comparable with other prospective studies(11,23,35,41,42) with similar age 
inclusion criteria (onset ≤16 years) ranging from 12 to 13 years. However, in the absence of 
definite age cut off to delineate pSLE patients from those with adult onset SLE, various 
Indian and foreign authors have used variable age limits of upto 14 years(4,36,51), 15 
years(11,34), 16 years(23,25,35,40,42,44), 17 years(41) and 18 years(28,45,46,49) as for 
defining patients with pSLE. The age of onset and diagnosis has been found to vary in these 
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studies accordingly. The cut off age of 16 years adopted in our study corresponds to the cut 
off age adopted by the department of Paediatrics of the institution.  
The number of patients with SLE diagnosed in pre-pubertal (13.6%) and post-pubertal 
(53.6%) age group was higher in our study in comparison to pSLE patients in a Chinese 
study(101) (8.3% and 40% respectively). Number of patients with pSLE diagnosed in the 
pubescent age was relatively lower in our study in comparison to that of the Chinese 
study(101)(31.4% against 51%). The differences could be attributed to ethnic variations and 
different age cut off values.  
Gender 
The F:M ratio in our study was 4.6:1 which was similar to two previous studies(36,40) 
which reported a F:M ratio of 5.2:1 and 4.9:1 respectively. However, other studies on pSLE 
have reported the F:M ratio to be lower than the present study of 2.3:1 to 3.8:1 (4,37,38,44) 
and in other cases higher than that found in the present study of 6:1 to 
10.3:1(23,25,28,34,39,43,48,49,51).  
In the present study, patients diagnosed with SLE in prepubertal age group, the F: M ratio 
was lower (2.2:1) than the pubertal (4.8:1) and post-pubertal (5.8:1) age groups. This was 
similar to a French study(24) where the F: M ratio was 2:1 in the prepubertal and pubertal 
children, but 2.7:1 in post-pubertal patients. In a Chinese study(101) the F: M ratio was 
higher (7:1) in prepubertal age group than in pubertal (2.5:1) and post-pubertal (4.6:1) pSLE 
patients. However, there were only 8 patients in the prepubertal age group in this study(101). 
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     Table 19:  Comparative profile of the demographic data between the present study Vs previous studies on pSLE from India  
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Place Vellore Mumbai 
Chandig
arh 
Kolkata 
New 
Delhi 
Vellore Chennai 
New 
Delhi 
Mumbai 
Year of publication 
2011-
13* 
2013 2012 2010 2009 2009 1994 1993 1989 
Number of patients 140 25 40 44 54 70 59 83 20 
Study design Cs Cs Cs P R R R R B 
Mean age at 
diagnosis in years 
11.8 ± 
2.9 
9.2 12
 
- 
10.4 ± 
2.6 
 
10.5 - - 9.37 
Inclusion age group 
in years 
≤16 5-14 5-16 ≤12 2.5-14.4 4-15 <16 ≤16 <14 
F:M ratio 4.6:1 5.2:1 5.7:1 3.8:1 2.9:1 6:1 4.9:1 9.3: 1 2.3: 1 
     
     *years of study, R – Retrospective, P – Prospective, Cs – Cross-sectional, B – Bidirectional 
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Table 20: Comparative profile of the demographic data between the present study Vs previous studies on pSLE (excluding   
Indian studies) 
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Study design Cs P P R R Cs P B P P R P R P P 
No of patients 140 198 45 78 207 56 230 256 50 33 153 49 31 57 34 
Mean age at 
diagnosis in 
yrs 
11.8 
± 2.9 
12.6 
12.8 
± 2.5 
14 ± 
2.7 
10 ± 
2.7 
15 16.4 
13.1 
± 3.1 
12.9 
± 2.4 
- 
13.5 
± 5.5 
- 12.3 13 14 
Inclusion age 
group in years 
≤16 <17 <16 8-18 
2-
16 
9-18 <  18 3-18 <16 5-17 - <18 - 4-15 5-14 
F:M ratio 4.6:1 5.6: 1 4:1 10: 1 
2.7: 
1 
5.2: 1 9: 1 4.7:1 9: 1 6.6: 1 5.9: 1 6: 1 4.2: 1 4.2: 1 
10.3 : 
1 
*years of study, R – Retrospective, P – Prospective, Cs – Cross-sectional, B – Bidirectional   
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Mucocutaneous lesions in pSLE  
In most studies on pSLE, mucocutaneous manifestations of pSLE have been reported only in 
terms of photosensitivity, malar rash, discoid rash and oral ulcers as they form a part of the 
ACR criteria. Descriptive studies on the mucocutaneous manifestations of pSLE are 
sparse(6,11). Our study is the largest cross-sectional study on pSLE from India to the best of 
our knowledge.  
In the present study, a total of 77.9% of pSLE patients had mucocutaneous lesions during 
the course of their disease. This was comparable with other studies including a similar 
prospective study done by a paediatric dermatology division in Thailand where it was found 
to be 77%(11) as well as a retrospective Indian study where it was found to be 69.4%(40). A 
lower prevalence of mucocutaneous lesions ranging from 36%-62.5% was reported in few 
other Indian studies(4,35–37) .  
According to Gilliam and Sonthemier classification(53,62), the skin lesions occurring in 
SLE could be lupus specific and lupus non specific and their relative prevalence varies. In 
our study, of the 93 patients with cutaneous lesions, 58% had lupus specific lesions, 78.5% 
had lupus non-specific lesions and 36.5% had both. Our results were comparable to that of a 
retrospective British study(6) involving 25 pSLE patients, of whom, 72% had lupus specific 
lesions, 60% had lupus non-specific lesions and 32% had both.  
The lesions of ACLE (47.8%) (localized-34.2% and generalized-25.7%) were the most 
frequent lupus specific lesions during the course of their disease. The prevalence of malar 
rash in our study was comparable with two other retrospective studies which reported a 
prevalence of 30%(4) and 38.2%(44). There is a wide variability in the reported prevalence 
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of malar rash. According to a prospective study on skin lesions of pSLE based in 
dermatology division in Thailand(11), the reported prevalence of malar rash as 74% while it 
was  as low as 20% (5/25) according to a British study(6). Most other studies on pSLE have 
reported a prevalence of malar rash  ranging from 44%-83% (23,25,28,36,41,43,45,46,49–
51).  
CCLE was seen in 17.9% of the patients of whom 11.4% had disseminated DLE and 6.4% 
had localised DLE. The results were comparable to data from prospective and retrospective 
studies on pSLE/pCLE done in dermatology departments as well as non-dermatological 
setting  which reported a prevalence of CCLE in 8%-20% of the patients  
(6,11,28,41,44,45,50,51,121) . Unlike adults, in the paediatric age group, both localised and 
disseminated DLE  have been reported to have an equal risk for progression to SLE (70,71).  
The prevalence of SCLE in pSLE has been reported to be between 4%-9.6%(11,39,45) and 
this was similar to that found in our study which was 7.1%. While all our patients with 
SCLE had papulosquamous lesions with 3 of them having concomitant annular lesions, 
Dickey et al(6) found annular variant of lesions to be twice as common as the 
papulosquamous variety in their patients.   
LE panniculitis was seen in 1.4% of our patients, comparable to data reported by Mondal et 
al(2.3%)(37).  
Bullous LE was seen in only one patient (0.7%) which was confirmed on biopsy and DIF. A 
low prevalence of bullous LE (2%) was also reported by Wananukul et al(11).  
Alopecia was noted in 64.2% of our patients during the course of their disease. Non scarring 
alopecia (including diffuse non-scarring type, lupus hair and alopecia areata) was a feature 
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noted in 35.7% of our patients during the study period. Studies similar to ours have reported 
a lower prevalence of non scarring alopecia varying from 16%- 26%(6,11). Alopecia has 
been reported in 83.1% of pSLE patients in a retrospective Indian study(25). Scarring 
alopecia in SLE occurs as a result of discoid lesions involving the scalp and was observed in 
5.7% of our patients which was comparable to that reported by Wananukul et al who 
reported a prevalence of 5%(11).   
Cutaneous vascular disease was seen in 35% of our patients and was similar with that 
reported by Dickey et al (6) who reported a prevalence of 36%.  
Cutaneous vascular disease included Raynaud‟s phenomenon, palpable purpura, periungual 
telangiectasia, digital ulcer and gangrene, livedo reticularis and urticarial vasculitis which 
was seen in 12.1%, 11.4%, 5%, 2.8%, 2.8% and 1.4% of our patients respectively. The 
prevalence of Raynaud‟s phenomenon was similar to that of other Indian studies that 
reported a prevalence of 10%(4) and 12.5%(39). High prevalence of Raynaud‟s  ranging 
from 36%- 39% has been reported in patients from the west(45,49). Wananukul et al(11) 
reported urticarial vasculitis in 2% of their patients which was comparable to that of our 
study which was 1.4%.   
Acanthosis nigricans was noted in 5% of our patients. While it has been described as a lupus 
non-specific lesion, it could occur as a result of childhood obesity and corticosteroid therapy 
for SLE. No studies on pSLE have described the prevalence of acanthosis nigricans.  
Photosensitivity was reported by 32.9% of pSLE patients in our study. Prevalence of 
photosensitivity has found to be as high as 73.5%(25) and 87%(39) in studies from northern 
India. Variable prevalence of photosensitivity may be attributable to differences in skin type, 
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climactic and geographical differences as well as the patient‟s understanding of the skin 
lesions being attributable to sun exposure.  
Oral ulcers were seen in 54.3% of our patients during the course of their disease. This was 
comparable to the prevalence reported by Wananukul et al of 46%(11) and other prospective 
studies(28,41,49,51) which reported a prevalence ranging from 38%-49.1%.   
Nasal ulceration was noted in only one of our patients with SLE, however, was reported in 
10% of patients by Hiraki et al(46) and has not been mentioned in most studies.  
Miscellaneous lesions 
Some of the miscellaneous skin lesions seen in our pSLE patients have been discussed 
below. 
Acquired ichthyosis has been reported in SLE and other autoimmune conditions and has 
been suggested to be a marker of autoimmunity(122–124). It may probably occur as a 
manifestation of abnormal host immune response with involvement of granular layer of the 
skin and keratohyaline granules(125) . It may range from minor dryness and roughness to 
large plaques with desquamation, especially symmetrically involving the extensor aspect of 
the limbs. About 13.5% of our pSLE patients had acquired ichthyosis. The occurrence of 
acquired ichthyosis in paediatric SLE has been rarely reported(126).  
Herpes zoster has been found to be one among the commonest viral infection affecting 
patients with SLE(127) and reported as the fourth commonest major infection occurring in 8 
out of 120 patients with pSLE, analyzed over two years(128).  Another study from USA 
reported that out of 170 patients with pSLE seen over 12 yrs, 9 had herpes zoster(127), and 
that all patients who had herpes zoster were found to have a significant rise in the disease 
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activity prior to onset of infection and were on prednisolone along with adjuvant 
immunosuppresants(127,128).  In our study, 3 patients with SLE developed herpes zoster. 
Of the three, 2 developed the same during the study period and their SLEDAI score was 2 
and 16 at the time of presentation with zoster.  
Scabies is a common infestation occurring in immunocompetent and immunocompromised 
individuals with a prevalence of 5-10% in India(129,130). It is disproportionately higher in 
children hailing from low socio-economic status(129). SLE and other conditions requiring 
treatment with immunosuppresants have been identified as a predisposing factor for crusted 
scabies(131). In our study, 3 patients were found to have scabies, one of whom had crusted 
scabies. The patient with crusted scabies was on 0.5mg/kg of steroid. Crusted scabies in 
SLE(132–134) and also scalp infestation of 2 SLE patients with Sarcoptes scabiei mite has 
been reported(135). However, occurrence of crusted scabies in pSLE has not been 
previously reported.  
Granuloma annulare has not been reported in association with pSLE and the occurrence of 
granuloma annulare in SLE is rare(136,137). One of our patients was found to have 
recurrent annular lesions with superficial scaling and was initially thought to have SCLE. 
However, repeated biopsies from the lesion were suggestive of granuloma annulare.  
Mucocutaneous pigmentation has been reported in 10-25% of the patients on 
hydroxycholoroquine(138).In our study, 6.3% of patients were found to have pigmentation 
thought to be secondary to use of hydroxycholorquine. 
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Table 21: Comparative profile of mucocutaneous lesions between the present study Vs previous Indian studies  
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Mucocutaneous lesions 
(cumulative) 
77.9 36* 62.5 54 
69.4*
 
 
- 60 
Photosensitivity 32.9 - - - 20.3 73.5 
- 
Malar rash 34.2 44 - - - 
83.1 
 
30 
Discoid lesions 17.9 - - 4.5 - - - 
SCLE 7.1 - - - - - - 
Lupus panniculitis 2.1
# 
- - 2.3 - - - 
Alopecia 64.2 - - 20 49 83.1 25 
Digital ulcer/gangrene 2.8
# 
  2.3    
Raynaud’s phenomenon 12.1
# 
- - - 0 28.9 10 
Oral ulcers 54.3 12 30 20 37.2 - 10 
Others - - - - - - 
5**
 
 
The figures are in percentage; *cutaneous rash, ** each of genital ulcer, necrotic lesion and hyperpigmentation, # during study duration 
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Table 22: Comparative profile of mucocutaneous lesions between the present study Vs previous studies (excluding Indian 
studies) 
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lesions (cumulative) 
77.9 - 92.3 - - - - - - - 77 - 
Photosensitivity 32.9 ~30 73 44 44.6 20 53 24 40.8 39 40 44 
Malar rash 34.2 ~60 76.9 38.2 69.6 66 70.4 74 59.1 71 74 79 
Discoid lesions 17.9 ~10 35.8 10.1 18.9 - 12.6 8 26.5 10 19 15 
SCLE 7.1 - - - 9.6 - - - - - - - 
Alopecia 64.2
 
- 52.5 39.6 41.4 29 - 22 - 48 32 - 
Digital ulcer/gangrene 2.8
# 
- - - - 5 - - - - - - 
Raynaud’s 
phenomenon 
12.1
# 
- - - 39.3 19 - 10 36.7 26 - 20 
Oral ulcers 54.3
 
~40 67.9 22.2 28.6 30 49.1 20 40.8 48 46 38 
Others  - - - 
3.6
g 
, 
9.4
c 
10
n 
43* 
- - - - - - 
The figures are in percentage; *cutaneous rash, # during study duration, g – genital ulcer, c – chilblain, n – nasal ulcer  
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SLEDAI score 
We used SLEDAI-2K(98) (Annexure I) in our study as it takes into account not only new 
onset proteinuria, rash, oral ulcers or alopecia, but also the persistence of these parameters in 
the patient which indicates ongoing disease activity(98).  
 The SLEDAI score in our patients ranged between 0 and 35. The mean SLEDAI score was 
found to be 8.79 ± 7.14 and the median SLEDAI (interquartile range) score was 8 (2-14). 
This was comparable with the SLEDAI scores in the Chinese pSLE patients with the mean 
ranging from 10.6-14.7 depending on the age group of pSLE patients(101). Hiraki et al(46) 
reported a mean SLEDAI score of 13.1 ± 8.4 in their patients at the time of diagnosis.  In 
our study, there were 5.7% patients (8/140) who were treatment naïve at the time of 
inclusion into the study with disease duration ranging from 0 to 3 months and mean 
SLEDAI score at presentation was 13.25 ± 7. This was comparable to that reported by 
Hiraki et al(46). 
In our study we studied the association of pSLE related skin manifestations with disease 
activity. We found that presence of skin lesions - either lupus specific or nonspecific lesions 
in a patient with pSLE had a higher disease activity than those without these lesions (p 
<0.001). Patients with both lupus specific and non specific lesions concomitantly were 
found to have a higher disease activity than those with either lesion (p <0.001).  This is 
evident by the fact that presence of mucocutaneous lesions including vasculitis, 
inflammatory rash (specific lesions), alopecia and oral ulcers adds to the SLEDAI score by 
8, 2, 2 and 2 respectively. As there were no similar studies on pSLE for comparison, we 
compared our results with a study on adult SLE patients(65). Zecevic´ et al(65) found that 
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the median SLEDAI scores were higher in patients with both lupus specific and non-specific 
lesions simultaneously than with either lesion exclusively. However, patients with only 
lupus non-specific lesions had a higher SLEDAI score than patients with only lupus specific 
lesions. The comparative data has been tabulated (Table-23).  
Table 23: Comparison of SLEDIA score in skin lesions between the present study and 
a study on adult SLE(65) 
Parameter 
Present study 
(pSLE) 
Zecevic et al(65) 
(adult SLE) 
Total number of patients 140 66 
Total number of patient visit records and 
SLEDAI scores 
190 65 
Total number of patients with either lupus 
specific or lupus non-specific lesions 
93 65 
Only lupus specific lesions 32/ 190 (16.84 %) 38/ 65 (58.46%) 
Median SLEDAI score 
(± standard error) 
6 ± 0.895 
6.5 ± 0.58 
 
Only lupus non-specific lesions 64/ 190 (33.68%) 
4/65 (6.15%) 
 
Median SLEDAI score 
(± standard error) 
8 ± 0.893 
17.5 ± 2.14 
 
Both lupus specific and non-specific lesions 34/190 (17.9%) 35.38% 
Median SLEDAI score 
(± standard error) 
13.5 ± 1.28 18 ± 1.69 
 
It can thus be inferred that unlike non-specific lesions, the presence of lupus specific lesions 
alone does not confer a high disease activity. This could be explained by the difference in 
underlying pathophysiologic mechanisms in lupus(65). T-cell mediated inflammation is 
responsible for specific lesions which may not involve widespread involvement/damage; 
whereas immune complex mediated damage is responsible for non-specific lesions like 
vasculitis and is more often associated with greater systemic damage thus higher disease 
activity.  This is further substantiated by the differential weightage given to various 
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mucocutaneous lesions on the SLEDAI, i.e., vasculitis has been given a score of 8; while an 
inflammatory cutaneous rash (specific lesions) have been given a score of 2 on the SLEDAI 
scale.  
In our study the mean SLEDAI noted in patients with ACLE(12.56) was comparable to that 
reported by Zecevic et al in adult SLE (12.51)(65).  
No significant association between individual lupus specific and non-specific lesions and 
disease activity was noted by Zecevic et al(65). In our study, specific lesions ACLE (both 
malar rash and generalized ACLE) and CCLE were found to have a positive association 
with SLEDAI (p <0.001 and 0.008 respectively) and no such association was noted in case 
of SCLE. Localized DLE and disseminated DLE when analyzed separately did not have any 
statistically significant association with SLEDAI. 
Although the patient with bullous LE had a very high SLEDAI score of 34, the association 
was not statistically significant since it involved only one patient.  
Interestingly annular lesions of SCLE were found to have a high negative Kendal tau 
correlation coefficient (τ = - 0.85) disease activity; however the association was not 
statistically significant due to small numbers studied.  
Non-scarring alopecia and cutaneous vascular disease were found to correlate with disease 
activity (p <0.001, τ = 0.25 and 0.26 respectively). Individual lesions including diffuse non 
scarring alopecia (telogen effluvium), palpable purpura and periungual telangiectasia 
showed a significant association (p <0.001, <0.001, 0.011, τ = 0.26, 0.35 and 0.15 
respectively). Although patients with livedo reticularis, digital ulcer/gangrene, erythema 
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multiforme and leg ulcers had high median SLEDAI scores, the association was not 
statistically significant due to relatively low numbers. Mucosal lesions too were associated 
with disease activity (p <0.001, τ = 0.342). 
Acanthosis nigricans had a statistically significant negative correlation (p = 0.011) with 
disease activity, however, the Kendal tau correlation coefficient value was low (-0.156).  
IL-17 in cutaneous lesions of lupus erythematosus 
A number of cytokines including IL-6, IL-10, IL-12, IL-17, IL-22, IL-23, Type 1 IFN and 
TNF-α have been implicated in the pathogenesis of SLE(9,112). The roles of various 
cytokines in disease causation and pathogenesis varies and are potential therapeutic 
targets(9).  While the levels of these cytokines in patients with lupus have been studied in 
the past, there are few studies on the expression of these cytokines in skin lesions(112,117). 
Through our study we aimed to understand the interplay of IL-17 in lupus specific and non-
specific lesions and whether there was any correlation between its expression in skin with 
disease activity.  
A total of 22 patients had skin biopsies done for the IL-17 immunohistochemical staining, of 
which clinically 15 had lupus specific lesions, 7 had non-specific lesions.  Of those with 
lupus specific lesions, 7 patients had ACLE, 5 had DLE and 3 had SCLE.  IL-17 count – 
measured as IL-17 positive cells including lymphocytes, fibroblasts, and endothelial cells in 
5 high power fields, was found to be higher than 200 for the SCLE specimens, ranged from 
24 to 280 for ACLE specimens and was upto 112 for all the DLE specimens.  Mean IL-17 
count was higher in patients with SCLE than those with ACLE (p = 0.01) and CCLE (p 
<0.01). No statistical difference was noted in mean IL-17 count in patients with ACLE and 
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DLE (p = 0.39). While Tanasescu et al(117) reported that IL-17 expression in lymphocytes 
was found to be significantly higher in lesional skin of all patients (n=66) including DLE, 
SCLE and normal skin in SLE than in healthy controls (p <0.001), in another study(112), 
84.8% of lesional skin specimens (n=33) stained positively for IL-17. In both these 
studies(112,117), no significant differences were noted in pattern of expression of IL-17 
among various specific cutaneous lesions of LE.  
In patients with lupus specific lesions the IL-17 count ranged from 24 to >400 while in 
patients with non-specific lesions, the IL-17 count ranged from 57 to 307. It was found that 
the mean IL-17 count in lupus non-specific lesions (146, median=168) was higher than the 
mean count in lupus specific lesions (134.2, median 80) but was not statistically significant 
(p = 0.83). 
It has been proposed that significant expression of IL-17 in cutaneous lesions of lupus 
implies the role IL -17 in the pathogenesis of skin lesions of LE(112,117). It is unclear 
whether the presence of IL-17 in skin is the cause or effect of skin lesions of lupus(117). 
However, since  high levels of the same have been demonstrated in serum and even in 
normal skin of patients with lupus(117) it is likely that IL-17 as a proinflammatory cytokine 
plays a role in both systemic as well as cutaneous manifestations of lupus. TH17 
lymphocytes may be implicated in the cutaneous and visceral lesions on SLE(35,117).   
Correlation of expression of IL-17 with SLEDAI scores 
While previous studies on cutaneous IL-17 expression included patients with SLE as well as 
DLE and SCLE without systemic involvement(112,117), in our study, IL-17 expression was 
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studied in pSLE patients with different specific and non-specific lupus lesions. There have 
been no previous studies on correlation of SLEDAI and IL-17 expression in skin.  
In our study, there was no statistically significant linear correlation of IL-17 expression in 
lupus specific lesions with SLEDAI score, but a linear correlation was noted in case of IL-
17 expression in non-specific lesions and SLEDAI score (R=0.487). However, the number 
studied was small. In a study done on expression of IL-17 in lupus specific cutaneous 
lesions(112), no correlation was found between IL-17 expression and Cutaneous Lupus 
Erythematosus Disease Area Severity Index (CLASI) which is a measure of disease activity 
and damage.  
Previous studies(113,117,121) involving adult SLE patients have shown that the serum 
levels of IL-17 were found to be higher in patients with SLE in comparison with healthy 
controls. However, one of the studies found no correlation of the same with SLEDAI(121). 
An Indian study(35) on pSLE (n=40) reported that high serum levels were found in pSLE 
patients in comparison with controls and correlated with SLEDAI (R=0.447) . They also 
found that patients with cutaneous involvement had high serum IL-17 levels (p=0.002). 
Serum IL-17 analysis was not done in our patients.  
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CONCLUSIONS  
 In our study on 140 patients with pSLE, the prevalence of mucocutaneous lesions was 
77.9%. The mean age at diagnosis of SLE was 11.8  2.9 years and the female to male 
ratio was 4.6:1. The prevalence of mucocutaneous lesions and demographic features in 
our study were similar to that reported by majority of the studies.  
 The relative prevalence of most of the individual mucocutaneous features was found to 
be similar to previous studies done in dermatological and non-dermatological settings.   
However, the prevalence of malar rash was relatively lower in our study (34.2% against 
44%-83%).  
 ACLE was the commonest lupus specific lesion seen in 47.8% (malar rash in 34.2% and 
generalized ACLE in 25.7%) where as SCLE and CCLE were seen in 17.9% and 7.1% 
of the patients respectively. Alopecia (64.2%) and cutaneous vascular disease (35%) 
were the most frequent non-specific lesions. Oral ulcers were seen in 54.3% patients 
while 32.9% patients had photosensitivity. Lupus nephritis (54.3%) and arthritis (26.4%) 
were the commonest forms of systemic involvement.  
 The mean SLEDAI score in our patients was 8.79 ± 7.14 and the median SLEDAI (inter-
quartile range) score was 8 (2-14). 
 LE related lesions were found to have a prognostic significance and the presence of 
either lupus specific or non-specific lesion was associated with higher SLEDAI score (p 
< 0.001).   
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 The SLEDAI score was higher in the presence of both lupus specific and non-specific 
lesions concomitantly than with presence of either lesion alone (p < 0.001).  
 Lupus non-specific lesions were found to be associated with higher SLEDAI score than 
lupus specific lesions but this was not statistically significant (p = 0.32) 
 Lupus non-specific lesions were found to be associated with higher mean IL-17 
expression than lupus specific lesions (p = 0.83). 
 Among lupus specific lesions, there was no statistical difference in IL-17 expression 
between ACLE and DLE (p = 0.39) but the mean IL-17 expression was higher in case of 
patients with SCLE than with ACLE (p = 0.01) or DLE (p < 0.01).   
 A linear correlation was found to exist between IL-17 expression in lupus non-specific 
lesions with SLEDAI score (R = 0.487). There was no significant linear correlation 
between the IL-17 expression in lupus specific lesions and SLEDAI score (R = -0.235).  
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LIMITATIONS AND RECOMMENDATIONS 
 
Limitations  
1. The sample size required for studying the correlation of IL-17 expression with 
SLEDAI score fell short by 2 patients. It was studied in 22 patients instead of 24 
patients as calculated as some eligible patients were unwilling for a skin biopsy, 
especially from a lesion on the face. 
2. Previous treatment received by the patient may have influenced the SLEDAI score. 
Since our hospital is a tertiary care centre and serves as a referral centre for 
paediatric rheumatology patients, most patients were on treatment prior to their 
inclusion into the study.   
3. In patients without medical records, we had to rely on historical data of disease 
duration of SLE and age of diagnosis. 
Recommendations 
 All patients with pSLE must be evaluated by the dermatologist at presentation and 
follow up, must be screened for mucocutaneous lesions as they serve as important 
indicators of disease activity. 
 More studies need to be done to assess the role of IL-17 in pathogenesis of skin lesions 
in SLE. Resuts of these studies may influence the use of biological agents such as 
Brodalumab (anti-IL-17 receptor antibody), Ixekizumab and Secukinumab (anti-IL-17 
antibody) in the management of SLE patients with skin lesions. 
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SUMMARY 
Background 
SLE is the most common connective tissue disorder occurring in children and about 15% of 
all SLE patients have paediatric onset of the disease. The clinical course and mucocutaneous 
features in pSLE are known to be different from that in adults and mucocutaneous features 
have a prognostic significance in SLE. Interleukin-17 is one of the newer pro-inflammatory 
cytokines that has been found to have a role in pathogenesis of SLE and related skin lesions. 
pSLE is not a well researched subject in the sub-continent and paucity of studies on skin 
lesions in pSLE and IL-17 expression in LE related skin lesions prompted us to take up this 
study.   
Objective  
Our primary objective was to study the profile of cutaneous lesions in patients with 
paediatric onset systemic lupus erythematosus. Secondary objectives were to study the 
association of SLEDAI score with lupus specific and non-specific lesions and to study of 
expression of Interleukin – 17 (IL-17) in skin biopsies of lesions seen in paediatric onset 
SLE and its association with SLEDAI score.  
Methods 
A hospital based cross-sectional study was conducted in department of Dermatology, 
Venereology and Leprosy, Christian Medical College, Vellore over a period of 27 months 
with approval from the Institution Review Board (IRB No. 7626).  Patients with onset of 
SLE ≤ 16 years were screened at the Dermatology and Paediatric Rheumatology out-patient 
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clinic and included in the study after obtaining an informed consent. Demographic and 
clinical data including details of mucocutaneous features were recorded and disease activity 
at the time of visit to the hospital was calculated using SLEDAI-2K. Details of follow up of 
a small subset of patients (30/140) with recurrent, persistent or new onset mucocutaneous 
complaints were recorded. Patients with active skin lesions who were willing for biopsy 
were included for the analysis of IL-17 expression in skin biopsies after histopathological 
examination. Based on the study by Oh et al(112), the sample size required for studying the 
association of IL-17 expression in biopsies of skin lesions with SLEDAI score was 
calculated to be 24 patients with 80% power and 5% level of significance. Data on skin 
lesions was expressed in numbers and percentages and association of SLEDAI score with 
mucocutaneous lesions was studied using t-test and Kendall‟s tau statistics. Correlation 
between IL-17 expression and SLEDAI score was done using Spearman‟s Rho correlation 
coefficient. The data was analyzed using SPSS version 17.0.  
Results 
A total of 140 patients with onset of SLE ≤ 16 years were included in the study over a 
duration of 27 months, of which 80.7% patients were ≤ 16 years of age and 19.3% were 
aged >16 years at the time of inclusion into the study. There were a total of 115 females and 
25 males and the F: M ratio was 4.6:1. The mean age at diagnosis of SLE was 11.8  2.9 
years, in males it was 10.9 ± 3.4 years and in females it was 11.8 ± 2.8 years. Majority of the 
patients were from Tamil Nadu (41.4%), West Bengal (16.4%) and Andhra Pradesh 
(15.7%).   
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A total of 109 (77.9%) patients had mucocutaneous lesions during the course of their disease 
and 100 (71.4%) patients had mucocutaneous lesions during the study period. Alopecia 
(64.2%) and oral ulcers (54.3) were the most common lesions during the disease course. 
There were 100/140 (71.4%) patients  who had mucocutaneous lesions during the study 
period and  93/100 patients had skin lesions (with or without mucosal lesions) including 
lupus specific lesions only in 20 patients, lupus non-specific lesions only in 39 patients and 
34 patients had both lupus specific and lupus nonspecific lesions concomitantly. 7/100 
patients had oral mucosal lesions only. During the study period, lupus specific lesions 
including ACLE, SCLE, CCLE and bullous LE were seen in 25.7%, 14.3%, 6.4% and 0.7% 
of the patients respectively while lupus non specific lesions including non-scarring alopecia 
and cutaneous vascular disease were seen in 35.7% and 25% of the patients respectively. 
Forty-six (32.9%) patients had photosensitivity. Lupus nephritis (76, 54.3%) and arthritis 
(37, 26.4%) were the commonest forms of systemic involvement.  
The mean SLEDAI score in our patients was 8.79 ± 7.14 and the median SLEDAI (inter-
quartile range) score was 8 (2-14). Patients with either lupus specific or nonspecific lesions 
had a higher SLEDAI score than those without skin lesions (p <0.001). Patients with both 
lupus specific and non specific lesions concomitantly were found to have a higher SLEDAI 
score than those with either of the lesions (p <0.001). The mean and median SLEDAI score 
of patients with only lupus non-specific lesions was higher than that of patients with only 
lupus specific lesions, but the difference was not statistically significant (p = 0.32). 
Individual lesions associated with higher SLEDAI score included ACLE (both localized and 
generalized) (p <0.001), CCLE (p <0.01), diffuse non-scarring alopecia (p <0.001), 
cutaneous vascular disease (p <0.001) including palpable purpura (p <0.001) and periungual 
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telangiectasia (p = 0.01). Mucosal lesions were also associated with disease activity (p 
<0.001). 
IL-17 expression was noted in all the 22 skin biopsies performed, including 15 lupus 
specific lesions and 7 lupus non specific lesions. The mean IL-17 count in lupus non-
specific lesions (146) was higher than the mean count in lupus specific lesions (134.2) but 
was not statistically significant (p = 0.83).Among lupus specific lesions mean IL-17 count 
was higher in patients with SCLE than those with ACLE (p = 0.01) and CCLE (p <0.01). No 
statistical difference was noted in mean IL-17 count in patients with ACLE and DLE (p = 
0.39). There was no significant linear correlation between the IL-17 expression in lupus 
specific lesions and SLEDAI score (R = -0.235) but a linear correlation was noted in case of 
IL-17 expression in patients with lupus non-specific lesions and SLEDAI score (R
 
= 0.487). 
However, the number of observations was small.    
Conclusions 
In our study done on 140 patients with pSLE, we found that the demographic features and 
prevalence of mucocutaneous features in our patients were similar to that previously 
reported. The relative prevalence of most of the individual mucocutaneous features was 
found to be similar to previous studies done in dermatological and non-dermatological 
settings.   However, the prevalence of malar rash was relatively lower in our study. ACLE 
(47.8%) was the commonest lupus specific lesion and alopecia (64.2%) was the most 
frequent non-specific lesion. Oral ulcers were seen in 54.3% patients while 32.9% patients 
had photosensitivity. Lupus nephritis (54.3%) and arthritis (26.4%) were the commonest 
forms of systemic involvement. The mean SLEDAI score in our patients was 8.79 ± 7.14 
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and the median SLEDAI (inter-quartile range) score was 8 (2-14) was comparable to 
previous data. LE related lesions were found to have a prognostic significance and the 
presence of either lupus specific or non-specific lesion was associated with higher SLEDAI 
score (p <0.001). The SLEDAI score was higher in the presence of both lupus specific and 
non-specific lesions concomitantly than with presence of either lesion alone (p<0.001). 
Lupus non-specific lesions were found to be associated with higher SLEDAI score than 
lupus specific lesions but this was not statistically significant (p = 0.32). Lupus non-specific 
lesions were found to be associated with higher mean IL-17 expression than lupus specific 
lesions but this was not found to be statistically significant (p = 0.83). Among lupus specific 
lesions, there was no statistical difference in IL-17 expression between ACLE and DLE (p = 
0.39) but the mean IL-17 expression was higher in case of patients with SCLE than with 
ACLE (p = 0.01) or DLE (p <0.01). A linear correlation was found to exist between IL-17 
expression in lupus non-specific lesions with SLEDAI score (R = 0.487) but the number of 
observations were small. There was no significant linear correlation between the IL-17 
expression in lupus specific lesions and SLEDAI score (R = -0.235).  
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Annexure I 
 
Systemic Lupus Erythematosus Disease Activity Index – 2000 (SLEDAI -2K) 
Enter weight in SLEDAI score column if descriptor is present at the time of visit or in the 
preceeding 10 days. 
Wt SLEDAI  
Score  
Descriptor Definition 
8  Seizure Recent onset, exclude metabolic, infectious or drug cause. 
8  Psychosis Altered ability to function in normal activity due to severe 
disturbance in the perception of reality. Include 
hallucinations, incoherence, marked loose associations, 
impoverished thought content, marked illogical thinking, 
bizarre, disorganized, or catatonic behavior. Excluded 
uremia and drug causes. 
8  Organic 
Brain 
Syndrome 
Altered mental function with impaired orientation, memory 
or other intelligent function, with rapid onset fluctuating 
clinical features. Include clouding of consciousness with 
reduced capacity to focus, and inability to sustain attention 
to environment, plus at least two of the following: 
perceptual disturbance, incoherent speech, insomnia or 
daytime drowsiness, or increased or decreased psychomotor 
activity. Exclude metabolic, infectious or drug causes. 
8  Visual 
Disturbance 
Retinal changes of SLE. Include cytoid bodies, retinal 
hemorrhages, serious exodate or hemorrhages in the 
choroids, or optic neuritis. Exclude hypertension, infection, 
or drug causes. 
8  Cranial 
Nerve 
Disorder 
New onset of sensory or motor neuropathy involving 
cranial nerves. 
8  Lupus 
Headache 
Severe persistent headache: may be migrainous, but must be 
nonresponsive to narcotic analgesia. 
8  CVA New onset of cerebrovascular accident(s). Exclude 
arteriosclerosis. 
8  Vasculitis Ulceration, gangrene, tender finger nodules, periungual 
infarction, splinter hemorrhages, or biopsy or angiogram 
proof of vasculitis. 
4  Arthritis ≥ 2 joints with pain and signs of inflammation (i.e. 
tenderness, swelling, or effusion). 
4  Myositis Proximal muscle aching/weakness, associated with elevated 
creatine phosphokinase/adolase or electromyogram changes 
or a biopsy showing myositis. 
4  Urinary 
Casts 
Heme-granular or red blood cell casts. 
4  Hematuria >5 red blood cells/high power field. Exclude stone, 
infection or other cause. 
4  Proteinuria >0.5 gm/24 hours 
4  Pyuria >5 white blood cells/high power field. Exclude infection. 
2  New Rash Inflammatory type rash. 
2  Alopecia Abnormal, patchy or diffuse loss of hair. 
2  Mucosal 
Ulcers 
Oral or nasal ulcerations. 
2  Pleurisy Pleuritic chest pain with pleural rub or effusion, or pleural 
thickening. 
2  Pericarditis Pericardial pain with at least 1 of the following: rub, 
effusion, or electrocardiogram confirmation. 
2  Low 
Complement 
Decrease in CH50, C3, or C4 below the lower limit of 
normal for testing laboratory. 
2  Increased 
DNA binding 
>25% binding by Farr assay or above normal range for 
testing laboratory. 
1  Fever >38°C. Exclude infectious cause. 
1  Thrombocyto
penia 
<100,000 platelets/mm3. 
1  Leukopenia <3,000 White blood cell/mm3. Exclude drug causes. 
TOTAL SLEDAI SCORE : ___________ 
[Data from Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity 
index 2000. J Rheumatol. 2002 Feb;29(2):288–91] 
Annexure II 
  
The 1982 revised the American College of Rheumatology criteria for classification of 
systemic lupus erythematosus with 1997 revision 
 
Criterion Definition 
Malar rash Fixed erythema, flat or raised, over the malar eminences, tending to spare the 
nasolabial folds 
Discoid rash Erythematosus raised patches with adherent keratotic scaling and follicular 
plugging: atrophic scarring may occur in older lesions 
Photosensitivity Skin rash as a result of unusual reaction to sunlight, by patient history or 
physician observation 
Oral ulcers Oral or nasopharyngeal ulceration, usually painless, observed by physician 
Arthritis Nonerosive arthritis involving two or more peripheral joints, characterized by 
tenderness, swelling, or effusion 
Serositis Pleuritis—convincing history of pleuritic pain or rubbing heard by a physician 
or evidence of pleural effusion or pericarditis— documented by ECG or rub or 
evidence of pericardial effusion 
Renal disorder Persistent proteinuria greater than 0.5 g/d (or >3 + if quantitation nor 
performed) or cellular casts—may be red cell, hemoglobin, granular, tubular, 
or mixed 
Neurological 
disorder 
Seizures in the absence of offending drugs or known metabolic derangements 
(e.g., uremia, ketoacidosis, or electrolyte imbalance) or psychosis in the 
absence of offending drugs or known metabolic derangements (e.g., uremia, 
ketoacidosis, or electrolyte imbalance) 
Hematological 
disorder 
Hemolytic anemia with reticulocytosis or leukopenia less than 4000/mm
3
 total 
on two or more occasions, or lymphopenia less than 1500/mm
3
 on two or more 
occasions, or thrombocytopenia less than 100,000/mm
3
 in the absence of 
offending drugs 
Criterion Definition 
Immunological 
disorder 
   a)     Positive anti-DNA antibody to native DNA in abnormal titer, or 
   b)     Presence of anti-Sm nuclear antigen, or 
   
c)     Positive finding of antiphospholipid antibodies based on 1) an abnormal 
serum level of IgG or IgM anticardiolipin antibodies, 2) a positive test 
result for lupus anticoagulant using a standard method, or 3) a false-
positive serological test and confirmed by Treponema pallidum 
immobilization or fluorescent treponemal antibody absorption test. 
 
Antinuclear 
antibody 
An abnormal titer of antinuclear antibody by immunofluorescence or an 
equivalent assay at any point in time and in the absence of drugs known to be 
associated with drug-induced lupus syndrome 
[Data from Tan EM, Cohen AS, Fries JF et al: The 1982 revised criteria for the classification of 
systemic lupus erythematosus, Arthritis Rheum 25:1271-1277, 1982; Hochberg MC: Updating 
the American College of Rheumatology revised criteria for the classification of systemic lupus 
erythematosus, Arthritis Rheum 40:1725, 1997] 
The proposed classification is based on 11 criteria. For the purpose of identifying patients in 
clinical studies, a person is defined as having SLE if any 4 or more of the 11 criteria are present, 
serially or simultaneously, during any interval of observation. 
 
 
 
 
 
 
 
 
 
 
SLICC classification criteria 
 
Clinical criteria 
 
1. Acute cutaneous lupus, including: 
Lupus malar rash (do not count if malar discoid) 
Bullous lupus 
Toxic epidermal necrolysis variant of SLE 
Maculopapular lupus rash 
Photosensitive lupus rash 
        in the absence of dermatomyositis OR  
   Subacute cutaneous lupus (nonindurated psoriaform and/or annular polycyclic lesions that 
resolve without scarring, although occasionally with postinflammatory dyspigmentation or 
telangiectasias) 
 
2. Chronic cutaneous lupus, including: 
Classic discoid rash 
Localized (above the neck) 
Generalized (above and below the neck) 
Hypertrophic (verrucous) lupus 
Lupus panniculitis (profundus) 
Mucosal lupus 
Lupus erythematosus tumidus 
Chillblains lupus 
Discoid lupus/lichen planus overlap 
 
3. Oral ulcers 
Palate 
Buccal 
Tongue OR 
 nasal ulcers 
in the absence of other causes, such as vasculitis, Behcet’s disease, infection (herpesvirus), 
inflammatory bowel disease, reactive arthritis, 
and acidic foods 
 
4. Nonscarring alopecia (diffuse thinning or hair fragility with visible broken hairs) 
in the absence of other causes such as alopecia areata, drugs, iron deficiency, and 
androgenic alopecia 
 
5. Synovitis involving 2 or more joints, characterized by swelling or effusion OR 
     tenderness in 2  or more joints and at least 30 minutes of morning stiffness 
 
 
 
 
 
6. Serositis 
Typical pleurisy for more than 1 day 
OR pleural effusions 
OR pleural rub 
Typical pericardial pain (pain with recumbency improved by sitting forward) for more than 
1 day 
OR pericardial effusion 
OR pericardial rub 
OR pericarditis by electrocardiography 
in the absence of other causes, such as infection, uremia, and Dressler’s pericarditis 
 
7. Renal 
       Urine protein–to-creatinine ratio (or 24-hour urine protein) representing 500 mg protein/24    
hours OR  
        Red blood cell casts 
 
8. Neurologic 
Seizures 
Psychosis 
Mononeuritis multiplex 
in the absence of other known causes such as primary vasculitis 
Myelitis 
Peripheral or cranial neuropathy 
in the absence of other known causes such as primary vasculitis, infection, and diabetes 
mellitus 
Acute confusional state 
in the absence of other causes, including toxic/metabolic, uremia, drugs 
 
9. Hemolytic anemia 
 
10. Leukopenia (<4,000/mm
3 
at least once) 
 in the absence of other known causes such as Felty’s syndrome, drugs, and portal 
hypertension OR 
      Lymphopenia (<1,000/mm
3 
at least once) 
         in the absence of other known causes such as corticosteroids, drugs, and infection 
 
11. Thrombocytopenia (<100,000/mm
3 
at least once) 
        in the absence of other known causes such as drugs, portal hypertension, and thrombotic 
thrombocytopenic purpura 
 
 
 
 
 
 
 
Immunologic criteria 
 
1. ANA level above laboratory reference range 
 
2. Anti-dsDNA antibody level above laboratory reference range (or > 2-fold the reference range 
if tested by ELISA) 
 
3. Anti-Sm: presence of antibody to Sm nuclear antigen 
 
4. Antiphospholipid antibody positivity as determined by any of the following: 
Positive test result for lupus anticoagulant 
False-positive test result for rapid plasma reagin 
Medium- or high-titer anticardiolipin antibody level (IgA, IgG, or IgM) 
Positive test result for anti–2 
-glycoprotein I (IgA, IgG, or IgM) 
 
5. Low complement 
Low C3 
Low C4 
Low CH50 
 
6. Direct Coombs’ test in the absence of hemolytic anemia 
 
* Criteria are cumulative and need not be present concurrently. 
To classify a patient as having SLE, the patient should have biopsy proven lupus nephritis with 
ANA or anti-dsDNA (OR)  the patient should satisfy four of the above criteria, which includes  
at least one clinical and one immunologic criteria.  
 
Annexure III 
Patient Information Sheet 
Study Title:   
“To study the cutaneous profile of juvenile onset systemic lupus erythematosus and the expression of IL – 17 
in cutaneous lupus erythematosus” 
Purpose of research:  
Systemic lupus erythematosus (SLE) is a disease the exact aetiology of which is not known. It 
occurs more commonly in adult women but can occur in younger age group and in males too. The 
disease is said to have a different course and varies in severity if it starts at an early age (less than 16 
years) when compared with adult onset of the disease. In this study I intend to study the various skin 
manifestations associated with the disease occurring in children and adolescent population. Also a 
particular substance secreted by the white blood cells in our body known as Interleukin 17 (IL-17) is 
known to be associated with the skin lesions in SLE. I further intend to confirm the same by 
performing a biopsy of the affected skin.              
Expected duration of the Subject’s participation:  
Only at the time of presentation of the patient at the Dermatology Unit -1 OPD/ Paediatric 
Rheumatology OPD/ in-patients with skin lesions of SLE 
Description of the procedures: 
This study would involve recording of the patient’s relevant details and detailed examination of skin 
lesions. In selected patients, a skin biopsy may be required for confirmation of the diagnosis of 
cutaneous lupus erythematosus and also for IL-17 analysis. This skin biopsy will be taken under 
adequate local anaesthesia. There may be one or two stitches at the biopsy site which shall be 
removed after one week. Clinical photographs of the skin lesions may be taken.  
Risks or discomforts to the Subject:    
As the study does not include any trial treatment, there is no additional risk for the patient due to 
participation in study. The patient will not incur any additional cost by taking part in the study.  Skin 
biopsy may be associated with some minor discomfort/side effects including: 
 Pain – adequate local anaesthesia will be given by means of a thin (26 gauge) needle to 
minimize the pain 
 Minimal bleeding at the site of the biopsy – which can be easily controlled by applying 
pressure. One or two stitches may be required which shall be removed after a week 
 There is a slight possibility of infection – all aseptic precautions will be taken to 
minimize the risk of infection 
 Minimal scar formation at the biopsy site 
 
Benefits to the Subject:  
Biopsy of the skin lesions can help in confirmation of the type of skin lesions and further help in the 
management of the condition. 
  Benefits to others: 
 Information gathered from this study might help in the understanding of the cutaneous aspects of 
juvenile onset SLE. An understanding of the role of IL 17 in cutaneous lesions of SLE may in future 
contribute to exploration of potential treatment options for SLE. 
Confidentiality:  
Only the investigators of this study will be able to access the patient’s medical records.  Patient’s 
identity will not be revealed in any form or released to third parties or published. 
Participation:   
The patient’s participation in the study entirely voluntary and the patient is free to withdraw from the 
study at any time, without stating any particular reason. Refusal to participate or withdrawal from 
the study will not involve any penalty or loss of benefits to which the patient is otherwise entitled 
Kindly note: 
a. Termination - the patient’s participation in the study may be terminated if the patient has illnesses 
which may interfere with the results of the study 
b. Additional costs to the patient that may result from participation in the study – nil  
d. Notifications during the course of the research – The patient / patient’s representative will be 
notified in a timely manner if significant new findings develop during the course of the research 
which may affect the patient’s willingness to continue participation. 
f. Approximate number of Subjects enrolled in the study – 99 
Contact person:  Dr._________, Dept of Dermatology, Venereology and Leprosy, Christian 
Medical College and Hospital, Vellore. Ph – 0416 2283527 
 
úSôVô°«u RLYp Rôs
Bn®u RûXl× :
ÏZkûR TÚYj§p úRôp NmUkRlThP £vPªd íTv G¬j§úUhPv Utßm
ARu ùY°lTôÓ IL 17 ÏhúP²Vv íTv G¬j§úUhPv.
Bn®u úSôdLm :
CkR úSô«u N¬Vô] LôWQm A±VlTP®pûX. CÕ ùTôÕYôL ùTiLÞdÏ
YÚ¡u\ úSôn. B]ôp £±VYoLÞdÏm, BiLÞdÏm áP YWXôm. CkR úSôn
ùT¬VYoLû[ Lôh¥Ûm, £±VYoLÞdÏ HtThPôp, A§Lû[ RôdLjûR EiÓ
TiQ Yônl×Ls Es[]. CkR Bn®p, Sôu £ßYoLs, Y[oLÜm ùTiLs
Utßm BiL°u EP-u CkR úSô«]ôp HtTÓ¡u\ úRôp Uôt\eLû[
Ï±jÕ BnÜ ùNn¡ú\u. CkR úRôp úSôûV EiÓTiQ LôWQUôL CÚlTÕ
Interleukin-17 GuTÕ. CkR ùYsû[ AàdL[ôp ÑWdLlTÓ¡\Õ. CRû]
Eß§lTÓjR úRôp T¬úNôRû]Ùm (Biopsy) ùNn¡ú\u.
CkR Bn®p TeÏdùLôs[ úYi¥V úSWm :
úSôV° GlùTôÝÕ úRôp®Vô§ ©¬Ü-1 / ÏZkûRL°u ØP¿d¡Vp ©¬ÜdÏ
YÚmúTôÕ UhÓm úRôp NmUkRlThP SLE úSô«Ls TôodLlTÓm.
Bn®û] Tt± GÓjÕûWjRp.
CkR Bn®p úSôVô°«u ®YWeLs Utßm úRôp T¬úNôRû] ùNnVlTÓm.
úRoÜ ùNnVlThP úSôVô°dÏ úRôp T¬úNôRû]Ùm (Biopsy) ùNnVlTÓm. IL-17
BnÜm ùNnVlTÓm. úRôp T¬úNôRû] ùNnYRtÏ Øu]o. Y- ùR¬VôUp
CÚlTRtÏ F£ A°dLlTÓm. úRôp T¬úNôRû] ùNnRl©u]o Juß ApXÕ
CWiÓ ûRVp úTôPlTPXôm. AkR ûRVp JÚ YôWj§p GÓdLlTÓm. úRô-u
×ûLlTPm GÓdLlTPXôm.
CkR Bn®p TeúLt¡u\YoLÞdÏ HtTÓm Tô§l×Ls  :
CkR Bn®tÏ Øu]o GkR £¡fûNÙm ùNnVlTPôRRôp, úSôVô°LÞdÏ
A§LUô] Tô§l× CpûX. CkR Bn®p TeÏùTßYRtÏ GkR R² LhPQØm
ùNÛjR úRûY«pûX.
 Y- - ùR¬VôUp CÚlTRtÏ £ß F£ RWlTÓm.
 Ïû\kR A[Ü CWjRm YWXôm - Juß ApXÕ CWiÓ ûRVp úTôPlTPXôm.
ûRVp JÚ YôWj§p GÓdLlTÓm.
 úSôn ùRôtß YÚYRtÏ Yônl× EiÓ - ÑjRUô] Øû\«p T¬úNôRû]
ùNnVlTÓm.
 RÝm× HtTP Yônl× Es[Õ. ( £±R[úY )
SuûULs (TeúLtTYÚdÏ)
úRôp T¬úNôRû] ùNnY§]ôp GkR®RUô] £±V úSôn Guß
LiÓ©¥dLlTÓm. Utßm ARtÏ Ht\ £¡fûN ùNnVXôm.
SuûULs (Ut\YoLÞdÏ)
úUÛm úSôVô°«u UÚjÕY ùRôPof£dÏ CkR Bn®û] TVuTÓj§d
ùLôs[lTÓm.
CWL£V úLôl×  :
CkR BnûY ùNnTYodÏ UhÓúU EeLs T§Ü ®YW úLol× ûLVô[
Ø¥Ùm. EeLû[ Ï±jR ®YWeLs VôÚdÏm A±®dLlTPôÕ.
TeÏùTßYÕ :
CkR Bn®p TeÏ ùTßYRtÏ ¿eLs Ru²fûNVôL AàLXôm. ¿eLs
CkR Bn®-ÚkÕ GlúTôÕ úYiÓUô]ôÛm ®XLXôm. CkR Bn®p
TeÏùTßYRtÏ UßjRôúXô, ®X¡]ôúXô GkR ATWôRØm ®§dLlTPôÕ.
Ød¡V Ï±l× :
 ¿dÏRp - CkR Bn®-ÚkÕ úSôVô°dÏ HRôYÕ UôßRp HtThPôp,
Bn®-ÚkÕ EP]¥VôL ¿dLlTÓm.
 CkR Bn®p TeÏùTßYRtÏ R² LhPQm CpûX.
 CkR Bn®u úTôÕ úSôVô° / AYûW NôokRYoLs ×§RôL
LiÓ©¥dLlThPôp ùR¬®dLlTP úYiÓm. ©\Ï CkR BWôn£«p ùRôPoYÕ
úSôVô°«u ®ÚlTj§tÏ EhThPÕ.
 TeÏùTßTYoL°u Gi¦dûL-99.
ùRôPo×dÏ : Dr.úLô®k S.ªhPp,  Department of Demotology, Venereology and Lep-
rosy Unit-I, CMCH, Vellore. Ph 0416-2283527
Annexure V 
अध्ययन सूचना ऩत्र 
शोध का शीषषक : फचऩन भें प्रयाम्भबत हुए प्रणारीगत रूऩुस एरयधीभेटोसस Systemic Lupus 
Erythematosus ( एस एर ई- SLE) के त्वचीम रूऩ व त्वचीम रूऩुस एरयधीभेटोसस भें आई एर -१७ 
(IL-17)  की अभबव्मम्तत का अद्द्ममन I 
शोध के कारण की व्याख्या : 
प्रणारीगत रूऩुस एरयधीभेटोसस Systemic Lupus Erythematosus ( एस एर ई- SLE) एक ऐसा योग 
है म्जसके होन ेकी वजह के सॊऩूणण कायण अऻात हैं I मह ज्मदातय वमस्क भहहराओॊ भें होता है ऩय 
ऩुरुषों भें औय फच्चों भें बी हो सकता है I वमस्कों भें होन ेकक तुरना भें इस योग का ऩाठ्मक्रभ औय 
गॊबीयता अरग होती जफ मह योग फचऩन भें शुरू होता है (१६ सार स ेकभ उम्र) I इस शोध भें भैं 
फचऩन व ककशोयावस्था भें होन ेवारे इस योग के साये त्वचीम रूऩों का अद्द्ममन कयना चाहता हूॉ I हभाये 
श्वेत यतत कोभशकाओॊ द्वाया उत्ऩाहदत ऩदाथण आई एर -१७, एस एर ई के त्वचीम रूऩों भें ऩामा जाता है 
I  भैं आगे इस फात की ऩुम्टट, प्रबाववत त्वचा ऩय की गमी फामोप्सी द्वाया कयना चाहता हूॉ I  
मरीज़ के भागीदारी रहन ेकी अऩेक्षऺत अवधध : 
केवर भयीज के डभाणटोराजी मूननट १ ओऩीडी / फार चचककत्सा रुभाटोराजी ओऩीडी भें आन ेऩय, व जो 
भयीज़ अस्ऩतार भें बती होत ेहैं, औय म्जनको एस एर ई के त्वचीम रऺण हैं उन्हें इस अद््ममन भें 
शाभभर ककमा जामेगा I 
प्रक्रिया का वणषन : 
इस शोध भें भयीज़ स ेजरुयी जानकायी री जाएगी औय त्वचा की जाॉच की जाएगी I कुछ भयीजों भें रूऩुस 
एरयधीभेटोसस के त्वचीम रूऩों के ऩूणण ननदान के भरए व आई एर १७ के ऩयीऺण के भरए प्रबववत त्वचा 
स ेस्थानीम सॊग्माहयण (त्वचा को सुन्न कयना) के उऩयाॊत फामोप्सी की जाएगी I  फामोप्सी की जगह ऩय 
एक मा दो टाॉके रगान ेकी जरूयत ऩड़ सकती है म्जस ेएक हफ्त ेफाद ननकार हदमा जाएगा I भयीज़ के 
त्वचीम रऺणों के पोटो भरए जा सकत ेहैं I 
शोध में भाग ऱेन ेस ेमरीज़ को जोखिम व असुववधाए ं:  
इस शोध भें ककसी प्रकाय के प्रमोगात्भक मा ऩयीऺण उऩचाय का प्रमोग नहीॊ ककमा जा यहा है I इस भरए 
शोध भें बाग रेन ेस ेभयीज़ को ककसी प्रकाय का नमा जोखिभ मा असुववधाएॊ नहीॊ होंगी औय उऩचाय का 
िचण नहीॊ फढेगा I त्वचा की फामोप्सी स ेथोडीसी / भाभूरीसी असुववधा हो सकती है जो इस प्रकाय हैं -  
 ददण - ददण कभ कयन ेके भरए ऩमाणप्त रूऩ स ेत्वचा को एक फहुत ही ऩतरी सूई (२६ गोज) स े
स्थानीम सॊग्माहयण (local anaesthesia) द्वाया  त्वचा को सुन्न ककमा जामेगा I  
 थोडासा िनू का फहाना - जो भसपण  दफाव स ेयोका जा सकता है I एक मा दो टाॊकों की जरूयत 
ऩड़ सकती है म्जन्हें एक हफ्त ेफाद ननकार हदमा जाएगा I  
 फामोप्सी की जगह ऩय फहुत ही कभ रोगों भें हरके सॊक्रभण होन ेकी गुॊजाइश है म्जसस ेफचन ेके 
भरए ऩूणण रूऩ स ेसड़न योकनेवारे सावधाननमों री जाएॊगी I 
 फामोप्सी की जगह ऩय भात्र छोटा सा/ हल्का सा ननशान ऩड़ सकता है I 
शोध में भाग ऱेन ेस ेमरीज़ को ऱाभ : त्वचीम रऺणों के फामोप्सी स ेरूऩुस के त्वचीम रूऩों की ऩूणण रूऩ 
स ेऩुम्टट की जा सकती है औय सही उऩचाय देन ेभें सहामक हो सकती है I  
औरों को ऱाभ/ समाज का ऱाभ : शोध स ेएकत्र की गमी जानकायी स ेफचऩन भें होन ेवारे रूऩुस 
एरयधीभेटोसस के त्वचीम रूऩों को सभझन ेभें सहामक हो सकती है I एस एर ई के त्वचीम रऺणों भें 
आई एर १७ के भहत्व की जानकायी आगे बववटम भें इस योग के नए उऩचाय िोजन ेभें सहामक हो 
सकती है I 
गोऩनीयता : केवर इस शोध भें बाग रेन ेवारे शोधकताणओॊ को भयीज़ के भेडडकर रयकॉडण की जानकायी 
उऩरब्ध होगी I भयीज़ की ऩहचान औय अन्म जानकायी ककसी बी रूऩ स ेककसी तीसये ऩऺ को नहीॊ फताई 
जाएगी / मा प्रकाभशत नहीॊ की जाएगी I 
भागीदारी : भयीज़ की इस शोध भें बागीदायी सॊऩूणण रूऩ से उसके भज़ी औय सहभनत से होगी औय उस े
ककसी बी सभम बफना कोई वजह इस शोध भें बाग रेन ेस ेइनकाय कयन ेका ऩूणण अचधकाय है I इससे 
उसे ककसी बी तयह का जुयभाना नहीॊ देना ऩड़गेा I  इस शोध स ेककसी बी सभम फाहय आन ेऩय उसकी 
चचककत्सा ऩय कोई असय नहीॊ होगा औय नाही वह राब िोएगा म्जसका वह अन्मथा हकदाय था I 
आऩ की जानकारी के लऱए  
१. शोध भें भयीज़ की बागीदायी सभाप्त की जा सकती है अगय भयीज़ को कोई एसा दसूया योग है म्जसस े
ऩरयऺण के ऩरयणाभ इ फदराव आ सकता है I 
२. शोध भें बाग रेन ेस ेककसी प्रकाय स ेभयीज़ का िचाण नहीॊ फढेगा I  
३. अगय शोध के दौयान कोई ऐसी जानकायी का ऩता चरता है म्जससे भयीज़ के बागीदायी ऩय असय ऩड़ 
सकता है, तो ऐसी जानकायी भयीज़ मा उसके प्रनतननचध को सभम ऩय दे दी जाएगी I  
४. शोध भें बाग रेन ेवारे भयीजों की सॊख्मा (अॊदाज़) - ९९  
प्रधान अन्वेषक - डॉ _______, डमाषटोऱाजी, वेनेरोऱाजी और कुष्ट रोग ववभाग - १, क्रिस्चचयन मेडडकऱ 
कॉऱेज और अचऩताऱ, वेल्ऱोरे -४  
फोन - ०४१६ - २२८३५२७, ०४१६ -२२८२८२९. 0416-2283527, 0416-2282829. 
Annexure VI 
Child Assent Form 
Title of the study: To study the cutaneous profile of juvenile onset systemic lupus 
erythematosus and the expression of IL – 17 in cutaneous lupus erythematosus 
Protocol number:  
Principal investigator: _________________________ 
Address: Department of Dermatology, Venereology and Leprosy Unit 1, Christian Medical 
College and Hospital (CMCH), Vellore. Phone no: 0416-2283527 
Location where the study will be conducted: Department of Dermatology, Venereology and 
Leprosy Unit-1, and Paeditric Rheumatology OPD, CMCH. 
We want to tell you about a research we are doing. A research study is a special way of finding 
out more about a disease. We are trying to find out more about the clinical presentation of skin 
lesions in this disease and about the role of a substance named interleukin 17 in the causing these 
skin lesions. You are being asked to join the study because we feel that you could be an ideal 
subject for the condition being studied. 
The doctor will examine your skin thoroughly and take down the details in a special proforma. If 
felt necessary he would click photographs of the skin lesions. For a special testing, a biopsy of 
the skin, where we remove a small bit of skin, may be required.  
Can anything bad happen to me? 
We want to tell you about some things that might hurt or upset you if you are in this study. Skin 
biopsy may be associated with some minor discomfort/side effects including: 
 Pain – adequate local anaesthesia will be given by means of a thin (26 gauge) needle to 
minimize the pain 
 Minimal bleeding at the site of the biopsy – which can be easily controlled by applying 
pressure. One or two stitches may be required which shall be removed after a week 
 There is a slight possibility of infection – all aseptic precautions will be taken to 
minimize the risk of infection 
 Minimal scar formation at the biopsy site 
Can anything good happen to me? 
We do not know if participating in this research study will help you feel better or get well. But 
biopsy of your skin lesions can help in confirmation of the type of skin lesions you are suffering 
from and further help in the management of your condition. 
Will anyone know I am in the study? 
We will not tell anyone that you took part in this study. When the study is completed, we will 
write a report about what we find out. We won’t use your name in the report. 
 
What happens if I get hurt? 
There is a negligible risk of getting hurt. Your parents/ guardians have been informed about the 
same and to seek urgent medical attention as soon as possible in case of any eventuality 
What if I do not want to do this? 
You don’t have to be in this study. It is entirely your wish. If you agree now, but refuse later, that 
is okay too. All you need to do is to tell us. 
If you want to participate in this study, please sign below – 
[   ] Yes, I want to be a part of this study  
[   ] No, I do not want to be a part of this study 
Name of the child: 
Signature/ thumb impression of the child: 
Date: 
Witness mediator  
Name:  
Signature: 
Date: 
Person obtaining Assent: 
I have explained the research at a level that is understandable by the child and believe that the 
child understands what is expected during the study. 
Printed name:  
Signature: 
Date: 
Witness mediator 
Name: 
Signature: 
Date: 
Jl×Rp T¥Ym
BWônf£«u RûXl× : ÏZkûR TÚYj§p HtTÓm úRôp ®Vô§. NmUkRlThP £vPªd
íTv G¬j§úUhPv Utßm ARu ùY°Tôh¥u IL-17 ÏhúP²Vv íTv G¬jÕúUhPv.
®iQlT T¥Y Gi.
BWônf£Vô[o : Dr. úLô®kj  ªhPp
®XôNm : úRôp ©¬Ü, Tô-Vp Utßm ùRôÝúSôn ©¬Ü-1,
¡±vÕY UÚjRY Lpí¬, úYío.
ùRô. Gi.0416-2283527
BWônf£ SPdÏm
CPm : úRôp ®Vô§ NmUkRlThP ©¬Ü, Tô-Vp
Utßm ùRôÝúSôn ©¬Ü-1, Utßm ÏZkûRLs
ØP¿d¡Vp OPD CMCH.
GeLs BWônf£ Tt± ®[dLUôL ùR¬®dL ®Úm×¡ú\ôm. CkR BWônf£«u
êXm úSôûVl Tt± Cuàm £\lTô] Øû\«p ùR¬kÕ ùLôs[ ERÜm UÚjÕY
Ã§VôL úRôp NmUkRlThP ®Vô§Lû[ ùR¬kÕ ùLôs[ ØVt£ ùNn¡ú\ôm. IL17 ARu
êXm úRô-p HtTÓm ®Vô§Lû[ A±V ØVp¡ú\ôm. SôeLs ùNnV úTô¡\ BWônf£dÏ
EeLÞûPV TeL°l× GeLÞdÏ ªÏkR ER®VôL CÚdÏm.
UÚjÕYo EeLs EPm©u úRôp ØÝYûRÙm úNô§jÕ A§p LôQlTÓm Ï±l×Lû[
JÚ Rô°p Ï±jÕ ùLôsYôoLs. úRûYlThPôp Tô§dLlThP úRôp TÏ§Lû[ ×ûL TPm
©¥lTôoLs. úRûYlThPôp Tô§dLlThP TÏ§«p CÚkÕ £±V NûRûV GÓjÕ AûR
£\l× T¬úNôRû]LôL AàlTlTÓm.
 G]dÏ CR]ôp HRôYÕ Tô§l× HtTÓUô?
CkR BWônf£«p CÚdÏm úTôÕ Y- ApXÕ LxPTm CÚdÏm GuTûR ùNôpX
®Úm×¡ú\ôm. NûR BWônf£«]ôp £X ®û[ÜLs HtTPXôm AûYLs:
Y- - úRûYlTÓm A[®tÏ AkR TÏ§ UhÓm UÚkÕúTôL F£ úTôPlTÓm.
£±V A[Ü CWjR L£Ü NûR GÓjR TÏ§«p HtTÓm - CWjR L£ûY LhÓlTÓjR
£±R[Ü AÝjRÜm, Juß ApXÕ CWiÓ ûRVp úTôPlTÓm AkR ûRVp JÚ YôWj§tÏ
©\Ï ©¬dLlTÓm.
AlTÏ§«p ºr ©¥dL Yônl× EiÓ - AûRdLhÓlTÓjR ÑjRUô] Øû\Lû[
UÚjÕYoLs ûLVôÞYôoLs. NûR GÓjR TÏ§«p £±V RÝm× HtTPXôm.
 G]dÏ CR]ôp HRôYÕ SpXÕ HtTÓUô?
CkR BWônf£ T¥l©p ¿eLs TeÏ ùLôiPôp Su\ôL CÚdÏm Guú\ô ApXÕ
®ûW«p ÏQUûPVÅoLs Guú\ô GeLÞdÏ ùR¬VôÕ. B]ôp AûR BWônf£«u
êXm GkR YûLVô] úRôp®Vô§Vôp Tô§dLlThÓsÇoLs Guß Ø¥Ü ùNnVXôm.
úUÛm EeLÞûPV ®Vô§ûV LhÓlTÓjR AÕ ER®VôL CÚdÏm.
 Sôu CkR BWônf£«p NmUkRlTh¥ÚlTÕ VôÚdLôYÕ ùR¬ÙUô?
¿eLs CkR BWônf£ T¥l©p CÚlTûR SôeLs VôÚdÏm ùR¬®dLlTP UôhúPôm.
CkR BWônf£«u Ø¥®p SôeLs LiP±kÕ EeLs ®Vô§«u RuûUûV GÝ§
ûYjÕd ùLôsúYôm. A]ôp EeL°u ùTVûW ETúVô¡dL UôhúPôm.
 G]dÏ Tô§l× HtThPôp Gu]YôÏm?
ùTôÕYôL Tô§l× HtTPôÕ, JÚ úYûX Tô§l× HtThPôp EP]¥VôL ùTtú\ôo
(ApXÕ) TôÕLôYXoLÞdÏ ùR¬®dLlTÓm. úRûYlThPôp AYNW UÚjÕY ER®
ùNnVlTÓm.
 CkR BWônf£ T¥l× G]dÏ úYiPôm Gu\ôp Sôu Gu] ùNnV úYiÓm?
Li¥lTôL CkR BWônf£«p CÚdL úYiÓm Guß AY£Vm CpûX. CÕ
ØÝYÕm EeLÞûPV ®ÚlTm. JÚ úYûX CkR NûR BWônf£«p TeÏ ùLôsYRtÏ
ClùTôÝÕ ®ÚlTm CpûX Gu\ôÛm TWYô«pûX. B]ôp AûR ¿eLs GeLÞdÏ
ùR¬®jÕ ®P úYiÓm.
¿eLs CkR BWônf£ T¥l©p TeÏ ùLôs[ ®Úm©]ôp RVÜ ùNnÕ ¸úZ
ûLùVôlTm úTôPÜm.
(    ) Bm, Sôu CkR BWônf£lT¥l©p TeÏ ùLôs[ ®Úm×¡ú\u
(    ) CpûX, Sôu CkR BWônf£lT¥l©p TeÏ ùLôs[ ®ÚmT®pûX.
ÏZkûR«u ùTVo :
ûLùVôlTm/ûLúWûL :
úR§ :
Nôh£Vô[o :
ùTVo :
ûLùVôlTm :
úR§ :
úSôVô°«u Jl×Rp :
G]dÏ CkR BWônf£ Tt± SuÏ ×¬kÕ ùLôsÞm T¥dÏ ®Y¬dLlThPÕ.
ÏZkûRVô¡V G]dÏ CkR BWônf£«u úTôÕ Gu] SPdÏm Guß ×¬kÕd ùLôiúPu.
T§dLlThP ùTVo :
ûLùVôlTm :
úR§ :
Nôh£Vô[o :
ùTVo :
ûLùVôlTm :
úR§ :
Annexure VIII 
फार सहभति पाभम 
शोध का शीषमक :  फचऩन भें प्रयाम्भबि हुए प्रणारीगि रूऩुस एरयधीभेटोसस Systemic Lupus 
Erythematosus ( एस एर ई- SLE) के त्वचीम रूऩ व त्वचीम रूऩुस एरयधीभेटोसस भें आई एर -१७ (IL-17)  
की अभबव्मम्ति का अद्द्ममन I 
प्रोटोकार सॊख्मा :  
प्रधान अन्वेषक  व जगह जहाॉ अध्ममन ककमा जा यहा है -  डॉ ______, डभामटोराजी, वेनेयोराजी औय कुष्ट योग 
ववबाग, क्रिम्चचमन भेडडकर कॉरेज औय अचऩिार, वेल्रोये -४. 0416-2283527, 2282829 
 
हभ आऩको इस अध्ममन के फाये भें फाताना चाहत ेहैं I एक योग के फाये भें अधधक जानकायी प्राप्त कयन े
के लरए हभ शोध अध्ममन का प्रमोग कयत ेहैं I  
इस शोध भें हभ फचऩन व ककशोयावस्था भें होन ेवारे इस योग के साये त्वचीम रूऩों का अद्द्ममन कयना 
चाहत ेहैं औय आई एस एर ई के त्वचीम रूऩों भें इॊटयल्मुककन १७ (आई एर -१७) का क्मा भहत्व है, मह 
सभझन ेकी कोलशश कय यहे हैं I हभ आऩस ेइस अध्ममन भें बाग रेन ेके लरए इस लरए कह यहे क्मोंकक 
हभें रगता है की आऩ इस अध्ममन के लरए उऩमुक्त योगी हैं I डॉक्टय आऩके त्वचा की ऩूर्ण रूऩ स े
जाॉच कयन ेके फाद एक ववशषे proforma भें जाॉच का वववयर् लरखेंगे I 
मदद ज़रुयत ऩड़ी तो व ेनैदाननक तस्वीयें बी खीचेंगे I  एक ववशषे ऩयीऺर् के लरए, त्वचा की फामोप्सी 
की ज़रुयत ऩड़ सकती है जजसभे चभड़ ेका एक छोटा सा टुकड़ा ननकारा जाता है I   
इस अध्ममन भें बाग रेन ेसे भुझ ेकुछ फुया हो सकिा है तमा ? 
त्वचा की फामोप्सी स ेथोडीसी / भाभूरीसी असुववधा हो सकती है जो इस प्रकाय हैं -  
• ददण - ददण कभ कयन ेके लरए ऩमाणप्त रूऩ स ेत्वचा को एक फहुत ही ऩतरी सूई (२६ गोज) स े
स्थानीम सॊग्माहयर् (local anaesthesia) द्वाया  त्वचा को सुन्न ककमा जामेगा I  
• थोडासा खनू का फहाना - जो लसपण  दफाव स ेयोका जा सकता है I एक मा दो टाॊकों की जरूयत 
ऩड़ सकती है जजन्हें एक हफ्त ेफाद ननकार ददमा जाएगा I  
• फामोप्सी की जगह ऩय फहुत ही कभ रोगों भें हरके सॊक्रभर् होन ेकी गुॊजाइश है जजसस ेफचन ेके 
लरए ऩूर्ण रूऩ स ेसड़न योकनेवारे सावधाननमों री जाएॊगी I 
• फामोप्सी की जगह ऩय भात्र छोटा सा/ हल्का सा ननशान ऩड़ सकता है I 
इस अध्ममन भें बाग रेन ेसे भुझ ेतमा पामदा होगा? 
हभें मह ऩता नहीॊ है कक अगय इस अध्ममन भें बाग रेन ेआऩको फेहतय रगेगा मा नहीॊ I आऩके त्वचीम 
रऺर्ों के फामोप्सी कयन ेसे उनका ऩूर्ण रूऩ स ेननदान ककमा जा सकता है जजसस ेआऩके योग के 
धचककत्सा भें सहामक हो सकती है I  
तमा क्रकसी औय को ऩिा चरेगा की भैं इस अध्ममन भें बाग रे यहा हूॉ ?  
हभ ककसी को नहीॊ फताएॉगे कक आऩ इस अध्ममन भें बाग रे यहे हैं I  अध्ममन के सभाप्त होन ेऩय हभ 
एक रयऩोटण तैमाय कयेंगे जजसभ ेहभ आऩका नाभ नहीॊ लरखेंगे I  
मदद भुझ ेचोट रगी िो तमा होगा ?  
आऩको चोट रगन ेकी सॊबावना नगण्म है I रेककन आऩके भाता वऩता को सूधचत कय ददमा गमा है कक 
अगय आऩको ककसी प्रकाय की ऩयेशानी हो तो व ेतुयॊत आऩको डॉक्टय के ऩास ददखाएॉ I  
अगय भैं इस अध्ममन भें शाभभर नहीॊ होना चाहूॉ िो भुझ ेतमा कयना ऩड़गेा ? 
अध्ममन भें बाग रेन ेका ननर्णम आऩ का है I अगय आऩ इसभें शालभर होन ेस ेसहभत होकय, कपय 
शालभर न होना चाहें तब बी कोई भुजककर नहीॊ है I  आऩ को केवर अऩना ननर्णम हभें फताना है I मदद 
आऩ इस अध्ममन भें बाग रेना चाहत ेहैं तो कृऩमा नीच ेहस्ताऺय कयें I  
[  ] हाॉ, भैं इस अध्ममन भें बाग रेना चाहिा / चाहिी हूॉ  
[  ] नहीॊ, भैं इस अध्ममन भें बाग नहीॊ रेना चाहिा / चाहिी हूॉ  
फच्च ेके हचिाऺय / अॊगूठे का तनशान 
फच्च ेके नाभ                                                             ददनाॊक :                          
गवाह भध्मचथ के हचिाऺय                  नाभ                            ददनाॊक :                          
चवीकृति प्राप्ि कयन ेवारा व्मम्ति  
भैंन ेअध्ममन के फाये भें फच्च ेको उसके द्वाया सभझ ेजान ेवारे स्तय ऩय सभझामा है I भेया ऩूर्ण 
ववकवास है कक फच्चा मह सभझ गमा है कक अध्ममन भें बाग रेन ेके लरए उसे क्मा कयना ऩड़गेा I 
शोधकताण के हचिाऺय  
शोधकताण का नाभ :                                                               ददनाॊक :                          
गवाह भध्मचथ के हचिाऺय                   नाभ                           ददनाॊक :                          
 
Annexure IX 
 
Informed Consent Form  
(For participation in a research study) 
 
Study Title: To study the cutaneous profile of juvenile onset systemic lupus erythematosus 
and the expression of IL – 17 in cutaneous lupus erythematosus 
Study Number: 
Date of Birth / Age: _______ 
 
I________________________________________________ 
 
 son/daughter of ___________________________________ 
 
(i) I confirm that I have read and understood the information sheet dated _________ for the 
above study and have had the opportunity to ask questions. [ ] 
(ii) I understand that my participation in the study is voluntary and that I am free to withdraw at 
any time, without giving any reason, without my medical care or legal rights being affected. [ ] 
 (iii) I understand that the Sponsor of this study, others working on the Sponsor’s behalf, the 
Ethics Committee and the regulatory authorities will not need my permission to look at my 
health records both in respect of the current study and any further research that may be 
conducted in relation to it, even if I withdraw from the trial. I agree to this access. However, I 
understand that my identity will not be revealed in any information released to third parties or 
published. [ ] 
(iv) I agree not to restrict the use of any data or results that arise from this study provided such 
a use is only for scientific purpose(s) [ ] 
(v) I agree to take part in the above study. [ ] 
 
Signature (or Thumb impression) of the Subject/Legally Acceptable Representative: 
__________________________________ 
Date: _____/_____/______ 
Signatory’s Name: _________________________________ 
 
 
Signature of the Investigator: ________________________ 
Date: _____/_____/______ 
Study Investigator’s Name: _________________________ 
 
 
Signature of the Witness: ___________________________ 
Date: _____/_____/_______ 
Name of the Witness: ______________________________ 
 
 
UÚjÕY¬u Uô§¬«p TeúLtTRtLô] Jl×Rp T¥Ym
BWônf£«u ùTVo : úRôp ®Vô§ NmUkRUô] ÏZkûR TÚYj§p
ùY°lTÓjÕm IL-17  íTv G¬j§úUhPv.
TôPj§u Gi : _______________________________
©\kR úR§/YVÕ : _______________________________
Sôu......................................................................ULu ULs........................................................
LÚjÕ...........................................úR§«p CkR T¥YjûRÙm úUtLiP YÏl©u
úSôdLjûRÙm SuÏ A±kÕd ùLôiúPu.
CÕ NmUkRUôL ùTôßl©p Es[YoLs NhPéoYUô] ÏÝûY NôokRYoLs.
JÝeÏ TÓj§VYoLs B¡úVôodÏ T¥l× NmUkRUôLúYô BWônf£ NmUkRUôLúYô
GuàûPV UÚjÕY T§úYÓLû[ ûLVô[ Sôu CkR T¥l©p CÚkÕ ®X¡d
ùLôiPôÛm AàU§ úRûY«pûX GuTûR NmU§d¡ú\u.
G]Õ NmTkRlThP ®TWeLÞm CkR T¥l©u Ø¥ÜLû[Ùm A±®Vp
NmUkRUôL TVuTÓjÕYûR Sôu UßdLUôhúPu.
úUtLiP T¥l©p TeÏ ùT\ NmU§d¡ú\u.
úSôVô°/NhPéoY AàU§ A°dLlThPYo
ûLùVôlTm/ûLúWûL : _______________________________
úR§ : _______________________________
ûLùVôlTªÓTY¬u ùTVo : _______________________________
T¬úNô§lTY¬u ûLùVôlTm : _______________________________
úR§ : _______________________________
T¬úNô§lTY¬u ùTVo : _______________________________
Nôh£Vô[¬u ûLùVôlTm : _______________________________
úR§ : _______________________________
Nôh£Vô[¬u ùTVo : _______________________________
Annexure XI 
शोध अध्ययन में भाग ऱेने हेत ुसहमतत ऩत्र 
शोध का शीषषक :  
बचऩन में प्रराम्भभत हुए प्रणाऱीगत ऱूऩुस एररधीमेटोसस Systemic Lupus Erythematosus ( एस एऱ ई- SLE) के 
त्वचीय रूऩ व त्वचीय ऱूऩुस एररधीमेटोसस में आई एऱ -१७ (IL-17)  की अभभव्यम्तत का अध्ययन I 
शोध क्रमाांक : 
जन्म ततथथ / आयु : 
 मैं _______________________________________________________________ 
सुऩुत्र/ सुऩुत्री _________________________________________________________ 
 मैंन ेउऩरोक्त शोध अध्ययन के सूचना ऩत्र को ऩड़ व समझ लऱया है व मुझ ेउससे सम्बॊधधत प्रश्न ऩूछने 
का अवसर प्रदान ककया गया है I 
 मैं जानता हूॉ कक शोध में भागीदारी सॊऩूर्ण रूऩ से मेरी मर्ज़ी और सहमतत से है और मुझ ेककसी भी समय 
बबना कोई वजह इस शोध में भाग ऱेने से इनकार कर सकता हूॉ, बबना मेरी धचककत्सा व ़ानूनी अधधकार 
प्रभाववत हुए I 
 मई जानता हूॉ कक शोध अध्ययन के स्ऩोंसर व उससे जुड़ ेऱोग व एधिक्स कमेटी, रेगुऱेटोरी अधधकारी को 
मेरा स्वास्िय ररकार्ण इस शोध अध्ययन और आगे अन्य अनुसन्धान में शालमऱ करने हेत ुमेरे ऩररऺर् स े
बाहर आने के उऩराॊत भी मेरी अनुमतत की जरूरत नहीॊ होगी I मैं जानता हूॉ कक मेरी ऩहचान और अन्य 
जानकारी ककसी भी रूऩ स ेककसी तीसरे ऩऺ को नहीॊ बताई जाएगी / या प्रकालशत नहीॊ की जाएगी  
 मैं इस शोध अध्ययन के ककसी भी जानकारी या ऩररर्ाम के वैऻातनक उदे्दश्य हेत ुउऩयोग में बाधक नहीॊ 
बनूॉगा ( इस शोध अध्ययन के जानकारी या ऩररर्ाम का उऩयोग केवऱ वैऻातनक उदे्दश्य के लऱए होगा ) I 
 मैं इस शोध अध्ययन में भाग ऱेन ेके लऱए सहमतत देता हूॉ I 
 
मरीज़/ मरीज़ का क़ानूनी प्रतततनथध के हस्ताऺर / अांगूठे का तनशान - 
हस्ताऺर करने वाऱे का नाम :                                      ददनाॊक :                          
शोधकताष के हस्ताऺर : 
शोधकताण का नाम :                                               ददनाॊक :                                  
गवाह के हस्ताऺर :  
गवाह का नाम :                                                  ददनाॊक : 
 
1 
 
DATA COLLECTION PROFORMA  
 
 
Date:                                                                                   Serial no: 
 
Name:                                                                                  CMCH No: 
 
Age:                                                                                     Sex: 
 
Address:                                                                              Contact number:  
 
History  
 
Duration of disease: 
 
Past history of mucocutaneous complaints/ lesions: Yes / No 
  
Patient’s description of past lesions: 
 
Case notes of past cutaneous complaints: 
 
 
Presenting Mucocutaneous Complaints:  Yes / No  
 
 
Presenting Mucocutaneous Complaints 
 
Duration and other details   
 
Oral ulcers/ nasal ulcers 
 
 
Photosensitivity 
 
 
 
Skin lesions 
 
 
 
Alopecia 
 
 
 
Raynaud’s phenomenon 
 
 
Comments:  
 
 
 
 
 
 
 
 
 
2 
 
 
History of systemic symptoms in preceding ten days and comments : Yes/No 
 
Joint pain and swelling of ≥ 2 joints  
Fever (>38oC) 
Seizure                                                           Psychosis   
Organic Brain Syndrome                                            Visual Disturbance                                 
Cranial Nerve Disorder                                            Lupus Headache                                                                 
CVA                                                               Proximal muscle pains  
Pleuritic chest pain                                              Pericardial pain  
 
 
 
 
 
History of medication in the past 3 months: 
 
Drug 
 
Duration and Dose / Comments 
 
Topical steroids 
 
 
Oral steroids 
 
 
HCQ  
Mycophenolate mofetil 
Azathioprine 
Cyclosporine 
Cyclophosphamide/ 
 
 
Others  
 
 
ON EXAMINATION:   
 
Systems Review:     
 
Swelling/ tenderness of joint/s:  yes / no.                                          No of joints involved : <2/ ≥2 
 
Evidence of Serositis – CVS: 
                                       RS: 
CNS: 
 
Any other specific detail on systemic examination: 
 
Diagnosis of systemic involvement:  
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Cutaneous Examination  
 
Specific lesions  Yes/No & Site   Non - Specific lesions  Yes/No & Site 
    
1. Discoid lesions 
 
 1.Palpable purpura 
 
 
2. Verrucous lesions 
 
 2.Urticarial vasculitis  
 
 
3. Tumid lesions 
 
 3.Livedo reticularis 
 
 
4. Mucosal lesions 
(oral/conjunctival) 
 4.Raynaud’s phenomenon  
5. Panniculitis 
 
 5.Erythema multiforme  
6. Papulosquamous 
lesions   
 6.Periungual telangiectasiae  
7. Annular lesions 
 
 7.Leg ulcers 
 
 
8. Malar rash 
 
 8.Lupus hair 
 
 
9. Generalized ACLE  9.Telogen effluvium 
 
 
10. Bullous lesions  10. Alopecia areata 
 
 
11. Others  12. Sclerodactyly 
 
 
 
 
 13. Rheumatoid Nodule  
  14. Tender finger nodules  
  15. Digital ulcer/ 
gangrene 
 
  16. Urticarial wheals 
 
 
 
Oral/ Nasal ulcers: 
 
 
Miscellaneous skin lesions: 
 
 
Comments: 
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Biopsy performed: Y / N                                                                     Photographs taken: Y / N 
HPE: 
 
IL-17: 
 
 
Investigations       
1. Hemoglobin 
 
  
2. Total WBC count   
3. Differential count   
4. Platelet count 
 
  
5. Serum creatinine 
 
  
6. LFT   
7. Urine(Microscopy/ 
Pyuria/Proteinuria/Hematuria) 
 
  
8. Serology 
 ANA 
 
 Complement (C3, C4) 
 
 Anti-ds DNA 
 
 Anti-Sm 
 
 Anti-SSa 
 
 Anti-SSb 
 
 Lupus Anticoagulant 
 
 Anticardiolipin antibody 
 
  
Others    
 
Total SLEDAI score:  
SANTA CRUZ BIOTECHNOLOGY, INC.
IL-17 (H-132): sc-7927
Santa Cruz Biotechnology, Inc. 1.800.457.3801 831.457.3800 fax 831.457.3801 Europe +00800 4573 8000 49 6221 4503 0 www.scbt.com
BACKGROUND
Cytokines are small, soluble proteins with pleiotropic effects on a variety of
cell types. Cytokines have a regulatory function over the immune system and
mediate aspects of inflammatory response. They exert their biological effects
through the binding of membrane-bound receptors which, in turn, initiate
signal transduction cascades and elicit physiological changes in their target
cell. Interleukin-17 (IL-17) and its cognate receptor, IL-17R, are an example
of such a cytokine receptor pair. Originally identified as a rodent cDNA termed
CTLA8, IL-17 is capable of inducing the secretion of IL-6 and IL-8 and aug-
menting the expression of ICAM-1 in human fibroblast cultures. The IL-17
protein exhibits a striking degree of homology with the HSV13 protein which
mimics its function. The IL-17 receptor is a type I transmembrane protein,
864 amino acids in length, that is highly expressed in spleen and kidney.
REFERENCES
1. Rouvier, E., et al. 1993. CTLA-8, cloned from an activated T cell, bearing
AU-rich messenger RNA instability sequences, and homologous to a
herpesvirus saimiri gene. J. Immunol. 150: 5445-5456.
2. Arend, W.P., et al. 1994. Binding of IL-1α, IL-1β, and IL-1 receptor antag-
onist by soluble IL-1 receptors and levels of soluble IL-1 receptors in
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CHROMOSOMAL LOCATION
Genetic locus: IL17A (human) mapping to 6p12.2; Il17a (mouse) mapping
to 1 A4.
SOURCE
IL-17 (H-132) is a rabbit polyclonal antibody raised against amino acids
24-155 of IL-17 of human origin.
PRODUCT
Each vial contains 200 µg IgG in 1.0 ml of PBS with < 0.1% sodium azide
and 0.1% gelatin.
STORAGE
Store at 4° C, **DO NOT FREEZE**. Stable for one year from the date of
shipment. Non-hazardous. No MSDS required.
RESEARCH USE
For research use only, not for use in diagnostic procedures.
APPLICATIONS
IL-17 (H-132) is recommended for detection of IL-17 of human and, to a lesser
extent, mouse and rat origin by Western Blotting (starting dilution 1:200,
dilution range 1:100-1:1000), immunoprecipitation [1-2 µg per 100-500 µg
of total protein (1 ml of cell lysate)], immunofluorescence (starting dilution
1:50, dilution range 1:50-1:500), immunohistochemistry (including paraffin-
embedded sections) (starting dilution 1:50, dilution range 1:50-1:500) and
solid phase ELISA (starting dilution 1:30, dilution range 1:30-1:3000).
Suitable for use as control antibody for IL-17 siRNA (h): sc-39649, IL-17
siRNA (m): sc-39650, IL-17 shRNA Plasmid (h): sc-39649-SH, IL-17 shRNA
Plasmid (m): sc-39650-SH, IL-17 shRNA (h) Lentiviral Particles: sc-39649-V
and IL-17 shRNA (m) Lentiviral Particles: sc-39650-V.
Molecular Weight of IL-17: 15 kDa.
Positive Controls: IMR-32 cell lysate: sc-2409 or LNCaP cell lysate: sc-2231.
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an autologous nucleus pulposus model of radiculopathy. Spine 34: 648-654.
8. Wang, D.D., et al. 2009. IL-17 potentiates neuronal injury induced by oxy-
gen-glucose deprivation and affects neuronal IL-17 receptor expression.
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IL-17 (H-132): sc-7927. Western blot analysis of human
recombinant IL-17.
IL-17 (H-132): sc-7927. Immunoperoxidase staining
of formalin fixed, paraffin-embedded mouse uterus
showing cytoplasmic and extracellular localization.
< IL-17
29 K -
21 K -
7 K -
Annexure XIV 
Protocol for automated immunostaining: 
1. Paraffin embedded tissue sections, cut at 4μ thickness, were floated in poly L-lysine 
coated slides and incubated overnight at 37˚C. 
2. These slides were then treated with 4% milk solution for 10 minutes to eliminate the 
hydrophobic effect and give positive charge to the slides. 
3. Then the slide labels were bar coded and the labeled slides were loaded in Ventana 
Benchmark XT autostainer (a fully automated immunostainer). 
4.  The steps included in the automated protocol were as follows:  
a. Deparaffinization 
b. Liquid coverslip application. 
c. Heat induced antigen retrieval by treating with standard CC1 solution (pH patent 
with the company) for one hour at 90˚C. 
d. Then the primary antibody – anti IL-17 antibody was added and incubated for 40 
minutes at 37˚C. Dilution used was 1:25.   
e. Then the secondary antibody (Multimer) was added and incubated for 8 minutes. 
f. Finally the slides were counterstained with Haematoxylin and incubated for 8 
minutes, followed by incubation with the bluing reagent for 4 minutes. 
(From antigen retrieval till counterstaining, in between every step the slides were 
washed with reaction buffer, the whole process is automated). 
Then the slides were brought to 80% alcohol (2 changes) to remove the liquid coverslip and then 
dried and mounted in DPX (Di-n-butyl Phthalate in Xylene). 
 


GLOSSARY TO THE MASTER CHART 
sno        Serial No        :             
ptid       Patient id        : ###        type    : ##    (1.New, 2.Followup)         
date       Date of visit    : <dd/mm/yyyy>        
Name    : ______________________________      
cmchno  : ________ 
age        Age in years     : ###                                sex     : ##    (1.Male, 2.Female) 
add        Address          : ##     
(1.TN, 2.AP, 3.Kerala, 4.Orissa, 5.WB, 6.Bihar-Jhar-MP-Chat, 7.Northeast, 8.Bangla, 9.Others) 
 
History: 
durdis     Duration of disease in years     : ##.# 
 
Complete diagnosis/features of the pt with SLE -    (1.Yes, 2.No) 
cns        CNS Lupus         : ##         
lupnep     Lupus nephritis   : ## 
arth       Arthritis          : ## 
myos       Myositis          : ## 
sero       Serositis          : ## 
seroys     If yes             : ##    (1.Pleural, 2.Pericardial, 3.Both) 
pancrea    Pancreatitis      : ## 
aiha       AIHA              : ## 
itp        ITP                : ## 
ttp        TTP                : ## 
 
hismuco    Past history of mucocutaneous complaints/lesions     : ##    (1.Yes, 2.No) 
hismucys   If yes, No of flares in the past                     : ## 
 
Past skin lesions:            (1.Yes, 2.No) 
 
malarra    Malar rash            : ## 
gacle      Generalised ACLE  : ## 
scle       SCLE                  : ## 
dle        DLE                   : ## 
oralulc    Oral ulcers           : ## 
hairls     Hair loss             : ## 
chrourt    Chronic urticaria     : ## 
pasvascu   Past vasculitic les   : ## 
blistles   Blistering lesions    : ## 
sloth      Others                : ##      
 
follup     Follow up             : ###        foldate    : <dd/mm/yyyy> 
pmuco     Presenting mucocutaneous complaints     : ##    (1.Yes, 2.No) 
sle            If yes related with  : ##    (1.SLE, 2.Not SLE) 
 
 
If SLE related 
orulc      Oral ulcers/nasal ulcers      : ##    (1.Yes, 2.No) 
photosen   Photosensitivity              : ##    (1.Yes, 2.No) 
skinlesi   Skin lesions                  : ##    (1.Yes, 2.No) 
alopec     Alopecia                      : ##    (1.Yes, 2.No) 
raynauds   Raynaud's phenomenon    : ##    (1.Yes, 2.No) 
 
History of systemic symptoms in preceding ten days and comments 
 
jtpain     Joint pain and sweling of more than 2 joints    : ##    (1.Yes, 2.No) 
fev        Fever                       : ##    (1.Yes, 2.No) 
seiz       Seizure                     : ##    (1.Yes, 2.No) 
psycho     Psychosis                  : ##    (1.Yes, 2.No) 
obs        Organic Brain Syndrome     : ##    (1.Yes, 2.No) 
vd         Visual Disturbance         : ##    (1.Yes, 2.No) 
cnd        Cranial Nerve Disorder     : ##    (1.Yes, 2.No) 
lh         Lupus Headache             : ##    (1.Yes, 2.No) 
pmp        Proximal muscle pains      : ##    (1.Yes, 2.No) 
pcp        Pleuritic chest pain       : ##    (1.Yes, 2.No) 
pp         Pericardial pain           : ##    (1.Yes, 2.No) 
 
History of medication in the past 3 months  
 
tsteroi    Topical steroids           : ##    (1.Yes, 2.No) 
osteroi    Oral steroids              : ##    (1.Yes, 2.No) 
osterys    If yes dose                : ###.## 
hcq        HCQ                         : ##    (1.Yes, 2.No) 
mm         Mycophenolate mofetil      : ##    (1.Yes, 2.No) 
azathio    Azathoprine                : ##    (1.Yes, 2.No) 
cyclos     Cyclosporine               : ##    (1.Yes, 2.No) 
cycmide    Cyclophosphamide           : ##    (1.Yes, 2.No) 
methot     Methotrexate             : ##    (1.Yes, 2.No) 
 
Systemic Examination: 
 
cns        CNS                         : ##    (1.Yes, 2.No) 
sweltend   Swelling/tende joints      : ##    (1.Yes, 2.No) 
swelys     If yes no. of joints inv   : ##    (1.Less than 2, 2.Greater than 2) 
evisero    Evidence of serositis      : ##    (1.Yes, 2.No) 
rs         RS                          : ##    (1.Yes, 2.No) 
anyoth     Any of ther detail         : ##    (1.Yes, 2.No) 
 
Cutaneous Examination  
 
A. Specific lesions                                        (1.Active, 2.Resolving, 3.Absent) 
disco      Discoid lesions            : ##     
verru      Verrucous lesions          : ##     
tumid      Tumid lesions              : ##     
pannicul   Panniculitis               : ##     
papulosq   Papulosquamous lesions    : ##     
annular    Annular lesions            : ##     
malarra    Malar rash                 : ##     
gacle        Gen ACLE          : ##     
lichenoi   Lichenoid lesions          : ##     
ccle       CCLE                        : ##     
scle       SCLE                        : ##     
acle       ACLE                        : ##     
 
Non-Specific lesions                                         (1.Active, 2.Resolving, 3.Absent) 
palpur     Palpable purpura           : ##     
urtivas    Urticarial vasculities     : ##     
liveret    Livedo reticularis         : ##     
rayphen    Raynaud's phenomenon      : ##     
erymult    Erythema multiforme        : ##     
peritel    Periungual telangiectas    : ##     
perihyp    Periungual hyperpigmen     : ##     
legulc     Leg ulcers                  : ##     
luphair    Lupus hair                 : ##     
dnsa       Diffuse non scarring alopecia     : ##     
aloparea   Alopecia areata            : ##     
scleroda   Sclerodactyly              : ##     
bulllesi   Bullous lesions            : ##     
rheumnod   Rheumatoid nodule          : ##     
tfn        Tender finger nodules      : ##     
dug        Digital ulcer/gangrene     : ##     
urtwheal   Urticarial wheals          : ##     
acannig    Acanthosis nigricans       : ##     
Others  
mucosal    Mucosal lesion/hard pala   : ##     
postinf    Post inflammatory hyperpigmentation in photodistributed areas     : ## 
postvas    Post inflammatory hyperpigmentation after vasculitis              : ## 
scaralop   Scarring alopecia         : ##     
nsml       Non specific mucosal lesion (Geog tong,apt ulcer)                 : ## 
paltel     Palmer Telangiectasia     : ##     
acqicg     Acquired ichthyosis/xerosis : ##     
hcq        HCQ induced hyperpigmentation     : ##     
nailchan   Nail changes              : ##    (1.Present, 2.Absent) 
oralcand   Oral candidiasis          : ##     
herpszos   Herpes zoster             : ##     
scabi      Scabies                   : ##     
tinvers    Tinea versicolor          : ##     
strdist    Striae distensae          : ##     
cushfac    Cushingoid facies         : ##     
acnevul    Acne vulgaris             : ##     
acneerup   Acneform eruption         : ##     
nsoth      Others                    : ##     
 
Investigations 
hemo       Hemoglobin                 : ##.## 
totwbc     Total WBC count            : ##### 
difct      Differential count 
              n    : ###        e    : ###    b    : ###    l    : ###     m    : ### 
ptct       Platelet count              : ####### 
prote      Proteinuria                 : ##    (1.Yes, 2.No) 
hem        Hematuria                  : ##    (1.Yes, 2.No) 
pyu        Pyuria                      : ##    (1.Yes, 2.No) 
cast         Cast                        : ##    (1.Yes, 2.No) 
sercreat   Serum creatinine           : ##.# 
lft           LFT                         : ##    (1.Normal, 2.Abnormal) 
 
Serology  
ana        ANA at first contact       : ##    (1.Positive, 2.Negative) 
anatype    Type of ANa               : ##    (1.Speckled, 2.Nucleolar, 3.Homo, 4.1and2, 5.1and3, 
6.2and3) 
anapos     If positive                 : ##    (1-4) 
c3         Complement C3              : ### 
c4         Complement C4              : ### 
antidis    Anti-ds DNA                : #### 
lupanti    Lupus Anticoagulant        : ##    (1.Positive, 2.Negative) 
anticard   Anticardiolipin antibody   : ##    (1.Positive, 2.Negative) 
antissa    Anti SSA                   : ### 
antissb    Anti SSB                   : ### 
antismit   Anti Smith                 : ### 
antirnp    Anti RNP                   : ### 
dct        DCT                         : ##    (1.Positive, 2.Negative) 
crp        CRP                         : ### 
esr        ESR                         : ### 
 
Totsledai Total SLEDAI Score        : ### 
 Biopsy details 
Patient id 
Patient name 
Clinical impression - (ACLE,SCLE,DLE, CV-cutaneous vasculitis, UV- urticarial vasculitis) 
On histological examination - (LS-lupus specific, LSS-suggestive of lupus specific, VP-
vasculopathic reaction, PII-perivascular inflammatory infiltrate, LCV –leukocytoclastic 
vasculitis) 
Average IL-17 count 
SLEDAI score 
 
sno ptid type date age sex add durdis cns lupnep arth myos sero seroys pancrea aiha itp ttp hismuco malarra gacle scle dle oralulc hairls
1 1 1 1/11/2012 10 2 1 1 2 2 1 2 2 2 2 2 2 1 2 2 2 2 1 2
2 2 1 6/24/2011 15 1 1 4 2 2 2 2 2 2 2 2 2 1 1 1 2 2 1 1
3 2 2
4 2 2
5 2 2
6 3 1 7/8/2011 18 1 1 7 2 2 2 2 2 2 2 2 2 2 1 1 2 2 2 1 1
7 3 2
8 4 1 12/16/2011 21 2 5 5 2 2 1 2 2 2 2 2 2 2 1 2 2 2 1 2 2
9 5 1 1/27/2012 16 2 2 2 2 2 1 1 2 2 2 2 2 2 1 2 2 2 2 1 1
10 5 2
11 5 2
12 6 1 2/17/2012 8 2 9 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
13 6 2
14 7 1 11/25/2011 13 1 1 0.5 2 1 2 2 2 2 2 2 2 1 1 1 2 2 1 1
15 7 2
16 7 2
17 7 2
18 7 2
19 8 1 12/2/2011 17 2 1 4 1 1 2 2 2 2 1 2 2 1 2 2 2 2 2 1
20 9 1 12/2/2011 12 2 2 2.6 2 2 2 2 2 2 1 2 2 1 2 2 2 2 1 2
21 9 2
22 10 1 12/2/2011 15 2 6 2 2 1 2 2 2 2 2 2 2 1 2 2 2 2 2 1
23 11 1 4/15/2011 16 1 1 3 2 2 2 2 2 2 1 2 2 1 2 2 2 2 1 1
24 11 2
25 12 1 1/6/2012 11 2 7 1.5 2 1 2 2 1 2 2 2 2 2 1 2 2 2 2 2 2
26 13 1 12/23/2011 14 2 5 1.5 2 1 2 2 2 2 2 2 2 1 2 2 2 2 1 1
27 14 1 12/23/2011 13 2 1 0.5 2 2 2 2 2 2 1 1 2 2 2 2 2 2 2 1
28 15 1 12/23/2011 13 1 1 0.5 1 2 2 2 2 2 2 2 2 1 1 1 2 2 1 1
29 16 1 12/23/2011 14 1 1 4 1 1 2 2 2 2 1 2 2 1 2 2 2 2 1 2
30 17 1 12/23/2011 15 2 2 1.5 2 1 2 2 2 2 2 2 2 2 1 1 2 2 2 2 1
31 18 1 7/8/2011 14 2 2 0.5 2 2 1 2 2 1 2 2 2 1 1 1 2 2 1 1
32 18 2
33 18 2
34 18 2
35 18 2
36 18 2
37 18 2
38 19 1 5/20/2011 15 2 1 2 2 1 2 2 2 2 2 2 2 2 1 2 1 2 2 1 1
39 19 2
40 19 2
41 19 2
42 19 2
43 19 2
44 19 2
45 20 1 6/8/2011 17 1 1 2 2 1 1 2 2 2 2 2 2 1 2 2 2 1 1 1
46 20 2
47 21 1 6/10/2011 10 2 2 0.7 2 2 1 2 2 2 2 2 2 1 1 2 2 2 1 1
48 22 1 8/11/2011 18 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
49 23 1 9/28/2011 17 2 6 1 2 1 1 2 1 2 2 1 2 2 1 2 2 2 2 1 1
50 24 1 6/8/2011 12 2 5 0.3 2 2 1 2 1 3 2 2 2 2 1 1 2 2 2 1 1
sno ptid type date age sex add durdis cns lupnep arth myos sero seroys pancrea aiha itp ttp hismuco malarra gacle scle dle oralulc hairls
51 25 1 4/9/2011 13 2 6 0.2 2 1 2 2 2 2 1 2 2 1 2 2 2 2 1 1
52 25 2
53 25 2
54 26 1 6/17/2011 13 2 1 3.3 2 1 2 2 2 2 2 2 2 1 2 2 2 2 1 1
55 27 1 4/15/2011 14 2 1 2 2 2 1 2 2 2 2 2 2 1 1 1 2 2 1 2
56 27 2
57 28 1 5/20/2011 14 2 7 0.5 2 1 2 2 2 2 2 2 2 2 1 1 2 2 2 2 2
58 28 2
59 29 1 5/20/2011 17 2 1 3.6 2 1 2 2 2 2 2 1 2 2 1 2 2 2 2 2 1
60 29 2
61 30 1 5/27/2011 14 2 1 3.5 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2
62 31 1 7/6/2011 12 2 2 0.2 2 2 2 2 2 2 2 2 2 1 2 2 2 1 1 1
63 32 1 9/23/2011 14 2 5 1 1 1 2 2 2 1 2 1 2 1 2 2 2 2 2 1
64 33 1 9/7/2011 15 2 5 2 2 1 2 2 2 2 1 2 2 1 2 2 2 2 1 1
65 34 1 9/9/2011 12 2 3 1 2 1 2 2 2 2 2 2 2 1 2 2 2 2 1 1
66 35 1 10/21/2011 14 2 7 1.3 2 1 2 2 2 2 2 2 2 1 2 2 2 2 2 1
67 36 1 6/10/2011 15 2 1 0.3 2 1 1 2 2 2 2 2 2 1 2 2 2 2 1 1
68 37 1 9/16/2011 15 2 1 2 2 1 2 2 2 2 2 2 2 1 2 2 2 2 2 1
69 38 1 8/5/2011 17 2 5 3 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
70 39 1 8/5/2011 12 2 2 0.3 2 1 2 2 2 2 2 2 2 1 2 2 2 2 2 1
71 40 1 8/19/2011 7 2 1 0 2 2 2 2 2 2 2 2 2 1 1 2 2 2 2 2
72 41 1 5/27/2011 9 1 2 1 2 2 2 2 2 2 2 2 2 1 2 1 2 2 2 2
73 42 1 8/19/2011 13 2 8 1 1 1 2 2 2 2 2 2 2 1 2 2 2 2 1 2
74 43 1 9/9/2011 10 1 5 2 2 1 2 2 2 2 2 2 2 1 1 2 2 2 1 2
75 43 2
76 44 1 7/15/2011 12 2 1 4 2 1 2 2 2 2 1 1 2 1 2 2 2 2 2 1
77 44 2
78 45 1 6/24/2011 9 1 6 0.6 2 1 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2
79 46 1 4/15/2011 6 1 2 0.5 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2
80 46 2
81 47 1 6/24/2011 17 2 5 3 2 1 2 2 2 2 2 2 2 1 2 2 2 2 1 1
82 48 1 6/24/2011 15 2 5 0.2 2 2 1 2 2 2 2 1 2 2 2 2 2 2 2 2
83 49 1 7/15/2011 18 2 1 3 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 1
84 50 1 7/16/2013 12 2 3 1.3 1 2 2 2 2 2 2 2 2 1 2 1 2 2 1 1
85 51 1 11/4/2011 15 2 1 3.5 2 1 1 2 2 2 1 2 2 1 2 1 2 2 2 2
86 51 2
87 51 2
88 52 1 10/7/2011 16 1 1 1.7 2 1 2 2 2 2 2 2 2 1 2 2 2 2 1 2
89 53 1 10/11/2011 17 2 5 4.2 2 1 2 2 2 2 2 2 2 1 2 2 1 2 1 1
90 54 1 12/9/2011 12 2 2 4 2 2 1 2 2 2 2 2 2 1 2 2 1 2 1 2
91 54 2
92 54 2
93 55 1 11/25/2011 15 2 1 1.8 2 2 1 2 2 2 2 2 2 1 2 2 2 2 1 1
94 56 1 5/4/2012 11 2 1 1.9 2 1 1 2 2 2 2 2 2 1 1 2 2 2 2 2
95 57 1 5/16/2012 14 2 1 1 2 2 1 2 2 2 2 2 2 1 2 2 2 2 2 1
96 58 1 5/21/2012 14 2 5 0.2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2
97 58 2
98 59 1 5/11/2012 11 2 1 2.6 2 1 2 2 2 2 1 1 2 1 2 2 2 2 2 2
99 60 1 3/16/2012 13 2 2 0.6 2 1 2 2 2 2 2 2 2 1 2 2 2 2 2 2
100 60 2
sno ptid type date age sex add durdis cns lupnep arth myos sero seroys pancrea aiha itp ttp hismuco malarra gacle scle dle oralulc hairls
101 61 1 2/10/2012 17 2 7 3 2 1 1 2 2 2 1 2 2 1 2 1 2 2 1 1
102 61 2
103 62 1 1/27/2012 13 2 1 6.8 2 1 1 2 2 2 2 2 2 1 1 2 2 2 1 2
104 62 2
105 62 2
106 63 1 2/10/2012 14 2 5 0.4 2 1 2 2 2 2 2 2 2 1 2 2 2 2 1 1
107 63 2
108 64 1 4/27/2012 16 2 7 8 2 1 2 2 2 2 2 2 2 1 1 2 2 2 2 2
109 65 1 4/20/2012 17 2 5 5 2 2 2 2 2 2 1 1 2 1 2 2 2 2 2 2
110 66 1 9/20/2011 15 1 2 0.5 2 1 2 2 2 2 2 2 1 1 2 2 2 2 2 2
111 66 2
112 67 1 7/27/2012 13 2 1 0.3 2 1 2 2 2 2 2 2 2 2
113 68 1 11/24/2012 12 2 1 2.5 2 1 2 2 2 2 2 1 2 1 1 1 2 2 1 1
114 69 1 9/14/2012 12 2 9 0.1 2 1 1 2 2 2 2 2 2 1 2 2 2 2 2 2
115 70 1 2/3/2012 13 2 7 0.2 2 1 2 2 1 2 2 2 2 2 1 2 2 2 2 2 2
116 71 1 2/17/2012 11 2 5 0.3 2 1 1 2 2 2 2 2 2 1 2 2 2 2 1 2
117 72 1 12/16/2011 18 2 1 7 2 1 2 2 2 2 2 1 2 1 2 2 2 2 1 2
118 73 1 2/10/2012 15 2 5 1.3 1 1 2 2 2 2 2 2 2 1 2 2 2 2 2 1
119 74 1 9/14/2012 16 2 1 3 2 1 2 2 2 2 2 2 2 2
120 75 1 9/14/2012 20 2 3 5 1 1 2 2 2 2 2 2 2 2
121 76 1 11/27/2012 13 2 6 0 2 1 2 2 1 2 2 2 2 2 1 2 1 2 2 2 2
122 77 1 3/17/2012 19 2 1 3 2 1 2 2 2 2 2 2 2 1 2 2 2 2 1 1
123 78 1 3/1/2012 2 1 5 0 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
124 79 1 1/6/2012 15 1 1 2 2 1 2 2 2 2 2 2 2 1 2 2 2 2 2 1
125 80 1 12/9/2011 14 2 3 3 2 1 2 2 1 2 2 1 1 2 1 2 2 2 2 1 1
126 81 1 12/9/2011 16 2 5 1.7 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 1
127 82 1 3/3/2012 16 2 2 0.3 1 2 2 2 1 2 2 1 2 2 2
128 83 1 3/16/2012 12 2 1 3.5 2 2 2 2 2 2 1 2 2 1 2 2 2 1 2 2
129 84 1 3/16/2012 16 2 5 0.8 2 1 1 2 2 2 1 2 2 1 2 2 2 2 2 2
130 85 1 3/23/2012 12 1 5 0.1 2 1 1 2 1 2 2 2 2 2 1 2 2 2 2 2 2
131 85 2
132 86 1 3/23/2012 13 2 1 0.8 2 1 2 2 2 2 2 2 1 1 2 2 2 2 2 1
133 87 1 8/10/2012 16 2 1 0.3 2 2 2 2 2 2 2 2 2 2
134 88 1 9/12/2012 14 2 6 0.5 2 1 2 2 2 2 2 2 2 1 2 1 2 2 2 1
135 89 1 1/17/2002 16 2 1 2 1 2 2 2 2 2 1 1 2 1 1 1 2 2 2 1
136 90 1 10/3/2012 10 2 1 0.4 2 2 2 2 2 2 2 2 2 1 1 2 2 1 2 2
137 91 1 11/9/2012 14 2 4 0.1 2 1 1 1 1 2 2 2 2 2 1 1 2 2 2 1 1
138 92 1 11/9/2012 13 2 5 0.2 2 2 2 2 2 2 2 2 2 1 1 2 2 2 1 2
139 93 1 10/19/2012 16 2 1 2.6 2 2 2 2 2 2 1 2 2 2
140 94 1 5/26/2012 10 1 1 4 2 2 2 2 2 2 2 2 2 1 2 2 2 1 2 2
141 95 1 10/19/2012 15 2 1 5 2 1 2 2 2 2 1 2 2 1 2 2 2 2 2 1
142 96 1 5/25/2012 13 1 2 2 2 2 2 2 2 2 2 2 2 1 1 2 2 2 1 1
143 97 1 5/6/2011 16 2 1 3.6 2 1 2 2 2 2 2 1 2 1 2 1 2 2 1 1
144 98 1 5/22/2012 12 2 7 2 2 1 2 2 2 2 2 2 2 1 1 2 2 1 2 1
145 98 2
146 99 1 5/23/2012 0 2 1 0.1 2 2 2 2 2 2 2 2 2 2
147 100 1 5/25/2012 9 1 6 2 2 1 1 2 2 2 2 2 2 2
148 101 1 5/7/2012 19 2 3 8 2 2 1 2 2 2 2 2 2 1 1 2 2 2 1 1
149 102 1 11/23/2012 14 2 1 0.3 2 1 2 2 2 2 2 2 2 2
150 103 1 11/22/2012 17 1 2 3 1 1 1 2 2 2 1 2 2 2
sno ptid type date age sex add durdis cns lupnep arth myos sero seroys pancrea aiha itp ttp hismuco malarra gacle scle dle oralulc hairls
151 104 1 6/15/2012 13 2 5 0.2 2 2 2 2 2 2 1 2 2 2
152 105 1 8/3/2012 14 2 9 0.5 2 1 2 2 1 2 2 2 2 2 1 1 2 2 2 2 2
153 106 1 6/15/2012 8 2 2 2 2 2 2 2 2 2 2 1 2 1 2 2 2 2 2 1
154 107 1 3/30/2012 9 2 1 0 2 2 2 2 2 2 1 2 2 2
155 108 1 6/4/2012 19 2 2 8 1 2 1 2 2 2 2 2 2 1 2 2 2 2 2 1
156 109 1 2/24/2012 16 2 1 1.5 1 2 2 2 2 2 2 2 2 1 2 1 2 2 2 2
157 110 1 4/13/2013 15 2 8 0.5 1 1 2 2 2 2 2 1 2 1 2 2 2 1 2 1
158 111 1 3/27/2013 16 2 5 1.5 2 2 1 2 2 2 2 2 2 1 2 2 2 2 2 1
159 112 1 4/5/2013 5 2 1 0.2 2 2 2 2 1 2 2 1 2 2 2
160 113 1 11/28/2012 11 2 3 0.4 2 2 1 2 2 2 2 2 2 1 2 1 2 1 2 2
161 113 2
162 114 1 2/13/2013 10 2 3 0.3 1 1 2 2 2 2 2 2 2 2
163 115 1 2/27/2013 20 2 1 5 2 2 2 2 2 2 2 2 2 1 1 2 2 1 1 2
164 116 1 1/30/2013 16 2 3 0.8 2 1 2 2 2 2 2 2 2 1 1 2 2 2 2 1
165 117 1 3/1/2013 13 1 1 0.3 2 2 1 2 1 3 2 2 2 2 1 2 2 2 2 2 2
166 118 1 5/25/2012 10 2 9 0.6 2 2 1 2 2 2 2 2 2 1 1 2 2 2 1 1
167 119 1 8/22/2012 33 2 1 22 1 2 2 2 2 2 2 1 2 1 1 2 2 1 1 1
168 120 1 12/12/2012 13 2 2 1 1 2 1 2 1 2 2 2 2 2 1 2 2 2 2 2 1
169 121 1 5/17/2013 14 2 4 0.7 2 2 2 2 2 2 2 2 2 1 2 2 2 2 1 1
170 122 1 2/1/2013 16 2 6 0.8 2 1 2 2 2 1 2 2 2 1 1 2 2 1 2 1
171 123 1 2/1/2013 13 2 1 0 2 1 2 2 2 2 2 2 2 2
172 124 1 4/5/2013 14 2 1 0.4 2 2 2 2 2 2 2 2 2 2
173 125 1 5/11/2013 17 2 7 10 2 1 1 2 1 3 2 2 2 2 1 2 1 2 2 2 2
174 126 1 2/8/2013 11 2 2 0.1 2 1 2 2 2 1 2 2 2 2
175 127 1 2/17/2013 16 2 2 0 2 2 2 2 2 2 1 2 2 2
176 128 1 11/23/2012 8 2 1 1.8 2 1 2 2 2 2 1 2 2 1 2 2 2 2 1 1
177 129 1 7/6/2013 8 2 6 0.2 2 1 2 2 2 2 2 2 2 2
178 87 2
179 94 2
180 130 1 8/16/2011 12 2 1 0.5 2 2 2 2 2 2 2 2 2 1 2 2 2 2 2 2
181 131 1 1/31/2013 19 2 1 6 2 2 2 2 2 2 2 2 2 1 2 2 2 2 1 2
182 132 1 7/20/2011 28 2 1 12.5 1 2 2 2 2 2 2 2 2 1 2 1 2 2 1 1
183 133 1 12/23/2011 18 2 2 7 2 2 2 2 2 2 2 1 2 1 2 1 2 2 2 2
184 134 1 4/17/2013 14 1 4 0 2 2 2 2 2 2 2 2 2 2
185 135 1 10/5/2012 16 2 1 2.5 2 2 2 2 2 2 2 2 2 1 2 2 2 1 2 1
186 136 1 4/15/2011 11 1 5 0.3 2 2 1 2 2 2 2 2 2 2
187 137 1 5/23/2011 18 2 3 2 1 2 1 1 2 2 2 2 2 1 1 2 2 2 2 2
188 138 1 5/2/2013 17 2 2 8 1 1 2 2 2 2 2 2 2 1 2 1 2 2 2 2
189 139 1 8/5/2011 13 1 8 1.3 2 1 2 2 2 2 2 2 2 2
190 140 1 8/5/2011 8 2 4 1.4 2 2 2 2 2 2 2 1 2 2
sno chrourt pasvascu sloth follup foldate pmuco sle orulc photosen skinlesi alopec raynauds jtpain fev seiz psycho obs vd cnd lh pmp pcp pp
1 2 2 2 0 1/11/2012 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2
2 1 1 2 0 6/24/2011 1 1 1 2 1 2 2 1 2 2 2 2 2 2 2 2 2 2
3 1 1/27/2012 1 1 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2
4 2 5/25/2012 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2
5 3 1/18/2013 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
6 2 2 2 0 7/8/2011 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2
7 1 12/9/2011 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
8 2 1 1 0 12/16/2011 1 1 2 1 1 1 2 1 2 2 2 2 2 2 2 2 2 2
9 2 2 2 0 1/27/2012 1 1 1 2 2 1 2 2 2 2 2 2 2 2 2 1 2 2
10 1 2/17/2012 1 1 2 2 2 1 2 2 1 2 2 2 2 2 2 1 2 2
11 2 7/4/2012 1 1 2 2 2 1 2 2 1 2 2 2 2 2 2 2 2 2
12 2 2 2 0 2/17/2012 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
13 1 5/11/2012 1 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2
14 2 2 2 0 11/25/2011 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
15 2 5/25/2012 1 1 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2
16 3 7/20/2012 1 1 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2
17 1 3/2/2012 1 1 2 1 1 1 2 2 2 2 2 2 2 2 2 2 2
18 4 9/28/2012 1 1 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2
19 2 2 2 0 12/2/2011 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
20 2 2 2 0 12/2/2011 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
21 1 5/25/2012 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
22 2 1 1 0 12/2/2011 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2
23 2 2 2 0 4/15/2011 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
24 1 12/2/2011 1 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2
25 2 2 1 0 1/6/2012 1 1 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2
26 2 2 2 0 12/23/2011 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
27 2 2 2 0 12/23/2011 1 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2
28 2 2 2 0 12/23/2011 1 1 2 1 1 2 2 2 2 2 2 1 2 2 2 2 2 2
29 2 2 2 0 12/23/2011 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
30 2 2 2 0 12/23/2011 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
31 2 1 2 0 7/8/2011 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2
32 1 10/7/2011 1 1 2 2 1 2 2 1 1 2 2 2 2 2 2 2 2 2
33 2 1/6/2012 1 1 2 1 1 2 2 2 1 2 2 2 2 2 2 2 2 2
34 3 5/18/2012 1 1 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2
35 4 1/25/2013 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2
36 5 4/5/2013 1 1 2 2 1 1 2 1 2 2 2 2 2 2 2 2 2 2
37 6 6/28/2013 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2
38 2 2 2 0 5/20/2011 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2
39 1 9/16/2011 1 1 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2
40 3 5/4/2012 1 1 1 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2
41 4 11/2/2012 1 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2
42 5 1/25/2013 1 1 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2
43 6 4/12/2013 1 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2
44 2 2/3/2012 1 1 2 2 2 1 2 1 2 2 2 2 2 2 2 2 2 2
45 2 2 2 0 6/8/2011 1 1 1 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2
46 1 3/23/2012 1 1 2 1 1 1 2 1 1 2 2 2 2 2 2 2 2 2
47 2 2 2 0 6/10/2011 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2
48 2 2 2 0 8/11/2011 1 1 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2
49 2 2 1 0 9/28/2011 1 1 1 1 1 1 1 1 1 2 2 2 2 2 2 2 1 2
50 2 2 1 0 6/8/2011 1 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
sno chrourt pasvascu sloth follup foldate pmuco sle orulc photosen skinlesi alopec raynauds jtpain fev seiz psycho obs vd cnd lh pmp pcp pp
51 2 2 1 0 4/9/2011 1 1 1 2 1 2 2 2 1 2 2 2 2 2 2 1 2 2
52 1 6/17/2011 1 1 2 2 2 1 2 1 2 2 2 2 2 2 2 2 2 2
53 2 1/4/2013 1 1 1 2 2 1 2 1 1 2 2 2 2 2 2 2 2 2
54 2 2 1 0 6/17/2011 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
55 2 1 0 4/15/2011 1 1 1 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2
56 1 4/27/2012 1 1 2 2 2 1 2 1 2 2 2 2 2 2 1 2 2 2
57 2 2 2 0 5/20/2011 1 1 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2
58 1 3/16/2012 1 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
59 2 2 1 0 5/20/2011 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
60 1 11/6/2012 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
61 2 2 2 0 5/27/2011 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
62 2 2 2 0 7/6/2011 1 1 1 1 1 1 2 1 1 2 2 2 2 2 2 2 2 2
63 2 2 1 0 9/23/2011 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
64 2 2 2 0 9/7/2011 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
65 1 1 1 0 9/9/2011 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2
66 2 2 1 0 10/21/2011 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
67 2 2 2 0 6/10/2011 1 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
68 2 1 1 0 9/16/2011 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
69 2 2 2 0 8/5/2011 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
70 2 1 1 0 8/5/2011 1 1 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2
71 2 2 0 8/19/2011 1 1 1 1 1 2 2 1 1 2 2 2 2 2 2 2 2 2
72 2 2 2 0 5/27/2011 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2
73 2 2 2 0 8/19/2011 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
74 2 2 2 0 9/9/2011 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
75 1 9/28/2012 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2
76 1 2 2 0 7/15/2011 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
77 1 5/18/2012 1 1 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2
78 2 2 2 0 6/24/2011 2 2 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2
79 1 2 2 0 4/15/2011 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2
80 1 4/13/2012 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
81 1 1 2 0 6/24/2011 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
82 2 2 2 0 6/24/2011 1 1 2 2 2 1 2 1 2 2 2 2 2 2 2 2 2 1
83 2 2 2 0 7/15/2011 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
84 2 2 1 0 7/16/2013 1 1 2 1 2 2 2 1 1 2 2 2 2 2 2 1 2 2
85 2 2 1 0 11/4/2011 1 1 2 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2
86 1 7/13/2012 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
87 2 10/20/2012 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
88 2 2 2 0 10/7/2011 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
89 2 1 1 0 10/11/2011 1 1 1 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2
90 2 2 2 0 12/9/2011 1 1 2 1 1 1 2 2 1 2 2 2 2 2 2 1 2 2
91 1 3/9/2012 1 1 2 2 1 1 2 1 2 2 2 2 2 2 2 2 2 2
92 2 7/27/2012 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2
93 2 2 2 0 11/25/2011 2 2 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2
94 2 2 2 0 5/4/2012 1 1 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2
95 2 1 1 0 5/16/2012 1 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2
96 2 2 2 0 5/21/2012 1 1 1 1 1 1 2 2 1 2 2 2 2 2 2 2 2 2
97 1 6/10/2013 1 1 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2
98 2 2 2 0 5/11/2012 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
99 1 2 2 0 3/16/2012 1 1 2 2 2 2 1 1 2 2 2 2 2 2 2 2 2 2
100 1 5/11/2012 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
sno chrourt pasvascu sloth follup foldate pmuco sle orulc photosen skinlesi alopec raynauds jtpain fev seiz psycho obs vd cnd lh pmp pcp pp
101 1 2 2 0 2/10/2012 1 1 2 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2
102 1 5/11/2012 1 1 1 1 1 2 1 1 2 2 2 2 2 2 2 2 2 2
103 2 1 1 0 1/27/2012 1 1 2 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2
104 1 5/18/2012 1 1 2 2 1 2 2 1 1 2 2 2 2 2 2 2 2 2
105 2 7/27/2012 1 1 2 2 1 1 1 1 1 2 2 2 2 2 2 2 2 2
106 2 2 2 0 2/10/2012 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
107 1 4/27/2012 1 1 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2
108 2 2 0 4/27/2012 1 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
109 2 2 2 0 4/20/2012 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
110 2 2 1 0 9/20/2011 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
111 1 6/15/2012 1 1 2 1 1 2 2 1 2 2 2 2 2 2 2 1 1 2
112 0 7/27/2012 1 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2
113 2 1 2 0 11/24/2012 1 1 2 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2
114 2 1 1 0 9/14/2012 2 1 2 2 2 2 2 2 2 2 2 2
115 2 1 2 0 2/3/2012 1 1 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2
116 2 1 2 0 2/17/2012 1 1 2 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2
117 2 2 1 0 12/16/2011 1 1 2 2 2 1 2 1 1 2 2 2 2 2 2 2 2 2
118 2 2 2 0 2/10/2012 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
119 0 9/14/2012 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
120 0 9/14/2012 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2
121 2 1 2 0 11/27/2012 1 1 1 2 1 1 1 2 1 2 2 2 2 2 2 2 1 1
122 2 1 2 0 3/17/2012 1 1 2 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2
123 2 1 2 0 3/1/2012 1 1 1 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2
124 2 1 2 0 1/6/2012 1 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2
125 2 2 2 0 12/9/2011 1 1 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2
126 1 2 2 0 12/9/2011 1 1 2 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2
127 0 3/3/2012 1 1 1 2 1 1 2 2 1 2 2 2 2 2 2 2 2 2
128 2 2 2 0 3/16/2012 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
129 2 1 2 0 3/16/2012 1 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2
130 2 2 2 0 3/23/2012 1 1 2 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2
131 1 6/15/2012 1 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2
132 2 2 2 0 3/23/2012 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
133 0 8/10/2012 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2
134 2 2 1 0 9/12/2012 1 1 1 2 2 2 2 2 1 2 2 2 2 2 2 1 2 2
135 2 1 1 0 8/17/2012 1 1 2 2 1 2 2 2 1 2 2 2 2 2 2 2 2 2
136 2 2 2 0 10/3/2012 1 1 1 2 1 1 2 1 1 2 2 2 2 2 2 2 1 2
137 2 2 2 0 11/9/2012 1 1 1 2 2 1 2 1 2 2 2 2 2 2 2 1 2 2
138 2 2 2 0 11/9/2012 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
139 0 10/19/2002 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
140 2 1 0 5/26/2012 1 1 2 1 1 2 2 2 1 2 2 2 2 2 2 2 2 2
141 2 2 2 0 10/19/2012 1 1 2 1 2 2 2 1 2 2 2 2 2 2 1 2 2 2
142 2 2 1 0 5/25/2012 2 2 2 2 2 2 2 2 2 2 2 2
143 2 2 2 0 5/25/2012 1 1 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2
144 2 2 2 0 5/22/2012 1 1 2 1 1 1 2 2 2 2 2 2 2 2 2 2 1 2
145 1 8/20/2012 1 1 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2
146 0 5/23/2012 1 1 2 2 1 2 2 2 1 2 2 2 2 2 2 2 2 2
147 0 5/25/2012 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
148 2 2 2 0 5/7/2012 1 1 2 1 1 2 1 1 1 2 2 2 2 2 2 2 2 2
149 0 11/23/2012 2 2 2 2 2 2 2 2 2 2 2 2
150 0 11/22/2012 1 1 2 2 2 1 2 2 1 2 2 2 2 2 2 2 2 2
sno chrourt pasvascu sloth follup foldate pmuco sle orulc photosen skinlesi alopec raynauds jtpain fev seiz psycho obs vd cnd lh pmp pcp pp
151 0 6/15/2012 1 2 2 2 2 2 2 2 2 2 2 2 2
152 2 2 2 0 8/3/2012 1 1 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2
153 2 2 2 0 6/15/2012 1 1 2 2 2 1 2 2 1 2 2 2 2 2 2 2 2 2
154 0 3/30/2012 2 2 2 2 2 2 2 2 2 2 2 2
155 2 2 2 0 6/4/2012 1 1 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2
156 2 1 1 0 2/24/2012 1 1 2 2 1 2 2 1 2 2 2 2 2 2 2 2 2 2
157 2 2 2 0 4/13/2013 1 1 2 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2
158 2 2 2 0 3/27/2013 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2
159 0 4/5/2013 1 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2
160 2 2 1 0 11/28/2012 1 1 1 2 1 1 2 1 1 2 2 2 2 2 2 2 2 2
161 1 2/2/2013 1 1 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2
162 0 2/13/2013 1 1 2 2 1 1 2 2 1 2 1 2 2 2 2 1 2 2
163 2 2 2 0 2/27/2013 1 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2
164 2 2 2 0 1/30/2013 1 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
165 2 2 1 0 3/1/2013 1 1 2 2 2 1 2 2 2 2 2 2 2 2 1 2 2 2
166 2 1 2 0 5/25/2012 1 1 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2
167 2 1 2 0 8/22/2012 1 1 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2
168 2 2 2 0 12/12/2012 1 1 2 2 1 1 2 2 2 2 2 2 2 2 2 2 2 2
169 2 2 2 0 5/17/2013 1 1 2 2 1 2 2 2 1 2 2 2 2 2 2 1 2 2
170 2 2 2 0 2/1/2013 2 2 2 2 2 2 2 2 2 2 2 2
171 0 2/1/2013 2 2 1 2 2 2 2 2 2 2 2 1
172 0 4/5/2013 1 1 2 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2
173 2 2 2 0 5/11/2013 1 1 2 2 2 1 2 2 1 2 2 2 2 2 2 1 2 2
174 0 2/8/2013 1 1 1 2 1 1 2 2 2 2 2 2 2 2 2 1 2 2
175 0 2/17/2013 1 1 1 2 1 1 2 1 1 2 2 2 2 2 2 2 2 2
176 2 2 2 0 11/23/2012 2 2 2 2 2 2 2 2 2 2 2 2
177 0 7/6/2013 1 1 1 2 1 2 2 2 1 2 2 2 2 2 2 2 2 2
178 1 1/25/2013 1 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2
179 1 5/17/2013 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2
180 2 1 2 0 8/16/2011 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2
181 2 2 2 0 1/31/2013 1 1 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2
182 2 2 2 0 7/20/2011 1 1 2 2 2 1 2 2 2 2 2 2 2 2 2 2 2 2
183 2 2 2 0 12/23/2011 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
184 0 4/17/2013 1 1 2 1 1 2 2 2 1 2 2 2 2 2 2 2 2 2
185 2 2 1 0 10/5/2012 2 2 2 2 2 2 2 2 2 2 2
186 0 4/15/2011 2 1 1 2 2 2 2 2 2 2 2 2
187 2 2 2 0 5/23/2011 1 1 1 1 1 2 2 1 2 2 2 2 2 2 2 1 2 2
188 2 1 2 0 5/2/2013 1 1 1 1 1 2 1 2 2 2 2 1 2 2 2 1 2 2
189 0 8/5/2011 2 2 2 2 2 2 2 2 2 2 2 2
190 0 8/5/2011 2 2 2 2 2 2 2 2 2 2 2 2
tsteroi sno osteroi osterys hcq mm azathio cyclos cycmide methot cns1 sweltend swelys evisero rs anyoth disco verru tumid pannicul
1 1 1 1 2 2 2 2 2 2 2 1 1 2 2 2 3 3 3 3
2 2 1 0.7 1 2 2 2 2 2 2 1 1 2 2 2 3 3 3 3
2 3 1 0.8 1 2 2 2 2 1 2 2 2 2 2 2 3 3 3 3
2 4 1 0.3 1 2 2 2 2 1 2 2 2 2 2 2 3 3 3 3
2 5 1 0.1 1 2 2 2 2 1 2 2 2 2 2 2 3 3 3 3
2 6 1 0.1 1 2 2 2 2 1 2 2 2 2 2 2 3 3 3 3
2 7 1 0.1 1 2 2 2 2 1 2 1 1 2 2 2 3 3 3 3
1 8 1 0.4 1 2 2 2 2 2 2 1 2 2 2 2 1 3 3 3
2 9 1 0.4 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 10 1 0.4 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 11 1 0.4 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 12 1 2 2 2 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 13 1 1 2 2 1 2 2 2 2 2 2 2 2 2 3 3 3 3
2 14 1 0.6 2 2 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 15 1 1 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 16 1 0.6 1 2 1 2 2 2 2 2 2 2 2 3 3 3 3
2 17 1 1.2 1 2 1 2 2 2 2 1 1 2 2 2 3 3 3 3
2 18 1 0.6 2 2 1 2 2 2 2 2 2 2 2 3 3 3 3
2 19 2 1 2 1 2 2 2 2 2 2 2 2 3 3 3 3
2 20 2 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 21 2 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 22 2 1 1 2 2 2 2 2 2 2 2 2 3 3 3 3
2 23 2 1 2 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 24 2 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 25 1 0.7 1 1 2 2 2 2 2 2 1 2 2 3 3 3 3
2 26 1 0.1 1 1 2 2 2 2 2 2 2 2 2 3 3 3 3
2 27 1 1 1 2 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 28 1 1 2 2 1 2 2 2 1 2 2 2 2 3 3 3 3
2 29 2 1 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 30 1 0.1 1 1 2 2 2 2 2 2 2 2 2 3 3 3 3
2 31 1 0.5 1 2 2 2 2 2 2 1 1 2 2 2 3 3 3 3
1 32 1 0.1 1 2 2 2 2 2 2 1 2 2 2 2 3 3 3 3
2 33 1 0.1 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 34 1 0.1 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 35 1 0.2 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 36 1 0.1 1 2 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 37 1 0.2 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 38 1 0.1 1 2 2 2 2 1 2 2 2 2 2 3 3 3 3
2 39 1 0.2 2 2 2 2 2 1 2 2 2 2 2 3 3 3 3
2 40 1 0.2 1 2 2 2 2 1 2 2 2 2 2 3 3 3 3
2 41 1 0.1 1 2 2 2 2 1 2 2 2 2 2 3 3 3 3
2 42 1 0.1 1 2 2 2 2 1 2 2 2 2 2 1 3 3 3
2 43 1 0.15 1 2 2 2 2 1 2 2 2 2 2 3 3 3 3
2 44 1 0.1 1 2 2 2 2 1 2 1 2 2 2 2 3 3 3 3
1 45 1 0.1 1 2 2 2 2 2 2 1 1 2 2 2 1 3 3 1
1 46 1 0.4 1 1 2 2 2 2 2 1 2 2 2 2 1 3 3 2
2 47 1 0.5 1 2 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 48 2 2 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 49 1 0.4 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 50 1 1 1 2 2 2 2 2 2 2 1 2 2 3 3 3 3
tsteroi sno osteroi osterys hcq mm azathio cyclos cycmide methot cns1 sweltend swelys evisero rs anyoth disco verru tumid pannicul
2 51 1 1 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 52 1 0.6 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 53 1 0.2 1 2 1 2 2 2 2 2 2 2 2 3 3 3 3
2 54 1 0.3 1 2 1 2 2 2 2 2 2 2 2 3 3 3 3
2 55 1 0.3 1 2 2 2 2 1 2 2 2 2 2 2 3 3 3
2 56 1 0.3 1 1 2 2 2 2 2 1 2 2 2 2 3 3 3 3
2 57 1 1.2 2 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 58 1 0.2 1 1 2 2 2 2 2 2 2 2 2 3 3 3 3
2 59 1 0.1 1 1 2 2 2 2 2 2 2 2 2 3 3 3 3
2 60 1 0.1 1 1 2 2 2 2 2 2 2 2 2 3 3 3 3
2 61 2 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 62 1 1.6 1 2 2 2 2 2 2 2 2 2 2 1 3 3 3
2 63 1 0.2 2 1 2 2 2 2 2 2 2 2 2 3 3 3 3
2 64 1 0.3 1 1 2 2 2 2 2 2 2 2 2 3 3 3 3
2 65 1 0.1 1 2 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 66 1 1.1 1 1 2 2 2 2 2 2 2 2 2 3 3 3 3
2 67 1 0.4 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 68 1 0.2 2 2 1 2 2 2 2 2 2 2 2 3 3 3 3
2 69 1 0.2 1 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 70 1 1.7 2 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 71 1 0.9 2 2 2 2 2 2 2 1 2 2 2 2 3 3 3 3
2 72 1 0.7 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 73 1 0.3 1 1 2 2 2 2 2 2 2 2 2 3 3 3 3
2 74 2 1 1 2 2 2 2 2 2 2 2 2 3 3 3 3
2 75 2 1 1 2 2 2 2 2 2 2 2 2 1 3 3 3
2 76 1 0.6 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 77 1 0.1 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 78 1 0.5 1 2 2 2 2 2 2 1 2 1 2 2 3 3 3 3
2 79 1 0.4 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 80 2 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 81 2 1 1 2 2 2 2 2 2 2 2 2 3 3 3 3
2 82 1 0.4 1 2 2 2 1 2 2 1 2 2 2 2 3 3 3 3
2 83 1 0.1 1 2 1 2 2 2 2 2 2 2 2 3 3 3 3
2 84 1 0.5 1 2 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 85 1 1 1 2 2 2 2 2 2 1 2 2 2 2 3 3 3 3
2 86 1 0.2 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 87 1 0.1 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 88 1 0.2 1 2 1 2 2 2 2 2 2 2 2 3 3 3 3
2 89 1 0.1 1 2 1 2 2 2 2 2 2 2 2 3 3 3 3
1 90 1 0.3 2 1 2 2 2 2 2 2 2 2 2 3 3 3 3
2 91 1 0.2 1 2 2 2 2 2 2 1 1 2 2 2 3 3 3 3
2 92 1 0.2 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 93 1 0.1 1 2 2 2 2 2 2 1 1 2 2 2 3 3 3 3
2 94 1 0.2 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 95 1 0.3 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 96 1 1.2 2 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 97 1 0.2 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 98 2 2 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 99 1 1.7 1 1 2 2 2 2 2 2 2 2 2 3 3 3 3
2 100 1 1 1 1 2 2 2 2 2 2 2 2 2 3 3 3 3
tsteroi sno osteroi osterys hcq mm azathio cyclos cycmide methot cns1 sweltend swelys evisero rs anyoth disco verru tumid pannicul
2 101 1 0.2 1 1 2 2 2 2 2 1 2 2 2 2 3 3 3 3
2 102 1 0.4 1 1 2 2 2 2 2 1 2 2 2 2 3 3 3 3
2 103 1 0.6 1 2 2 2 2 2 2 1 1 2 2 2 3 3 3 3
2 104 1 0.3 1 2 2 2 2 2 2 1 2 2 2 2 3 3 3 3
2 105 1 0.3 1 2 2 2 2 2 2 1 2 2 2 2 3 3 3 3
2 106 1 0.6 1 1 2 2 2 2 2 2 2 2 2 3 3 3 3
2 107 1 0.5 1 1 2 2 2 2 2 2 2 2 2 3 3 3 3
2 108 2 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 109 2 1 1 2 2 2 2 2 2 2 2 2 3 3 3 3
2 110 1 0.66 2 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 111 2 2 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 112 1 1 2 2 2 2 1 2 2 2 2 2 2 3 3 3 3
2 113 1 0.6 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 114 1 0.4 1 2 2 2 2 2 2 1 2 2 2 2 3 3 3 3
2 115 2 2 2 2 2 2 2 2 1 2 1 2 2 3 3 3 3
2 116 1 0.7 2 1 2 2 2 2 2 2 2 2 2 3 3 3 3
2 117 2 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 118 1 0.25 2 2 1 2 2 2 2 2 2 2 2 3 3 3 3
2 119 2 1 1 2 2 2 2 2 2 2 2 2 3 3 3 3
2 120 2 2 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 121 1 0.5 1 2 2 2 2 2 2 2 1 1 2 3 3 3 3
2 122 1 0.4 1 1 2 2 2 2 2 2 2 2 2 3 3 3 3
1 123 2 2 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 124 1 0.6 1 2 1 2 2 2 2 2 2 2 2 3 3 3 3
2 125 1 0.1 1 1 2 2 2 2 2 2 2 2 2 3 3 3 3
2 126 2 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 127 2 2 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 128 2 1 2 1 2 2 2 2 2 2 2 2 3 3 3 3
2 129 1 0.25 1 1 2 2 2 2 2 2 2 2 2 3 3 3 3
2 130 1 2 2 2 2 2 2 2 2 1 2 1 2 2 3 3 3 3
2 131 1 1 1 1 2 2 2 2 2 2 2 2 2 3 3 3 3
2 132 1 0.1 1 1 2 2 2 2 2 2 2 2 2 3 3 3 3
2 133 1 0.4 2 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 134 1 0.2 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 135 2 2 2 2 2 2 2 2 2 2 2 2 1 3 3 3
2 136 1 2 2 2 2 2 2 2 1 2 2 2 2 1 3 3 3
2 137 2 1 2 2 2 2 2 2 2 1 2 1 2 2 3 3 3 3
2 138 1 1 1 2 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 139 2 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 140 2 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 141 1 0.2 1 1 2 2 2 2 2 2 2 2 2 3 3 3 3
2 142 2 1 1 2 2 2 2 2 2 2 2 2 3 3 3 3
2 143 1 0.1 1 1 2 2 2 2 2 2 2 2 2 3 3 3 3
1 144 1 1 1 1 2 2 2 2 2 2 2 1 2 1 3 3 3
2 145 1 0.8 1 1 2 2 2 2 2 2 2 2 2 2 3 3 3
2 146 2 2 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 147 1 1 1 1 2 2 2 2 2 2 2 2 2 3 3 3 3
2 148 1 0.1 1 2 2 2 2 1 2 1 1 2 2 2 1 3 3 3
2 149 1 1.5 2 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 150 1 0.7 2 1 2 2 2 2 2 2 2 2 2 3 3 3 3
tsteroi sno osteroi osterys hcq mm azathio cyclos cycmide methot cns1 sweltend swelys evisero rs anyoth disco verru tumid pannicul
2 151 1 0.9 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 152 1 0.5 1 2 2 2 1 2 2 2 2 2 2 3 3 3 3
2 153 2 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 154 1 1.3 2 2 2 2 2 2 2 2 2 2 2 3 3 3 3
1 155 2 2 2 2 2 2 2 2 2 2 1 2 1 3 3 3
2 156 1 2 1 2 2 2 2 2 2 1 2 2 2 2 3 3 3 3
2 157 1 1 2 1 2 2 2 2 2 2 2 2 2 3 3 3 3
2 158 1 0.1 1 2 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 159 1 0.9 1 2 2 2 2 2 2 2 1 2 2 3 3 3 3
1 160 2 1 2 2 2 2 2 2 1 2 2 2 2 1 3 3 3
1 161 1 0.5 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 162 1 0.5 2 2 2 2 2 2 1 2 2 2 2 1 3 3 3
2 163 2 1 1 2 2 2 2 2 2 2 2 2 1 3 3 1
2 164 1 0.2 2 1 2 2 2 2 2 2 2 2 2 3 3 3 3
2 165 1 0.8 1 2 2 2 2 2 2 2 1 1 2 3 3 3 3
2 166 1 0.1 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 167 1 0.1 1 2 2 2 2 1 2 2 2 2 2 1 3 3 3
2 168 1 0.1 1 2 2 2 2 2 2 2 2 2 2 1 3 3 3
2 169 1 1 1 2 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 170 1 0.6 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 171 2 2 2 2 2 2 2 2 2 1 2 2 3 3 3 3
2 172 1 0.5 2 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 173 2 2 1 2 2 2 2 2 2 2 2 2 3 3 3 3
2 174 1 1 2 2 2 2 2 2 2 2 2 2 2 2 3 3 3
2 175 2 2 2 2 2 2 2 2 2 2 2 2 1 3 3 3
2 176 1 0.4 1 1 2 2 2 2 2 2 2 2 2 3 3 3 3
2 177 1 2 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 178 1 0.2 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 179 1 0.3 1 2 2 2 2 2 2 2 2 2 2 1 3 3 3
2 180 1 0.2 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 181 2 2 2 2 2 2 2 2 2 2 2 2 1 3 3 3
2 182 1 0.1 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 183 2 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 184 2 2 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 185 2 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
2 186 2 1 2 2 2 2 2 2 1 2 2 2 2 3 3 3 3
2 187 1 0.5 1 2 2 2 2 2 2 1 2 2 2 2 3 3 3 3
2 188 2 2 2 2 2 2 2 1 2 2 2 2 3 3 3 3
2 189 1 0.2 2 1 2 2 2 2 2 2 2 2 2 3 3 3 3
2 190 2 1 2 2 2 2 2 2 2 2 2 2 3 3 3 3
papulosq annular sno malarra1 gacle lichenoi ccle scle1 acle palpur urtivas liveret rayphen erymult peritel perihyp legulc luphair dnsa aloparea
3 3 1 1 3 3 3 3 1 3 3 3 3 3 3 3 3 3 1 3
1 3 2 3 3 3 3 1 3 3 3 3 3 3 3 3 3 3 3 3
3 3 3 3 3 3 3 3 3 3 1 3 3 3 3 3 3 3 1 3
3 3 4 3 3 3 3 3 3 3 1 3 3 3 3 3 3 3 3 3
3 3 5 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 6 3 3 3 3 3 3 3 3 3 1 3 3 3 3 3 3 3
3 3 7 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 8 3 3 3 1 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 9 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 10 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 1 3
3 3 11 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 1 3
3 3 12 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 13 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 1 3
3 3 14 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 15 1 3 3 3 3 1 3 3 3 3 3 3 3 3 3 3 3
1 3 16 3 3 3 3 1 3 3 3 3 3 3 3 3 3 3 3 3
3 3 17 1 1 3 3 3 1 3 3 3 3 3 3 3 3 3 1 3
3 3 18 1 3 3 3 3 1 3 3 3 3 3 3 3 3 3 3 3
3 3 19 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 20 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 21 3 3 3 3 3 3 3 3 3 3 3 3 1 3 3 3 3
3 3 22 3 3 3 3 3 3 3 3 3 1 3 3 3 3 3 3 3
3 3 23 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 24 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 1 3
3 3 25 3 3 3 3 3 3 3 3 1 1 3 3 3 3 3 1 3
3 3 26 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 27 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 1 3
3 3 28 2 2 3 3 3 2 3 3 3 3 3 3 3 3 3 3 3
3 3 29 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 30 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 31 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 32 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
1 3 33 3 1 3 3 1 3 3 3 3 3 3 3 3 3 3 3 3
3 3 34 1 1 3 3 3 1 3 3 3 3 3 3 3 3 3 3 3
1 1 35 3 3 3 3 1 3 3 3 3 3 3 3 3 3 3 3 3
3 3 36 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 1 1
1 1 37 3 3 3 3 1 3 3 3 3 3 3 3 3 3 3 3 3
3 3 38 1 3 3 3 3 1 3 3 3 3 3 3 3 3 3 3 3
3 3 39 3 3 3 3 3 3 1 3 3 3 3 3 3 3 3 1 3
3 3 40 3 3 3 3 3 3 1 3 3 3 3 3 3 3 3 1 3
3 3 41 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 1
3 3 42 3 3 3 1 3 3 3 3 3 3 3 3 3 3 3 1 2
3 3 43 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 1 3
3 3 44 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 1 3
3 3 45 3 3 3 1 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 46 3 1 3 1 3 1 3 3 3 3 3 3 3 3 3 3 3
3 3 47 3 1 3 3 3 1 3 3 3 3 3 3 3 3 3 3 3
3 3 48 3 3 3 3 3 3 3 3 3 3 1 3 3 3 3 3 3
3 3 49 3 1 3 3 3 1 1 3 3 3 3 3 3 3 3 1 3
3 3 50 3 3 3 3 3 3 2 3 3 3 3 3 3 3 3 1 3
papulosq annular sno malarra1 gacle lichenoi ccle scle1 acle palpur urtivas liveret rayphen erymult peritel perihyp legulc luphair dnsa aloparea
3 3 51 3 3 3 3 3 3 3 3 2 3 3 3 3 3 3 3 3
3 3 52 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 1 3
3 3 53 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 1 3
3 3 54 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 55 3 3 3 2 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 56 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 1 3
3 3 57 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 2 3
3 3 58 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 59 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 60 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 61 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 62 1 1 3 1 3 1 3 3 3 3 3 3 3 3 3 1 3
3 3 63 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 64 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 65 3 3 3 3 3 3 1 3 3 3 3 3 3 3 3 3 3
3 3 66 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 67 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 68 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 69 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 70 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 1 3
3 3 71 1 3 3 3 3 1 1 3 3 3 3 3 3 3 3 3 3
3 3 72 1 3 3 3 3 1 3 3 3 3 3 3 3 3 3 3 3
3 3 73 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 74 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 75 3 3 3 1 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 76 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 77 3 3 3 3 3 3 3 3 3 1 3 3 3 3 3 1 3
3 3 78 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 79 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 80 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 81 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 82 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 1 3
3 3 83 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 84 3 3 3 3 3 3 3 3 3 3 3 3 3 3 1 3 3
3 3 85 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 86 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 87 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 88 3 3 3 3 3 3 3 3 3 3 3 3 3 3 1 3 3
1 3 89 3 3 3 3 1 3 1 3 3 3 3 3 3 3 3 3 3
3 3 90 1 1 3 3 3 1 3 3 3 3 3 3 3 3 1 3 3
3 3 91 1 3 3 3 3 1 3 3 3 3 3 3 3 3 3 1 3
3 3 92 1 1 3 3 3 1 3 3 3 3 3 3 3 3 3 3 3
3 3 93 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 94 1 3 3 3 3 1 3 3 3 3 3 3 3 3 3 3 3
3 3 95 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 96 1 3 3 3 3 1 3 3 3 3 3 3 3 3 3 1 3
3 3 97 1 3 3 3 3 1 3 3 3 3 3 3 3 3 3 1 3
3 3 98 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 99 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 100 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
papulosq annular sno malarra1 gacle lichenoi ccle scle1 acle palpur urtivas liveret rayphen erymult peritel perihyp legulc luphair dnsa aloparea
3 3 101 3 3 3 3 3 3 3 3 3 3 3 3 3 3 1 1 3
3 3 102 2 3 3 3 3 2 3 3 3 3 3 1 3 3 3 3 3
3 3 103 3 3 3 3 3 3 1 3 3 1 3 3 3 3 3 3 3
3 3 104 3 3 3 3 3 3 1 3 3 3 3 3 3 3 3 3 3
3 3 105 3 3 3 3 3 3 1 1 3 1 3 1 3 3 3 1 3
3 3 106 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 107 2 3 3 3 3 2 3 3 3 3 3 1 3 3 3 3 3
3 3 108 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 109 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 110 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
1 3 111 3 1 3 3 1 1 3 3 3 3 3 3 3 3 3 3 3
3 3 112 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 1 3
3 3 113 3 1 3 3 3 1 3 3 3 3 3 3 3 3 3 3 3
3 3 114 3 3 3 3 3 3 2 3 3 3 3 3 3 3 3 3 3
3 3 115 2 3 3 3 3 2 3 3 3 3 3 3 3 3 3 1 3
3 3 116 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 117 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 118 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 119 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 120 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 121 3 3 3 3 3 3 1 3 1 3 3 3 3 3 3 3 3
3 3 122 3 3 3 3 3 3 3 3 2 3 3 3 3 3 3 3 3
3 3 123 3 1 3 3 3 1 1 3 3 3 3 1 3 3 1 1 3
3 3 124 3 3 3 3 3 3 3 3 3 3 3 3 3 3 1 3
3 3 125 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 126 3 3 3 3 3 3 3 3 3 3 3 3 1 3 3 3 3
3 3 127 1 3 3 3 3 1 1 3 3 3 3 1 1 3 3 1 3
3 3 128 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 129 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 130 2 2 3 3 3 2 3 3 3 3 3 3 3 3 3 1 3
3 3 131 3 3 3 3 3 3 3 3 3 3 3 3 3 3 1 1 3
3 3 132 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 133 1 3 3 3 3 1 3 3 3 3 3 3 3 3 3 1 3
3 3 134 3 3 3 3 3 3 3 3 3 3 3 3 3 3 1 3 3
3 3 135 3 3 3 1 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 136 1 2 3 1 3 1 3 3 3 3 3 3 3 3 1 1 3
3 3 137 3 3 3 3 3 3 3 3 3 3 3 3 3 3 1 3 3
3 3 138 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 139 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 140 3 1 3 3 3 1 3 3 3 3 3 3 3 3 3 3 3
3 3 141 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 142 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 143 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 144 1 3 3 1 3 1 3 3 3 3 3 3 3 3 3 1 3
3 3 145 2 3 3 2 3 2 3 3 3 3 3 3 3 3 3 3 3
3 3 146 3 1 3 3 3 1 3 3 3 3 3 3 3 3 3 3 3
3 3 147 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 148 3 3 3 1 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 149 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 150 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
papulosq annular sno malarra1 gacle lichenoi ccle scle1 acle palpur urtivas liveret rayphen erymult peritel perihyp legulc luphair dnsa aloparea
3 3 151 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 152 2 3 3 3 3 2 3 3 3 3 3 3 1 3 3 3 3
3 3 153 3 2 3 3 3 2 3 3 3 3 3 1 3 3 3 1 3
3 3 154 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 155 3 3 3 1 3 3 3 3 3 1 3 3 3 3 3 1 3
3 3 156 3 3 3 3 3 3 1 3 3 3 3 3 3 3 3 3 3
3 3 157 1 3 3 3 3 1 3 3 3 3 3 3 3 3 3 2 3
1 3 158 3 3 3 3 1 3 3 3 3 3 3 3 3 3 3 3 3
3 3 159 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 1 3
3 3 160 3 3 3 1 3 3 1 3 3 3 3 1 1 3 1 1 3
3 3 161 3 3 3 3 3 3 1 3 3 3 3 3 2 3 3 1 3
3 3 162 1 3 3 1 3 1 1 3 3 3 3 3 3 3 3 3 3
3 3 163 3 3 3 1 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 164 3 3 3 3 3 3 3 3 3 3 3 3 3 3 1 3 3
3 3 165 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 2 3
1 1 166 3 3 3 3 1 3 3 3 3 3 3 3 3 3 3 3 3
3 3 167 3 3 3 1 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 168 3 3 3 1 3 3 3 3 3 3 3 3 3 3 3 1 3
3 3 169 2 3 3 3 3 2 3 3 3 3 3 3 3 3 3 3 3
3 3 170 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 171 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 172 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 1 3
3 3 173 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 1 3
3 3 174 3 3 3 2 3 3 3 3 3 3 3 3 3 3 3 1 3
3 3 175 3 3 3 1 3 3 3 3 3 3 3 3 3 3 3 1 3
3 3 176 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
1 3 177 3 3 3 3 1 3 3 3 3 3 3 3 3 3 3 3 3
3 3 178 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 1 3
3 3 179 3 3 3 1 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 180 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 181 3 3 3 1 3 3 1 3 3 3 3 3 3 1 3 1 3
3 3 182 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 1 3
3 3 183 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 184 2 2 3 3 3 2 3 3 3 3 3 3 3 3 3 3 3
3 3 185 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 186 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 187 3 1 3 3 3 1 1 3 3 3 3 3 3 3 3 3 3
3 3 188 1 1 3 3 3 1 3 3 3 3 3 3 3 3 3 3 3
3 3 189 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
3 3 190 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
scleroda bulllesi rheumnod sno tfn dug urtwheal acannig mucosal postinf postvas scaralop nsml paltel acqicg hcq1 nailchan oralcand herpszos
3 3 3 1 1 3 3 3 1 3 3 3 3 3 3 3 2 3 3
3 3 3 2 3 3 3 3 3 1 3 3 3 3
3 3 3 3 3 3 1 3 3 1 3 3 3 3 3 3 2 3 3
3 3 3 4 3 3 1 3 2 3 3 3 3 3 3 3 2 3 3
3 3 3 5 3 3 3 3 3 1 1 3 3 3 3 3 2 3 3
3 3 3 6 3 3 3 3 2 3 3 3 3 3 3 3 2 3 3
3 3 3 7 3 3 3 3 2 3 3 3 3 3 3 3 2 3 3
3 3 3 8 3 3 3 3 3 1 1 3 3 3
3 3 3 9 3 3 3 3 2 3 3 3 3 3 3 3 2 3 3
3 3 3 10 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 11 3 3 1 3 3 3 3 3 3 3
3 3 3 12 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 13 3 3 3 3 3 3 3 3 2 3 3
3 3 3 14 3 3 3 3 1 1 3 3 3 3 3 3 2 3 3
3 3 3 15 3 3 3 3 3 1 3 3 3 3 3 3 2 3 3
3 3 3 16 3 3 3 3 3 1 3 3 3 3 3 3 2 3 3
3 3 3 17 3 3 1 3 3 1 3 3 3 3 3 3 2 3 3
3 3 3 18 3 3 3 3 3 1 3 3 3 3 3 3 2 3 3
3 3 3 19 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 20 3 3 3 3 3 3 3 3 3 3 1 1 2 3 3
3 3 3 21 3 3 3 3 2 3 3 3 3 3 1 1 2 3 3
3 3 3 22 3 3 3 3 3 3 1 3 3 3 3 3 2 3 3
3 3 3 23 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 24 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 25 3 3 3 3 3 3 3 3 3 1 3 3 2 3 3
3 3 3 26 3 3 3 3 2 3 3 3 3 3 3 3 2 3 3
3 3 3 27 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 28 3 3 3 3 3 1 3 3 3 1 1 3 2 3 3
3 3 3 29 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 30 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 31 3 3 3 1 3 1 3 3 3 3 3 3 2 3 3
3 3 3 32 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 33 3 3 3 3 3 1 3 3 3 3 3 3 2 3 3
3 3 3 34 3 3 3 3 3 1 3 3 3 3 3 3 2 3 3
3 3 35 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 36 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 37 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 38 3 3 3 3 3 1 3 3 3 3 3 3 2 3 3
3 3 3 39 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 40 3 3 3 3 1 3 3 3 3 1 3 3 2 3 3
3 3 3 41 3 3 3 3 2 3 3 3 3 1 3 3 2 3 3
3 3 3 42 3 3 3 3 1 3 3 3 3 1 3 3 2 3 3
3 3 3 43 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 44 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 45 3 3 3 3 1 1 3 3 3 3 3 3 2 3 3
3 3 3 46 3 3 3 3 2 1 3 1 3 3 3 3 2 3 3
3 3 3 47 3 3 3 3 3 1 3 3 3 3 1 3 2 3 3
3 3 3 48 3 3 3 3 1 3 3 3 3 3 3 3 2 3 3
3 3 3 49 3 3 3 3 1 1 3 3 3 3 3 3 2 3 3
3 3 3 50 3 3 3 3 1 3 3 3 3 3 3 2 3 3
scleroda bulllesi rheumnod sno tfn dug urtwheal acannig mucosal postinf postvas scaralop nsml paltel acqicg hcq1 nailchan oralcand herpszos
3 3 3 51 3 2 3 3 1 1 3 3 3 3 3 3 1 3 3
3 3 3 52 3 3 3 3 3 1 3 3 3 3 3 3 2 3 3
3 3 3 53 3 3 3 3 1 3 3 3 3 3 3 3 2 3 3
3 3 3 54 3 3 3 3 3 3 3 3 1 3 3 3 2 3 3
3 3 3 55 3 3 3 3 3 1 1 3 1 3 3 3 2 3 3
3 3 3 56 3 3 3 3 3 1 3 3 3 3
3 3 3 57 3 3 3 3 3 1 3 3 3 1 3 3 2 3 3
3 3 3 58 3 3 3 3 3 3 3 3 3 1 3 3 2 3 3
3 3 3 59 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 60 3 3 3 3 3 3 3 3 3 3
3 3 3 61 3 3 3 1 3 3 3 3 3 3 3 3 2 3 3
3 3 3 62 3 3 3 3 1 1 3 3 3 1 3 3 3 3
3 3 3 63 3 3 3 1 3 3 3 3 3 3 3 3 2 3 3
3 3 3 64 3 3 3 3 3 3 3 3 3 3 3 1 2 3 3
3 3 3 65 3 3 3 3 3 3 3 3 3 3
3 3 3 66 3 3 3 3 3 3 3 3 3 1 3 3 2 3 3
3 3 3 67 3 3 3 3 3 3 3 3 1 3 1 3 2 3 3
3 3 3 68 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 69 3 3 3 1 3 3 3 3 3 3 3 1 2 3 3
3 3 3 70 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 71 3 3 3 3 1 3 3 3 3 3 3 3 2 3 3
3 3 3 72 3 3 3 3 3 1 3 3 1 3 3 3 2 3 3
3 3 3 73 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 74 3 3 3 3 1 1 3 3 1 3 3 3 2 3 3
3 3 3 75 3 3 3 3 1 3 3 3 1 3 3 3 2 3 3
3 3 3 76 3 3 3 3 3 3 3 3 3 1 1 3 2 3 3
3 3 3 77 3 3 3 1 3 3 3 3 3 1 1 3 2 3 3
3 3 3 78 3 3 3 3 3 3 3 3 3 3 3 1 1 3 3
3 3 3 79 3 3 1 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 80 3 3 3 3 3 3 3 3 3 1 3 3 2 3 3
3 3 3 81 3 3 3 3 1 1 3 3 3 3 3 3 2 3 3
3 3 3 82 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 83 3 3 3 3 3 3 3 3 3 3 1 3 2 3 3
3 3 3 84 3 3 3 1 2 1 3 3 3 1 3 3 2 3 3
3 3 3 85 3 3 3 3 2 1 3 3 3 3 1 3 2 3 3
3 3 3 86 3 3 3 3 3 3 3 3 3 3 3 3 2 3 1
3 3 3 87 3 3 3 3 3 3 3 3 3 3
3 3 3 88 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 89 3 3 3 3 1 1 3 3 3 3 3 3 2 3 3
3 3 3 90 3 3 3 3 1 3 3 1 3 3 3 3 2 3 3
3 3 3 91 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 92 3 3 3 3 1 1 3 3 3 3
3 3 3 93 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 94 3 3 3 3 3 1 3 3 3 3 3 3 2 3 3
3 3 3 95 3 3 3 3 3 3 1 3 3 1 3 3 2 3 3
3 3 3 96 3 3 3 3 1 3 3 3 3 3 3 2 3 3
3 3 3 97 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 98 3 3 3 3 3 1 3 3 3 3 3 3 2 3 3
3 3 3 99 3 3 3 3 3 3 3 3 3 1 3 3 2 3 3
3 3 3 100 3 3 3 3 3 3 3 3 3 3 3 3 2 3 1
scleroda bulllesi rheumnod sno tfn dug urtwheal acannig mucosal postinf postvas scaralop nsml paltel acqicg hcq1 nailchan oralcand herpszos
3 3 3 101 3 3 2 3 1 1 3 3 1 3 3 3 2 3 3
3 3 3 102 3 3 3 3 2 3 3 3 3 3 3 3 2 3 3
3 3 3 103 3 3 3 3 3 3 1 3 3 3 3 3 2 3 3
3 3 3 104 3 3 3 3 3 3 1 3 3 3 3 3 2 3 3
3 3 3 105 3 3 3 3 3 3 1 3 3 3 3 3 2 3 3
3 3 3 106 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 107 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 108 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 109 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 110 3 3 3 3 3 3 3 3 3 3 1 3 2 3 3
3 3 3 111 3 3 3 3 1 3 3 3 3 3 3 3 2 3 3
3 3 3 112 3 3 3 3 3 3 3 3 3 3 1 3 2 3 3
3 3 3 113 3 3 3 3 3 3 1 3 3 3 3 3 2 3 3
3 3 3 114 3 3 3 3 3 3 3 3 3 3 3 3
3 3 3 115 3 3 3 3 3 1 3 3 3 3 3 3 2 3 3
3 3 3 116 3 3 3 3 3 1 1 3 3 1 3 3 2 3 3
3 3 3 117 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 118 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 119 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 120 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 1 3 121 3 3 3 3 1 3 1 3 3 3 3 3 2 3 3
3 3 3 122 3 3 3 3 3 3 1 3 3 3 3 3 2 3 3
3 3 3 123 3 3 3 3 1 3 1 3 3 3 3 3 2 3 3
3 3 3 124 3 3 3 3 3 3 1 3 3 3 3 3 2 3 3
3 3 3 125 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 126 3 3 3 3 3 3 3 3 3 3 3 1 2 3 3
3 3 3 127 3 3 3 3 1 3 3 3 3 3 3 3
3 3 3 128 3 3 3 3 3 1 3 3 3 3 3 3 2 3 3
3 3 129 3 3 3 3 3 3 3 3 3 3 1 3 2 3 3
3 3 3 130 3 3 3 3 3 1 3 3 3 3 1 3 2 3 3
3 3 3 131 3 3 3 3 1 1 3 3 3 1 3 3 2 3 3
3 3 3 132 3 3 3 1 3 3 3 3 3 3 3 3 2 3 3
3 3 3 133 3 3 3 3 3 3 3 3 3 1 3 3 2 1 3
3 3 3 134 3 3 3 3 1 1 3 3 3 3 3 3 2 3 3
3 3 3 135 3 3 3 3 3 1 1 3 3 3 3 3 2 3 3
3 3 3 136 3 3 3 3 1 1 3 1 3 3 3 3 2 1 3
3 3 3 137 3 3 3 3 3 3 3 3 1 1 1 3 2 3 3
3 3 3 138 3 3 3 3 3 1 3 3 3 3 3 3 2 3 3
3 3 3 139 3 3 3 3 3 3 3 3 3 3 1 3 2 3 3
3 3 3 140 3 3 3 3 3 1 3 3 3 3 3 3 2 3 3
3 3 3 141 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 142 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 143 3 3 3 3 3 1 3 3 3 3 3 3 2 3 3
3 3 3 144 3 3 3 3 3 1 1 3 3 1 3 3 2 3 3
3 3 3 145 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 146 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 147 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 148 3 3 3 3 2 3 3 3 3 3 1 3 2 3 3
3 3 3 149 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 150 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
scleroda bulllesi rheumnod sno tfn dug urtwheal acannig mucosal postinf postvas scaralop nsml paltel acqicg hcq1 nailchan oralcand herpszos
3 3 3 151 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 152 3 3 3 3 3 1 3 3 3 3 3 3 2 3 3
3 3 3 153 3 3 3 3 3 3 3 3 3 1 3 3 2 3 3
3 3 3 154 3 3 3 3 3 3 3 3 3 3 3 3
1 3 3 155 3 3 3 3 2 1 3 1 3 3 3 3 2 3 3
3 3 3 156 3 1 3 3 2 1 1 3 3 3 1 3 2 3 3
3 3 3 157 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 158 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 159 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 160 3 3 3 3 1 1 3 1 3 1 3 3 2 3 3
3 3 3 161 3 3 3 3 3 1 3 2 3 2 3 3 2 3 3
3 3 3 162 3 3 3 3 1 3 3 1 3 3 3 3 2 3 3
3 3 3 163 3 3 3 3 3 3 3 1 3 3 3 3 2 3 3
3 3 3 164 3 3 3 3 3 1 3 3 3 3 3 3 2 3 3
3 3 3 165 3 3 3 3 3 3 3 3 3 3 1 3 2 3 3
3 3 3 166 3 3 3 3 3 1 1 3 3 3 3 3 2 3 3
3 3 3 167 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 168 3 1 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 169 3 3 3 3 3 3 3 3 3 1 3 3 2 3 3
3 3 3 170 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 171 3 3 3 3 3 3 3 3 3 3 1 3 2 3 3
3 3 3 172 3 3 3 3 3 3 3 3 3 3 3 1 1 3 3
3 3 3 173 3 3 3 3 3 3 3 3 3 3 1 3 2 3 3
3 3 3 174 3 3 3 3 2 1 3 3 3 3 3 3 1 3 3
3 3 3 175 3 3 3 3 1 3 3 3 3 3 3 3 2 3 3
3 3 3 176 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 177 3 3 3 3 1 3 3 3 3 3 1 3 2 3 3
3 3 3 178 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 179 3 3 3 3 1 1 3 3 3 3 3 3 2 3 3
3 3 3 180 3 3 3 3 3 3 3 3 1 3 3 3 2 3 3
3 3 3 181 3 1 3 3 1 3 1 3 3 3 3 3 2 1 3
3 3 3 182 3 3 3 3 3 1 3 3 3 3 3 3 2 3 3
3 3 3 183 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 184 3 3 3 3 1 3 3 3 3 3 3 3 2 3 3
3 3 3 185 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 186 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 187 3 3 3 3 1 3 3 3 3 3 3 3 2 3 3
3 3 3 188 3 3 3 3 1 3 1 3 3 3 3 3 2 3 3
3 3 3 189 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
3 3 3 190 3 3 3 3 3 3 3 3 3 3 3 3 2 3 3
scabi tinvers strdist cushfac sno acnevul acneerup nsoth hemo totwbc n e b l m ptct cast hem pyu prote sercreat lft ana anatype anapos
3 3 3 3 1 3 3 3 8 5400 42 1 1 40 16 300000 2 2 2 1 0.6 1 1 1 3
3 3 3 3 2 3 3 3 11 7100 41 3 1 46 9 305000 2 2 2 2 0.7 1 1 4 3
3 3 3 3 3 3 3 3 13 8900 73 2 0 19 6 306000 2 2 2 2 0.8 1
3 3 3 3 4 3 3 3 13.1 7000 38 3 1 15 8 412000 2 2 2 2 0.8 2
3 1 3 3 5 3 3 3 2 2 2 2
3 3 3 3 6 3 3 3 14.1 5700 57 6 0 29 8 234000 2 2 2 2 0.9 1 1 1
3 3 3 3 7 1 1 3 13.2 6400 52 6 0 32 10 227000 2 2 2 2 0.9 1
3 3 3 3 8 3 3 3 12.2 3900 221000 2 2 2 2 0.9 1 1 3 3
3 3 3 1 9 1 3 1 9.8 13300 71 1 0 22 6 476000 2 2 2 2 0.8 1 1 1 4
3 3 3 3 10 1 3 3 2 2 2
3 3 3 3 11 3 3 3 8.8 14300 78 0 0 15 7 552000 2 2 2 2 0.8 1
3 3 3 3 12 3 3 3 9.1 9100 89 0 1 7 3 19000 2 2 1 1 2.7 2 1 1 3
3 3 3 3 13 3 3 3 2 2 2
3 3 3 3 14 3 3 3 10.3 6100 82 0 0 15 3 165000 1 1 1 1 1 1 1 1 4
3 3 3 3 15 3 3 3 10.6 6100 417000 2 2 2 2 0.7 1
3 3 3 3 16 3 3 3 10.5 3200 61 2 0 31 6 301000 2 2 2 2 0.7 1
3 3 3 3 17 3 3 3 10.5 5400 66 0 0 29 5 278000 2 2 2 2 0.7
3 3 3 3 18 3 3 3 11.2 4600 63 1 0 32 4 358000 2 2 2 2 0.7 1
3 3 3 3 19 3 3 3 11 4300 61 3 0 24 12 267000 2 2 2 2 0.7 1 1 1
3 3 3 3 20 3 3 3 9 5400 44 4 0 46 6 113000 1 2 2 1 0.6 2 1 1
3 3 3 3 21 3 3 3 9.3 4800 38 8 0 49 5 96000 2 2 1 1 0.7 1
3 3 3 3 22 3 3 3 12.6 7000 33 14 1 46 6 257000 2 2 2 2 0.6 1 1 1
3 3 3 3 23 1 1 3 15 6700 44 6 0 42 8 203000 2 2 2 2 1 1 1 1
3 3 3 3 24 1 3 3 15 6700 44 6 0 42 8 203000 2 2 2 2 1 1
3 3 3 3 25 3 3 3 10.7 5300 65 3 0 27 5 314000 1 1 2 1 0.7 2 1 1 4
3 3 1 3 26 3 3 3 12.4 7700 66 4 0 24 6 170000 2 2 2 2 0.7 2 1 3 4
3 3 3 1 27 3 3 3 14 14200 66 1 0 26 7 234000 2 2 2 2 0.8 1 1 1 4
3 3 1 1 28 3 3 1 13.7 8600 79 1 0 13 7 145000 2 2 2 2 0.7 1 2
3 3 3 3 29 3 3 3 14 4700 44 13 0 35 8 242000 2 2 2 2 0.9 1 1 1
3 3 3 3 30 3 3 3 12.4 5600 62 3 1 24 10 244000 2 2 2 2 0.8 1 1 1
3 3 3 3 31 3 3 3 10.7 6800 59 4 0 25 12 351000 2 2 2 2 0.7 1 1 2 2
3 3 3 3 32 3 3 3 9.8 5500 64 3 0 25 8 364000 2 2 2 2 0.7 1
3 3 3 3 33 3 3 3 10.1 9400 83 0 0 12 5 332000 2 2 2 2 0.9 1
3 3 3 3 34 1 3 3 9.8 9300 66 0 0 7 7 163000 2 2 2 2 0.8 1
3 3 3 3 35 3 3 1 9.3 4900 52 4 0 32 12 228000 2 2 2 2 0.9 1
3 3 3 3 36 3 1 1 9.1 5400 59 2 1 26 12 379000 2 2 2 2 0.8 1
3 3 3 3 37 3 3 3 9.4 5500 69 0 2 16 13 396000 2 2 2 2 0.8 1
3 3 3 3 38 3 3 3 12.1 4300 64 1 0 28 7 150000 2 2 2 2 0.7 1 1 1
3 3 3 3 39 3 3 3 12.1 3800 56 1 0 35 8 187000 2 2 2 2 0.7 1
3 3 3 3 40 3 3 1 12.1 3900 51 1 0 37 11 161000 2 2 2 2 0.7 1
3 3 3 3 41 3 3 3 13.3 4600 63 1 0 29 7 159000 2 2 2 2 0.8 1
3 3 3 3 42 1 3 3 12.4 4000 58 1 0 34 7 168000 2 2 2 2 0.8 1
3 1 3 3 43 1 3 3 12.7 5100 56 0 0 35 9 171000 2 2 2 2 0.8 1
3 3 3 3 44 3 1 3 11 4000 75 1 0 19 5 180000 2 2 2 2 0.7 1
3 3 1 1 45 3 3 3 11.6 4200 58 0 0 34 8 270000 1 2 2 1 0.7 1 1 2 2
3 3 1 1 46 3 3 3 12 3300 45 0 0 47 7 209000 2 2 2 1 0.7 1
3 3 3 3 47 3 3 1 10.7 8300 86 0 0 13 1 244000 2 2 2 2 0.7 1 1 1 4
3 3 3 3 48 3 3 3 8.8 2000 31 5 0 13 1 20000 1 1 1 1 1.2 2 1 1 3
3 3 3 3 49 3 3 3 7.8 4600 91 0 0 7 2 211000 1 2 1 1 0.7 2 1 3 4
3 3 3 3 50 3 3 3 11.4 7800 67 0 0 24 9 313000 2 1 1 2 0.7 1 1 3 4
scabi tinvers strdist cushfac sno acnevul acneerup nsoth hemo totwbc n e b l m ptct cast hem pyu prote sercreat lft ana anatype anapos
3 3 3 3 51 3 3 2 7.6 3800 45 1 6 48 91000 2 2 2 1 0.8 2 1 1 4
3 3 3 3 52 3 3 1 10 6600 50 0 0 40 10 45000 2 2 2 2 0.8 1
3 3 3 3 53 3 3 3 6.7 3100 78 0 0 12 10 208000 2 2 1 1 0.8 1
3 3 3 3 54 3 3 1 11.5 6900 58 1 1 33 7 554000 2 1 1 1 0.7 1 1 1
3 3 1 1 55 3 3 1 9.5 4600 50 5 0 35 10 227000 2 2 2 2 0.8 1 2
3 3 3 3 56 3 3 3 8.1 6300 59 3 0 30 8 297000 2 2 1 2 0.8 1 1 1
3 3 3 3 57 1 1 3 8 5100 51 0 0 38 11 143000 2 2 2 1 0.8 1 1 1 4
3 1 3 3 58 3 3 3 8.9 7300 74 1 0 16 9 120000 1 2 1 1 0.9 1
3 3 1 1 59 3 3 3 10.6 6100 50 4 0 37 9 276000 2 1 2 1 0.6 1 1 5
3 3 3 3 60 3 3 1 10.3 8600 56 1 0 34 9 315000 2 2 2 2 0.9 1
3 3 3 3 61 3 3 1 11 11000 67 3 0 24 6 296000 2 2 2 2 0.7 1 1 1
3 3 3 1 62 3 3 1 11.3 11700 70 0 0 27 3 414000 2 2 2 2 0.5 1 1 3 2
3 3 1 3 63 3 3 1 10.8 10000 77 1 1 15 6 256000 2 2 2 1 1 1 2
3 1 3 3 64 3 3 3 8.4 9700 57 0 0 37 9 197000 2 2 2 2 1 1 1 3
3 3 3 3 65 3 3 3 12.6 10300 49 2 0 44 5 314000 2 1 2 2 0.6 2 1 1 3
3 1 3 3 66 1 3 1 11.8 7400 49 0 0 40 11 151000 2 2 2 2 0.7 1 1 3 4
1 3 3 3 67 3 3 1 8.1 6700 56 2 0 34 8 211000 2 2 1 2 0.7 1
3 1 3 3 68 3 3 1 11.7 5200 60 5 0 25 10 202000 2 2 2 2 0.7 1 1 1
3 1 1 3 69 3 3 1 12.7 4900 71000 2 2 2 1 0.9 1 1 1
3 3 3 3 70 3 3 1 9.7 8500 33 1 0 54 12 516000 2 2 2 1 0.6 1 1 1 3
3 3 3 3 71 3 3 1 7.6 5100 64 1 1 29 5 245000 2 2 2 1 0.8 1 2 3
3 3 3 3 72 3 3 1 8.9 5500 68 0 0 24 8 134000 2 2 2 2 0.7 2 1 1 4
3 3 3 3 73 3 3 3 10.6 9800 93 0 0 4 3 313000 2 2 2 2 0.7 1 2
3 3 3 3 74 3 3 1 11.9 10300 36 4 0 56 4 135000 2 2 2 2 0.6 1 1 1
3 3 3 3 75 3 3 1 11.3 8900 32 5 0 57 6 112000 2 2 2 2 0.6 1
3 3 3 1 76 3 3 1 12.3 11634 67 0 0 23 5 103000 2 2 2 1 0.8 1 1 5
3 3 1 1 77 3 3 3 11.4 18800 67 2 1 22 8 286000 2 2 1 2 0.7 1
3 3 3 3 78 3 3 3 8.5 27000 77 0 0 20 3 500000 2 2 2 2 0.6 1 2
3 3 3 3 79 3 3 3 9.8 17100 56 5 1 34 4 406000 2 1 1 2 0.6 1 1 1
3 3 3 3 80 3 3 1 12.2 18300 51 6 0 36 7 490000 2 2 1 2 0.6 1
3 3 3 3 81 3 3 3 12 7100 52 3 1 36 8 216000 2 2 1 2 0.7 1 1 1
3 1 3 3 82 3 3 3 13 8700 60 4 0 25 11 223000 2 2 2 2 0.7 1 1 1 4
3 3 3 1 83 3 3 1 10.4 5900 47 5 0 40 8 273000 2 1 2 1 0.6 1 1 2 2
3 3 3 3 84 3 3 1 9.7 5000 74 0 1 14 11 308000 2 2 1 2 0.8 1 1 1 4
3 3 3 3 85 3 3 1 10.1 6600 59 5 0 32 4 492000 2 2 2 1 0.6 1 1 3
3 3 3 3 86 3 3 3 10.4 13200 67 3 1 21 8 602000 2 1 1 1 0.7 1
3 3 3 3 87 3 3 3 11.1 14400 67 3 0 19 11 683000 2 2 1 1 0.7 1
3 1 1 1 88 3 3 3 9.6 5800 48 7 0 35 10 274000 2 2 2 2 1.1 1 2
3 3 3 3 89 3 3 3 6.4 5200 42 22 0 29 6 220000 2 2 2 1 0.7 1 1 1
3 3 3 3 90 3 3 3 12.4 4800 62 0 0 33 5 310000 1 2 1 2 0.7 1 1 4
3 3 3 3 91 3 3 3 12.2 5000 64 0 0 30 6 265000 2 2 1 2 0.7 1
3 3 3 3 92 3 3 1 11.3 4400 49 3 0 37 11 242000 2 2 2 2 0.7 1
3 3 3 3 93 3 3 3 11.3 4200 51 1 2 39 7 142000 2 2 2 2 0.7 1 1 3 3
3 3 3 3 94 3 3 3 11.6 9000 43 2 0 48 7 347000 2 1 1 1 0.8 1 1 1 4
3 1 3 3 95 3 3 1 11.8 9000 47 3 0 41 9 275000 2 2 2 2 0.9 1 1 1 3
3 3 3 3 96 3 3 3 10.9 4700 20 0 0 69 11 213000 2 2 2 2 0.8 2 1 3 4
1 3 3 3 97 3 3 3 11.7 5800 44 4 0 44 8 174000 2 2 2 2 0.7 1
3 1 3 3 98 3 3 3 13.2 10300 33 3 0 60 4 155000 2 2 2 2 0.6 2 1 1
3 1 3 1 99 3 3 3 12.7 17500 47 0 0 47 6 332000 2 2 2 2 0.6 1 1 1 3
3 3 1 1 100 3 3 3 12.1 11200 75 0 0 20 34 292000 2 2 2 2 0.6 1 1 1 3
scabi tinvers strdist cushfac sno acnevul acneerup nsoth hemo totwbc n e b l m ptct cast hem pyu prote sercreat lft ana anatype anapos
3 3 3 3 101 3 3 1 8 8100 78 0 0 19 3 164000 1 2 1 1 0.7 2 1 1
3 3 3 3 102 3 3 1 8.2 8300 54 1 1 36 8 130000 2 2 2 1 0.7 2
3 3 3 3 103 3 3 3 11 10300 61 1 0 29 9 115000 2 2 2 2 0.9 1 1 1 3
3 1 3 3 104 1 3 3 10.3 6000 66 1 0 25 8 113000 2 2 2 2 0.9 1
3 3 3 3 105 3 3 3 10.1 9400 57 2 1 32 8 142000 2 2 2 1 0.9 1
3 3 3 3 106 3 3 3 12.1 19500 72 2 0 20 6 287000 2 2 2 1 0.6 1 1 1 4
3 3 3 3 107 3 1 3 12.5 13200 264000 2 2 2 1 0.6 1
3 3 3 3 108 1 3 1 12.8 6000 67 1 0 24 8 290000 2 2 2 2 0.7 1 1 1
3 3 3 3 109 3 3 1 12.7 5700 62 1 0 32 5 199000 2 2 2 2 0.9 1 1 1
3 3 3 3 110 3 3 3 12.1 6700 58 5 1 32 4 310000 2 2 2 2 0.7 1 1 4 2
3 3 3 3 111 3 3 3 11 6300 53 7 0 32 8 199000 2 2 1 2 0.8 1
3 3 1 3 112 3 3 3 9.4 12600 76 0 0 20 4 478000 2 1 1 1 0.4 1 1 1 1
3 3 3 3 113 3 3 3 12.4 5300 82 0 0 16 2 351000 2 2 2 2 0.7 1 1 1 4
3 3 3 1 114 1 3 3 12.2 16900 73 0 0 9 18 285000 2 1 2 1 0.8 1 1 3 3
3 3 3 3 115 3 3 1 8.9 2700 70 0 0 30 0 118000 2 1 1 1 1.2 1 1 1 3
3 3 1 1 116 3 3 1 12.6 9100 68 0 0 26 6 252000 2 1 1 2 0.8 2 1 1 2
3 3 3 3 117 3 3 1 12.3 7500 52 2 0 39 7 244000 2 2 2 2 0.9 1 2
3 3 3 3 118 3 3 3 10.3 7700 59 3 0 27 11 372000 2 2 1 2 0.8 1 1 4 2
3 3 3 3 119 3 3 3 12.7 6100 47 2 1 42 8 233000 2 2 2 1 0.9 1 1 1 2
3 3 3 3 120 3 3 1 11.1 8800 65 6 1 22 6 320000 2 2 2 6.5 2 2
3 3 3 3 121 3 3 3 9.1 16200 93 0 0 6 1 64000 1 1 1 1 1.5 1 1 1 4
3 1 3 3 122 1 3 3 12.2 6300 269000 2 2 2 1 0.8 1 1 1 2
3 3 3 3 123 3 3 3 7.2 10300 60 0 0 34 6 10000 2 2 2 1 0.6 2 1 1 3
3 3 3 1 124 1 3 3 11 6200 58 2 0 36 4 207000 2 2 2 1 0.7 1 1 6 3
3 3 3 3 125 3 3 3 12.5 8300 46 1 0 45 8 377000 2 2 2 2 0.8 1 1 1
3 3 3 3 126 3 3 3 10.9 6000 61 7 0 26 6 118000 2 2 2 2 0.8 2 1 1 3
3 3 3 3 127 3 3 3 6.4 3200 85 0 0 6 9 67000 1 1 2 1 0.9 2 1 1 4
3 3 3 3 128 3 3 3 10.9 7400 47 7 1 34 11 237000 2 2 2 2 0.7 1 1 1
3 1 1 3 129 3 3 3 11.3 13900 82 0 0 14 4 196000 2 2 2 2 0.9 1 1 3 4
3 3 3 3 130 3 3 3 6.3 7000 68 3 1 22 6 307000 1 1 1 1 0.8 1 1 1 4
3 3 3 3 131 3 3 3 13.1 12600 77 0 0 18 5 318000 2 1 2 2 0.7 1
3 1 3 3 132 3 3 1 11.8 9900 52 2 1 36 9 357000 2 2 2 2 0.8 1 1 1 2
3 3 3 1 133 3 3 3 12.5 5400 70 0 0 24 6 438000 2 2 2 2 0.8 1 1 1 3
3 3 3 3 134 3 3 3 6.3 5300 87 0 1 7 5 167000 2 2 1 1 1.1 2 1 1 4
3 3 3 3 135 3 3 1 9.8 2900 84 2 0 14 0 180000 2 2 2 2 0.7 1 1 4
3 3 3 3 136 3 3 3 8.7 4400 1 1 1 29 8 157000 2 2 2 1 0.8 1 1 3 4
3 3 3 3 137 3 3 3 10.5 4400 78 0 1 15 6 187000 2 2 2 1 0.7 1 1 3 4
3 3 3 3 138 3 3 3 9.6 8100 80 1 0 15 4 225000 2 2 2 2 0.8 1 1 1 4
3 3 3 3 139 3 3 1 7 5500 67 0 0 19 14 158000 2 2 2 2 0.7 1 1 1 2
3 3 3 3 140 3 3 3 10.5 3900 36 0 0 56 8 259000 2 2 1 2 0.7 2 2
3 3 1 1 141 1 3 3 11.8 9400 76 1 0 14 9 313000 2 2 2 1 0.6 1 1 4 2
3 3 3 3 142 3 3 3 13.6 8900 49 6 1 36 8 332000 2 2 2 2 0.9 1 1 1 4
3 3 3 3 143 3 3 1 11.5 6500 62 2 1 31 4 100000 2 2 2 2 0.7 1 1 1
3 3 3 3 144 3 3 1 11.7 13800 47 1 1 43 8 360000 2 1 1 1 0.7 1 2
3 3 3 3 145 3 3 3 13.4 8800 44 2 0 46 8 418000 2 2 2 1 0.6 1 1 1 1
3 3 3 3 146 3 3 1 6.3 8500 28 0 0 66 6 199000 2 2 2 2 0.6 1 1 1 2
3 3 3 3 147 3 3 3 12.5 9600 70 1 0 24 5 146000 2 1 1 1 0.6 1 1 3 3
3 3 1 3 148 3 3 1 8.8 4500 86 1 0 10 3 372000 2 2 1 1 0.8 1 1
3 3 3 3 149 3 3 3 11.1 4700 49 0 0 43 8 272000 2 2 2 1 0.7 1 1 1 3
3 3 1 1 150 3 1 1 12.1 3700 66 0 1 31 2 660000 2 2 2 1 1.2 1 1
scabi tinvers strdist cushfac sno acnevul acneerup nsoth hemo totwbc n e b l m ptct cast hem pyu prote sercreat lft ana anatype anapos
3 3 3 3 151 3 3 3 14.6 6300 50 1 0 43 6 133000 2 2 2 2 0.7 1 1 1 1
3 3 3 1 152 3 3 3 13.6 8900 68 1 0 23 1 257000 1 2 2 2 0.9 1 1 1 2
3 3 3 3 153 3 3 3 12.5 6600 63 0 0 29 8 74000 2 2 2 2 0.8 1 1 1 3
3 3 3 3 154 3 3 3 14.3 9900 54 0 0 41 5 251000 2 2 2 2 0.5 1 1 1 4
3 3 3 3 155 3 3 3 11.5 8100 52 3 0 38 7 288000 2 2 2 2 0.8 1 1 1 3
3 3 3 1 156 3 3 1 11.1 17800 58 1 1 36 4 92000 2 2 2 2 0.6 1 1 1 4
3 3 3 1 157 3 3 3 10.1 11600 55 0 0 35 10 242000 2 2 2 1 1 2
3 3 3 3 158 3 3 3 11.9 6900 72 1 0 18 9 117000 2 2 1 2 0.8 1 1 1 4
3 3 3 3 159 3 3 1 11.8 7700 76 0 0 13 11 133000 2 2 2 2 0.6 1 1 1 2
3 3 3 3 160 3 3 1 11.1 5300 55 2 1 33 9 284000 2 2 2 2 0.6 1 1 1 4
3 3 3 3 161 3 3 3 11.8 5200 56 0 0 31 13 260000 2 2 2 2 0.7 1
1 3 3 3 162 3 3 3 8.6 3700 78 1 0 16 5 174000 2 2 2 1 0.8 1 1 3 4
3 3 3 1 163 3 3 3 11.4 3700 257000 2 2 2 2 0.9 1 1 1
3 3 3 3 164 3 3 3 13.4 19000 30 1 0 58 11 522000 2 2 2 2 0.8 1 3 3
3 3 3 3 165 3 3 3 9.9 9400 43 2 0 45 10 362000 2 2 2 2 0.8 1 1 3 4
3 3 3 3 166 3 3 3 11.6 5800 58 2 0 33 7 249000 2 2 2 2 0.7 1 1 1 4
3 3 3 3 167 3 3 3 12.6 6100 284000 2 2 1 2 0.9 1 1 1 3
3 3 3 3 168 3 3 3 8.7 11800 89 0 0 9 2 277000 2 2 2 2 0.8 1 1 1 3
3 3 3 3 169 3 3 3 10 3700 52 0 0 36 12 308000 2 1 2 2 0.5 2 1 1 3
3 3 3 3 170 3 3 3 12.5 4800 43 2 0 42 13 238000 2 1 2 2 0.9 1 1 3 3
3 3 3 3 171 3 3 1 8.2 6100 70 1 1 23 5 140000 2 1 2 1 1.9 1 1 3 4
3 3 3 3 172 3 3 3 10 8900 53 1 0 38 8 328000 2 1 2 2 0.9 1 1 3 4
3 3 3 3 173 3 3 3 10.7 3900 120000 2 2 2 1 0.6 1 1 4
3 3 3 3 174 3 3 1 12.1 3400 73 0 1 21 5 75000 2 2 2 1 0.8 2 1 1 3
3 3 3 3 175 3 3 3 6.2 4600 58 1 1 32 8 337000 2 2 2 1 0.6 1 1 1
3 3 3 3 176 3 3 3 1.9 12500 61 2 0 31 6 576000 2 1 1 1 0.7 1 2
3 3 3 1 177 3 3 3 9.9 6000 53 1 0 38 8 370000 2 2 1 1 0.6 1 1 1 3
3 3 3 3 178 3 3 3 12.2 7700 68 4 0 28 4 267000 2 1 2 1 0.9 1
3 3 3 1 179 3 3 3 10 6000 39 3 0 46 12 361000 2 2 2 2 0.7 1
3 3 3 3 180 3 3 1 9.7 10600 79 10 1 14 6 404000 2 1 2 2 0.8 1 1 4
3 3 3 3 181 3 3 3 7.4 5200 91 1 0 4 4 257000 2 2 2 2 0.7 1 1 4 3
3 3 3 3 182 3 3 1 13 8400 263000 2 2 2 2 0.8 1 1 1
3 3 3 3 183 3 3 3 9.4 8500 71 2 0 20 7 228000 2 2 2 2 0.7 1 1 1
3 3 3 3 184 3 3 3 13.2 5200 45 2 0 39 14 235000 2 2 2 2 0.8 2 1 1 2
3 3 3 3 185 3 3 3 12.8 5500 41 3 0 46 10 266000 2 2 2 2 0.7 1 1 1 3
3 3 3 3 186 3 3 3 9.8 4800 52 3 0 39 6 204000 2 2 2 2 0.7 2 1 1 4
3 3 3 3 187 3 3 3 10.4 3200 203000 2 2 2 2 0.8 2 1 1 1
3 3 3 3 188 3 3 3 11 5600 66 0 1 11 12 108000 1 1 1 1 0.7 2 1 1 4
3 3 3 3 189 3 3 3 10.5 6800 42 2 0 44 12 370000 2 1 1 1 0.6 1 1 1 3
3 3 3 3 190 3 3 3 12.5 11400 53 10 0 31 6 235000 2 2 2 2 0.7 1 1 1 4
c3 c4 antidis lupanti anticard sno antissa antissb antismit antirnp dct totsledai
78 5 212 1 1 1 58 2 118 172 1 8
80 10 605 2 2 2 5 2 3 107 2 6
80 8 365 3 4
104 11 406 4 2
101 14 592 5 2
118 28 56 2 2 6 357 192 1 0
103 27 52 7 2
68 7 437 2 1 8 2 1 11 19 10
125 22 122 2 9 218 8 3 8
10 7
146 24 104 11 7
57 8 2 2 12 2 1 3 1 12
13 2
34 5 1139 2 2 14 215 3 339 1 22
115 11 206 15 4
31 5 838 16 6
39 12 446 17 8
42 5 831 18 6
92 7 88 2 1 19 1 1 2
32 5 235 1 2 20 1 8
38 5 181 21 14
107 15 19 2 22 2 0
107 21 69 2 23 0
107 21 69 24 2
49 5 1286 2 1 25 58 1 100 154 1 16
130 35 109 2 26 113 7 42 58 2 2
115 17 20 1 2 27 158 1 3 1 2
125 12 2 2 28 16 10
82 9 52 1 29 1 2
112 17 20 2 2 30 1 1 1 0 1 0
149 27 6 2 2 31 23 2 4 0 1 0
127 23 85 32 5
131 31 120 33 4
122 26 34 34 2
122 22 97 35 2
112 26 13 36 8
132 32 21 37 2
62 11 468 1 38 259 307 1 6
74 11 404 39 14
65 9 194 40 16
71 11 335 41 6
73 10 367 42 10
67 11 313 43 6
77 11 521 44 10
84 9 6 2 45 154 1 1 16
91 17 2 46 13
55 6 431 1 2 47 6 2 41 287 6
19 6 128 2 2 48 16 2 1 22
43 16 1370 1 2 49 1 27
77 11 1125 1 2 50 5 2 4 0 1 10
c3 c4 antidis lupanti anticard sno antissa antissb antismit antirnp dct totsledai
34 6 261 2 2 51 3 1 3 1 19
57 6 438 52 13
56 13 1164 53 1 16
65 8 367 2 2 54 12
88 6 408 2 1 55 7 1 7 0 1 4
121 8 74 56 18
69 11 98 1 1 57 16 1 285 4
58 11 240 58 12
62 10 738 2 1 59 12
35 6 613 60 4
145 16 4 1 1 61 1 0
115 11 269 2 2 62 2 5 0 1 8
122 44 7 1 2 63 4 2 1 0
75 17 503 1 2 64 82 2 7 24 1 4
43 5 885 2 2 65 2 3 3 0 1 14
85 11 59 2 2 66 185 98 4 0 1 2
75 13 657 2 67 201 9 16 287 1 4
82 6 46 1 2 68 0 1 2
115 24 106 2 2 69 2 5
31 6 302 2 70 3 1 142 328 10
34 9 240 2 71 52 7 94 181 1 17
36 16 275 2 2 72 139 1 252 283 1 6
158 35 2 2 2 73 1 1 1 4
109 24 63 1 2 74 61 159 1 2
69 14 257 75 8
58 6 43 1 1 76 1 6
99 6 11 77 4
168 13 6 2 78 1 2 1 0 1 9
73 6 160 2 2 79 1 0 8
79 9 22 80 6
115 28 15 1 2 81 1 6
14 10 35 1 2 82 53 1 6 267 1 10
79 14 351 2 2 83 13 1 7 0 2 16
93 5 281 2 2 84 193 266 291 1 9
49 5 1284 2 1 85 160 0 0 1 14
66 5 339 86 16
82 12 192 87 12
130 26 4 2 88 1 1 1 0
40 5 265 2 1 89 1 13
86 30 123 2 1 90 1 2 3 0 19
92 31 99 91 8
92 6
90 17 396 1 1 93 7 1 9 1 2
57 5 534 2 2 94 4 2 4 0 1 18
95 10 5 2 2 95 221 9 1 1 0
54 7 554 2 2 96 5 1 4 2 1 11
53 5 984 97 8
101 11 2 1 2 98 1 1 1 1 0
85 10 350 1 2 99 8 2 14 9 1 4
97 18 288 1 2 100 8 2 14 1 2
c3 c4 antidis lupanti anticard sno antissa antissb antismit antirnp dct totsledai
32 5 826 2 2 101 1 1 190 290 1 20
51 7 304 102 12
76 8 451 1 1 103 2 15 79 12
68 7 317 104 17
59 7 304 105 23
124 34 44 2 106 177 1 233 68 4
121 18 81 107 6
99 17 144 2 2 108 0
123 33 193 2 1 109 8 1 2
104 25 75 2 110 10 2 32 2 0
73 12 488 111 18
55 5 38 2 2 112 1 1 1 1 1 16
87 13 776 1 2 113 18 1 198 271 1 6
79 9 562 2 2 114 1 1 1 3 1 16
24 6 680 2 115 3 1 2 1 23
71 15 74 2 2 116 1 1 1 1 1 14
126 21 5 2 2 117 43 1 1 0 2
102 17 127 1 1 118 22 5 41 49 1 6
78 9 25 1 2 119 11 3 8 0 1 6
162 22 13 1 1 120 0
46 11 1109 2 2 121 4 1 152 225 1 34
106 29 1 2 122 1 4
17 6 873 1 2 123 5 3 8 1 18
84 9 33 2 124 2 3 3 0 2 8
87 17 577 1 1 125 0 0 1 4
102 29 214 1 2 126 20 1 1 0 1 2
28 5 1190 2 2 127 7 1 4 1 20
92 38 2 1 128 80 1 46 1 0
117 26 46 1 1 129 7 1 34 33 1 0
50 5 1266 2 130 661 1 77 1 27
93 18 9 131 8
92 10 191 2 132 1 1 2 0 2 2
81 5 113 2 2 133 190 3 135 263 1 10
31 12 1055 1 2 134 10 1 289 704 1 19
76 5 678 2 2 135 2 1 6 0 1 8
25 5 1298 1 1 136 10 1 13 20 1 19
38 6 1300 1 2 137 234 343 9 10 1 10
67 6 396 2 2 138 4 1 289 348 1 4
69 19 3 2 2 139 1 1 2 169 1 2
198 42 3 1 140 4 1 29 52 1 7
106 30 125 1 2 141 1 2 2 6
92 10 104 1 1 142 21 4 226 1 2
81 20 40 2 2 143 2 2
50 8 38 2 144 2 1 1 20
130 19 68 145 6
146 3 1 1 3
84 8 201 2 2 147 4 18 189 3 16
50 6 1167 2 2 148 202 289 1 14
35 6 41 2 149 2 1 3 2 2
42 5 5 2 2 150 12 1 79 1 8
c3 c4 antidis lupanti anticard sno antissa antissb antismit antirnp dct totsledai
26 14 31 2 2 151 11 1 8 1 1 2
101 12 121 2 2 152 203 3 4 3 1 14
25 203 1 2 153 3 1 50 193 1 8
95 27 183 2 1 154 80 1 10 2
120 18 16 2 2 155 1 4
136 18 317 1 2 156 4 1 29 352 1 15
107 21 7 2 2 157 1 1 26 49 9
105 19 139 2 2 158 215 7 128 147 1 10
119 28 2 2 159 3 1 2 16 1 2
42 6 268 1 2 160 220 65 195 266 1 22
64 6 116 161 14
32 7 1789 2 2 162 119 6 7 14 1 35
90 18 5 2 2 163 1 1 56 36 2 2
102 33 34 1 2 164 1 0
95 9 851 1 165 9 1 10 29 12
108 16 826 2 2 166 6 1 176 242 1 4
27 6 238 2 167 2 10
43 5 462 2 2 168 137 3 112 201 1 8
46 5 314 2 2 169 213 121 50 51 15
75 6 314 2 2 170 12 1 8 12 1 8
39 6 1359 2 1 171 25 1 42 64 1 15
60 4 669 2 1 172 7 1 8 14 1 10
60 7 173 1 1 173 1 15
26 14 719 1 174 170 2 3 4 1 17
39 6 34 2 2 175 1 1 2 1 12
66 6 5 2 2 176 2 3 2 1 14
70 22 1260 2 177 1 1 63 130 21
72 6 436 178 14
140 26 6 179 4
141 16 85 2 2 180 4 1 7 0 4
74 16 741 2 2 181 27 1 5 116 1 16
138 39 10 2 2 182 2
105 22 10 1 1 183 0
128 1 2 2 184 1 1 56 78 5
90 20 4 185 117 3 65 1 0
121 13 59 186 105 1 5
57 18 2 187 2 1 48 22
20 5 507 1 2 188 71 28
53 6 906 1 2 189 7 16 10 1 16
113 22 2 2 2 190 2 1 3 0 0
PT ID NO Clinical Impression hi topath AVERAGE - 17 count SLEDAI
20 ACLE LS 24 16
21 ACLE LSS 41 6
31 ACLE LSS 280 8
40 ACLE LSS 62 17
53 SCLE LS 400 13
66 SCLE LSS 204 18
89 ACLE LSS 194 8
90 DLE LS 24 19
94 DLE LSS 112 7
99 DLE LSS 80 3
111 DLE LSS 89 10
113 DLE LSS 44 22
115 DLE LS 31 2
120 SCLE LSS 400 8
137 ACLE LS 28 22
34 CV PII 168 14
41 UV PII 178 19
78 CV VP 57 18
82 CV VP 82 20
109 CV PII 171 14
23 CV VP 307 27
27 CV LCV 59 9
  
 
ACLE involving malar area and forehead 
 
 
 
 
ACLE involving malar area and forehead 
 
 
 
DLE involving the malar area 
 
 
Disseminated DLE involving the face and upper limbs 
  
 
DLE with scarring alopecia of the scalp 
 
 
 
 
 
 
SCLE – psoraisiform lesions over the back 
 
 
 
 
 
 
 
 
 
 
 
Bullous LE involving the forehead 
 
 
 
 
 
Lupus profundus involving the scalp 
 
 
  
 
Gangrene of all the fingers 
 
 
 
 
Gangrene of the toes with palpable purpura over the legs and feet 
 
  
 
Diffuse non-scarring alopecia 
 
 
 
 
Lupus hair 
 
 
 
 
 
 
Acanthosis nigricans and Tinea versicolour 
 
 
 
 
 
 
Papulonodular mucinosis 
 
 
 
 
  
 
Nasal erosions 
 
 
 
 
Palatal erosions with candidiasis 
 
 
 
Palmar erythema 
 
 
 
 
 
 
Non-blanching purpuric macules over the fingers 
 
 
 
 
 
Crusted scabies 
 
 
 
 
 
 
Granuloma annulare 
 
 
 
 
 
 
  
 
Acquired ichthyosis 
 
 
 
 
 
HCQ induced nail pigmentation 
 
 
DLE with hyperkeratosis, thinning of the epidermis, prominent basement 
membrane, basal cell vacuolization with superficial and deep perivascular & 
periadnexal inflammatory cell infiltrate (50x, PAS stain) 
 
 
Leukocytoclastic vasculitis - fibrinoid necrosis of the vessel wall with 
predominantly neutrophilic infiltrate (200x, H&E stain) 
 
 
Immunohistochemical staining with anti-IL-17 antibody – glomerulus (positive 
control) (200x) 
 
 
 
Immunohistochemical staining with anti-IL-17 antibody – sweat glands (internal 
positive control) (200x) 
  
 
Immunohistochemical staining of the endothelial cells, lymphocytes & fibroblasts 
with anti-IL-17 antibody (200x) 
 
 
 
Immunohistochemical staining with anti-IL-17 antibody – positively staining 
endothelial cells (vertical arrow), fibroblasts (horizontal arrow) and lymphocytes 
(arrow-head) (400x) 
 
 
Immunohistochemical staining of the endothelial cells (vertical arrow), 
lymphocytes (arrow head) & fibroblasts (horizontal arrow) with anti-IL-17 
antibody (400x) 
 
